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Introduction
Cystinosis (MIM 219800) is an autosomal recessive defect of lysosomal cystine carrier
leading to the accumulation of amino acid cystine in the lysosomes. The estimated inci-
dence of cystinosis is 1 in 100,000-200,000 life births [Gahl et al. 2001] with clustering
reported in France, French-speaking population of Quebec, Germany and UK [Bickel et al.
1952, Bois et al. 1976, Manz et al. 1985]. Although the disease has also been observed in non-
Caucasian patients, there are no epidemiological data available in these populations [Gahl
et al. 2001].
Cystinosis was first described as a clinical entity by Abderhalden in 1903 [Abderhalden
1903] and recognized as a main cause of generalized proximal tubulopathy, called De
Toni-Debré-Fanconi syndrome, in the late 1940’s [Fanconi et al. 1949]. Real progress in the
investigation of cystinosis started when amino acid chromatographic analysis allowed
measuring elevated cystine concentrations in tissues of cystinotic patients [Schneider,
Bradley et al. 1967, Schneider, Rosenbloom et al. 1967]. In the 1980’s it was demonstrated that cys-
tine accumulated within the lysosomes due to the impairment of cystine transport across
the lysosomal membrane [Gahl,Bashan et al. 1982, Jonas,Smith et al. 1982]. Treatment with amino
thiol cysteamine and the availability of renal transplantation dramatically improved the
prognosis of patients with cystinosis allowing them to survive into adulthood [Gahl et al.
1987, Malekzadeh et al. 1977]. Cysteamine, however, does not reverse Fanconi syndrome in the
majority of patients and multi-organ impairment continues after renal transplantation.
Clinical presentation and course of cystinosis
Three clinical forms of cystinosis varying in severity and age of onset are distinguished:
the most frequent and most severe infantile form, the intermediate late-onset or juvenile
form and ocular cystinosis [Gahl et al. 2001, Gahl et al. 2002].
Renal involvement
Infantile nephropathic cystinosis is the most frequent cause of inherited Fanconi syn-
drome in childhood. Fanconi syndrome is characterized by excessive urinary excretion of
amino acids, phosphate, bicarbonate, glucose, sodium, potassium, low molecular weight
proteins and other solutes, handled in renal proximal tubules [Foreman et al. 1998]. Patients
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are usually asymptomatic at birth and develop normally until 3-6 months, when they
manifest with failure to thrive, vomiting, constipation, polyuria and excessive thirst, peri-
ods of dehydration and sometimes rickets [Broyer et al. 1981, Niaudet et al. 1999, Schneider et al.
1990]. Growth retardation in case of late diagnosis may reach -4 SD [Niaudet et al. 1999].
Renal loss of sodium and potassium results in hyponatremia and hypokalemia, which
may be life threatening. Hypouricemia, decreased plasma carnitine and medullary
nephrocalcinosis related to increased calcium excretion are also observed [Saleem et al. 1995,
Theodoropoulos et al. 1995]. Total protein excretion can reach several grams per day and con-
tains both albumin and low molecular weight proteins. In untreated patients glomerular
filtration declines gradually and progresses towards renal failure before the age of 10
years [Gretz et al. 1983, Manz et al. 1994]. Renal graft survival is generally better in patients with
cystinosis compared to overall children and the disease does not recur in the transplant-
ed organ [Ehrich et al. 1991, Kashtan et al. 1995].
Renal pathology
The age at which the first morphological changes appear in the kidneys of patients with
cystinosis is unknown. No significant renal changes were observed in the fetus [Jackson et
al. 1962]. Serial renal biopsies in 2 cystinotic patients demonstrated that the typical “swan-
neck” deformity of proximal convoluted tubules appeared only after 6 months of life
[Mahoney et al. 2000]. In a large series of kidney specimens, the most striking feature was the
marked irregularities of renal tubular cells with the presence of flat cells with focal dis-
appearance of the brush border and very large cells with a prominent and hyperchro-
matic cytoplasm [Gubler et al. 1999]. Glomeruli could appear normal, but most contained
peculiar giant multinucleated podocytes, specific for cystinosis (see the illustration on
the cover). Cystine crystals located in the lysosomes or in cytoplasm were seen mostly
within interstitial cells and rarely within podocytes [Gubler et al. 1999]. Swollen mitochon-
dria in the renal tubular cells seen by Jackson in two children of 2 and 3 years [Gubler et al.
1999], were not described in other series [Gubler et al. 1999, Mahoney et al. 2000, Spear et al. 1971].
The deterioration of renal disease is accompanied by progressive tubulo-interstitial
lesions, including interstitial fibrosis, tubular atrophy and marked arteriolar thickening.
The progressive glomerular damage, leading to increasing albuminuria and hematuria,
consists of segmental or global collapse of the capillary tuft, accumulation of mesangial
matrix material, and, observed by electron microscopy, irregular thickening of glomeru-
lar basement membrane  and the effacement of podocyte foot processes [Gubler et al. 1999].
In transplanted kidneys cystine crystals, seen at graft biopsy, have no clinical relevance
as they are present in the host mononuclear cells [Spear et al. 1989].
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Extra-renal involvement
Ocular impairment
Ocular manifestations can be classified according to their localization and the type of
treatment in those, affecting the anterior segment of the eye, treated by topical cys-
teamine drops, and the retinopathy, treated by systemic cysteamine.
Corneal cystine crystals, pathognomonic for the disorder, are absent at birth and gen-
erally can be seen by an experienced ophthalmologist at the age of 1 year. These crystals,
causing reflections of light, result in photophobia with substantial discomfort. At 10-20
years, untreated patients may develop painful corneal erosions, punctate, filamentous or
band keratopathy, iris crystals and peripheral corneal neovascularization [Kaiser-Kupfer et
al. 1986, Tsilou et al. 2002]. Posterior synechiae leading to glaucoma, are rarely reported. The
prevalence of the anterior segment complications increases with age [Tsilou et al. 2002].
The degeneration of the retinal pigment epithelium, resulting in patchy depigmenta-
tion of the retina starting in the periphery and extending in time, may cause visual
impairment starting from the second decade of life [Broyer et al. 1981].
Endocrine impairment
The continuing multi-organ accumulation of cystine crystals leads to the impairment of
endocrine organs. Hypothyroidism is found in up to 70% of untreated patients with
cystinosis older than 10 years [Chan et al. 1970]. Impaired insulin production can be exac-
erbated by steroid therapy after renal transplantation and results in insulin-dependent
diabetes mellitus [Fivush et al. 1987]. While the puberty generally proceeds normally in
females, it is delayed in males, who may have primary hypogonadism and do not always
complete puberal development [Winkler et al. 1993]. No male patient with cystinosis has
been reported so far to have an offspring, while several females after renal transplanta-
tion have successful given birth [Reiss et al. 1988].
Central nervous system and muscle impairment
The prolonged survivals of patients with cystinosis after renal transplantation also
revealed the impairment of central nervous and muscular systems, which previously were
considered to be spared in these patients.
Two major types of cystinotic encephalopathy, developing mostly during the 3rd
decade, are distinguished: the first, presenting with cerebellar and pyramidal signs, men-
tal deterioration and pseudo-bulbar palsy and the second, associated with stroke-like
episodes [Broyer et al. 1996]. The most common imaging finding in these patients is cere-
Introduction and outline
13
bw.levtchenko  12-02-2006  15:13  Pagina 13
bral cortical atrophy seen on CT scan [Nichols et al. 1990], however, non-absorptive hydro-
cephalus, demyelinisation of the internal capsule and brachium pontis, mineralisation of
hemispheres and basal ganglia have also been reported [Vogel et al. 1990].
Recently unexplained idiopathic intracranial hypertension with normal neuroimaging
of the brain was described in 8 patients with cystinosis, warranting regular ophthalmic
examination to rule out papilla edema [Dogulu et al. 2004].
The vacuolar myopathy, resulting from excessive cystine accumulation in the muscle,
manifests generally after the 10th birthday [Gahl, Dalakas et al. 1988]. The patients suffer
from progressive muscle wasting and reduced strength with restrictive ventilatory defects
[Anikster et al. 2001]. High prevalence of swallowing difficulty (>50%) has been recently
reported in 101 patients with cystinosis aged 6 to 45 years [Sonies et al. 2005]. On barium
swallow examination the oral, pharyngeal and esophageal phases of swallowing were
abnormal in 24%, 51% and 73% of the patients respectively. The severity of swallowing
dysfunction had a direct relation with the severity of muscular disease and decreased
with the number of years on cysteamine therapy [Sonies et al. 2005].
Intelligence and school performance
Although IQ values of children with cystinosis are in the normal range, they exhibit
deficits in tactile recognition, spelling, mathematics and short-term visual memory,
requiring adapted school tasks [Ballantyne et al. 2000, Williams et al. 1994]. Compared to healthy
controls and to the chronic-disease control group, patients with cystinosis have signifi-
cantly more social difficulties [Delgado et al. 2005].
Other clinical features
Diminished skin and hair pigmentation, liver and spleen enlargement, portal hyperten-
sion and hypersplenism are also observed [Broyer et al. 1987, Gahl et al. 2001, Scotto et al. 1977,
DiDomenico et al. 2004]. Cytopenia, related to hypersplenism, is actually rarely seen in
patients treated with cysteamine [Garnadoux et al. 1999]. Despite the fact that cystine crys-
tals are found in the bone marrow of the cystinotic patients, there is no evidence that it
has consequences for the hematopoiesis. Increased risk of bone fractures in transplated
cystinosis patients can be related to cystine depositions in the bone, hypogonadism, dia-
betes mellitus and continued urinary phosphate wasting in some patients. Notably, dual-
energy X-ray absorptiometry (DEXA scan) does not  predict the risk of fractures in
cystinotic patients possibly due to the false elevation of bone mineral composition by
bone cystine crystals [Zimakas et al 2003].
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Cystinosis in adults
Renal transplantation has transformed cystinosis from a fatal pediatric disease into a
treatable one with which patients surviving into adulthood. The evaluation of 36 adult
American cystinosis patients aged 17-34 years, revealed a high rate of mortality and mor-
bidity. Seven patients died at the age 18-34 years from aspiration, pseudo-bulbar palsy,
and uremia or had unexplained sudden death. Twenty two percent of the patients were
blind or had severely impaired vision, 86% required thyroid hormone replacement, 30%
had a distal myopathy and more than 60% had swallowing difficulties. Only 11/36
patients received adequate cysteamine treatment [Theodoropoulus et al. 1993]. The long-term
prognosis of pediatric patients with cystinosis is probably better than those reported
above due to the current early and continuous administration of cysteamine.
Transition from pediatric to adult care providers remains an area of concern as
internists-nephrologists usually treating adult cystinosis patients are not trained to get
experienced with this rare previously untreatable disorder. Good communication
between paediatric and internists-nephrologists is required to guarantee the continua-
tion of the adequate medical care [Kleta et al. 2005].
Other clinical forms of cystinosis
Less severe clinical forms of cystinosis account for less than 5% of all patients. Generally
2 variants are distinguished: nephropathic late-onset or juvenile cystinosis and non-
nephropathic ocular cystinosis [Gahl et al. 2001].
Patients with nephropathic late-onset form (MIM 219900) manifest with a spectrum
of symptoms, varying from a milder, compared to the infantile form, proximal tubu-
lopathy to apparent nephrotic syndrome and generally have slower rate of renal disease
progression [Gahl et al. 2001, Hauglustaine et al. 1976, Langman et al. 1985]. Cystine crystals accu-
mulate also in the cornea and can be diagnostic. In term of the age of presentation there
is probably a continium between the infantile and the late-onset form, however, most of
the described patients were older than 10 years old.
Ocular non-nephropathic cystinosis (MIM 219750) affects cornea with cystine crystal
deposits causing photophobia. The kidneys, retina and other organs are spared in these
patients, but they do have elevated cystine leukocyte content and cystine crystals in bone
marrow [Anikster et al. 2000, Schneider et al. 1968].
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Genetic aspects
Cystinosis is caused by mutations in cystinosis gene (CTNS), which has been identified
by positional cloning strategy in 1998 [Town et al.1998]. CTNS maps to 17p13, spans 23 kb
of the genomic sequence and is composed of 12 exons, the first two of which are non-
coding [Town et al.1998]. CTNS encodes a 367 amino acid protein, cystinosin, having 7
transmembrane domains and is highly glycosylated at the N-terminal (Figure 1). In con-
trast to other lysosomal membrane proteins, cystinosin contains 2 lysosomal-targeting
sequences, one situated in C-terminal tail and the second – in the fifth inter-transmem-
brane domain (TM) loop [Cherqui et al. 2001].
Mutations of CTNS have been detected in the individuals with all 3 clinical variants of
cystinosis, demonstrating that these forms are allelic [Anikster et al. 2000, Attard et al. 1999, Town
et al. 1998]. The most common mutation found in the homozygous state in more than 50%
of Caucasian patients is a large 57 kb deletion spanning exons 1 to 10 plus a large amount
of the upstream sequence [Shotelersuk et al. 1998, Town et al. 1998]. FISH diagnosis of the 57 kb
deletion has been recently developed [Bendavid et al. 2004]. Over 50 other reported muta-
tions include small deletions, insertions, nonsense, missense, splicing mutations or muta-
tions in the promoter region [Attard et al. 1999, Kalatzis et al. 2002, Kiehntopf et al. 2002, Phornphutkul
et al. 2001, Town et al. 1998]. Patients with the infantile form of cystinosis generally have two
severe truncating mutations, with a loss of functional protein, while patients with the
CHAPTER 1
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Figure 1  Schematic presentation of cystinosin in the lysosomal membrane with the two targeting motifs
indicated (white bars).
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juvenile cystinosis have mutations affecting functionally less important regions of cysti-
nosin - inter-transmembrane loops or the N-terminal region, which account for their
milder phenotype [Attard et al. 1999, Thoene et al. 1999]. In patients with ocular non-nephro-
pathic cystinosis one severe mutation and one mild mutation, allowing significant resid-
ual cystinosin activity were reported [Anikster et al. 2000]. It has been suggested that the lack
of kidney involvement in ocular cystinosis can be also explained at least in some patients
by the presence of tissue specific factors that allow a splicing of a normal CTNS transcript
[Anikster et al. 2000].
Studies with an antibody against cystinosin will allow the distinction between an
abnormal intracellular localization and lowered cystinosin activity at the normal site [Haq
et al. 2002].
The regulation of CTNS has not yet been elucidated. CTNS promoter can bind the
transcriptional factor Sp-1 and has sequence homology to AP-2, AP-4 and NF-1 regula-
tory elements. It shares the promoter sequence with CARKL (carbohydrate kinase-like
gene) with unknown function, which is also deleted in patients with 57 kb deletion
[Phornphutkul et al. 2001].
Recently the first animal model of cystinosis has been generated, using a promoter
trap approach [Cherqui et al. 2002]. Ctns knockout mice, lacking the last 4 exons of the
murine ctns gene, accumulated cystine in all organs tested, with cystine levels rising with
age. Cystine concentrations in liver, kidney and muscle were increased by factor 1350, 413
and 120 respectively in mice of 1 year old. The ctns -/- mice presented with ocular abnor-
malities, reduced motility and myopathy in some animals. Interestingly, despite the high
level of cystine within the kidney, ctns -/- mice do not develop Fanconi syndrome. The
comparison of mice and man may elucidate the origin of proximal tubulopathy in
humans. Although the phenotype observed in ctns -/- mouse model was less severe than
that observed in human, this animal model is an important tool for studying the patho-
genesis of the disease [Cherqui et al. 2002]. Regarding the therapy, the mice model might be
used to investigate cystine depletion under cysteamine administration in the different tis-
sues, including the central nervous system.
The mutations of cystinosis gene, leading  to premature termination codon (PTC), can
be at least partially corrected in vitro by an aminoglycoside gentamicin, inducing PTC
readthrough and enhancing full-length protein production [Helip-Wooley et al. 2002].
Whether gentamicin has therapeutical potentials in patients carrying this specific type of
mutations merits further investigation.
Introduction and outline
17
bw.levtchenko  12-02-2006  15:13  Pagina 17
Function of cystinosin
Although lysosomal localization of cystinosin was predicted in the 1980s [Jonas,Smith et al.
1982], only almost 20 years later it could be confirmed by the construction of a cystinosin-
green fluorescent fusion protein and the colocalization of this fusion protein with an
antibody directed against another lysosomal membrane protein, LAMP-2 in transfected
cells [Cherqui et al. 2001]. Immunocytochemical experiments with recently generated anti-
cystinosin antisera, also confirmed the lysosomal localization of cystinosin [Haq et al. 2002].
How cystinosin  transports cystine across the lysosomal membrane is not yet com-
pletely understood.
Stimulation of the cystine exodus from lysosomes loaded with cystine dimethylester
was associated with increase in lysosomal transmembrane pH gradients and decrease in
the potential difference across the lysosomal membrane [Smith, Greene et al. 1987].
The role of transmembrane proton gradient for cystine transport was demonstrated
by Kalatzis et al. [2001], who partially redirected cystinosin to the plasma membrane in
COS cells by deletion of it’s C-terminal targeting motif. When these cells were placed into
an acid extracellular medium, a clear increase in cystine uptake occurred. This effect was
strongly inhibited after disruption of the transmembrane pH gradient by nigericin, indi-
cating that cystinosin operates as a H+ symporter, i.e. that it couples a translocation of
cystine to a translocation of protons in the same direction (Figure 2). Thus, the H+
ATPase, acidifying the lysosomal matrix, will actively stimulate cystinosin-mediated cys-
tine export from the lysosomes [Kalatzis et al. 2001]. A similar mechanism for export of neu-
tral amino acids [Sagne et al. 2001] and of sialic acid and glucuronic acid [Mancini et al. 2000]
has been described.
The relationship between the transport activity of cystinosin and associated clinical
phenotype has been studied by deleting C-terminal sorting motif, resulting in expression
of mutated protein on the plasma membrane of COS-cells and studying the uptake of
[35S]L-cystine from the extracellular medium by these cells compared to the cells express-
ing wild-type cystinosin [Kalatzis et al. 2004]. Interestingly, the majority of mutants allow-
ing synthesis and lysosomal membrane localization of cystinosin, identified in patients
with infantile form of cystinosis (16 from 19), demonstrated completely abolished cys-
tine uptake. However, 3/19 “infantile” mutants demonstrated well detectable residual
cystinosin activity. Two of four mutants from patients with milder juvenile form of cysti-
nosis showed no cystine uptake and two of four had the residual activity of cystinosin.
The reasons of this incomplete correlation of cystinosin transport activity and the sever-
ity of the clinical phenotype are unexplained and require further study [Kalatzis et al. 2004].
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Recently a functional homologue of cystinosin has been identified in Saccaromyces
Cerevisiae (28% identity/46% similarity to cystinosin). Ers1 protein encoded by ERS1
gene is localized on the vacuolar and endosomal membrane of the yeast and is responsi-
ble for the resistance to an aminoglycoside hydromycin B. An expression of wild type
cystinosin, but not of particular cystinosin mutants can complement loss of function of
Ers1 protein in the yeast. Ers1 function is modified by a novel Meh1 protein, regulating
the acidification of the yeast vacuole. A homologue of Meh1 protein is not yet identified
in humans. Yeast model system might be usefull for studying cystinosin function and for
identifying other genes which are involved in the regulation of cystinosin [Gao et al. 2005].
Surprisingly, in I-cell disease, caused by a misrouting of lysosomal hydrolases due to a
defect in the synthesis of the mannose-6-phosphate recognition marker, cystine is stored
in the lysosomes to the same degree as in cystinosis [Tietze et al. 1986]. The defective func-
tion of cystinosin in this disorder may be attributed to inadequate processing by prote-













Figure 2  Cystine and protons are transported out of the lysosome by cystinosin. In cytoplasm cystine is con-
verted to cysteine. The protons in the interior of the lysosome are provided by H+ - ATPase.
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Possible pathogenetic mechanisms of cystinosis
Despite current good understanding of the genetic basis of the disease, the mystery of
how cystine accumulation causes clinical signs of cystinosis is not yet solved.
Before the existence of the animal model of cystinosis, several studies have been done
using cystine-loaded proximal tubules. Foreman et al. [1987] have first demonstrated that
the incubation of proximal tubules with cystine dimethyl ester (CDME) led to increased
intracellular cystine concentrations comparable to those measured in patients with cysti-
nosis. Lipid soluble CDME passes across cell membranes and is cleaved by intracellular
esterases liberating cystine. The vast majority of cystine cleaved from CDME localizes in
the lysosomes [Sakarcan et al. 1994]. Cellular cystine accumulation decreased transepithelial
potential difference and inhibited volume absorption, active glucose and phosphate
transport in isolated perfused rabbit proximal convoluted tubules and amino acid trans-
port in rats after CDME treatment [Foreman et al. 1987, Salmon et al. 1990].
ATP depletion
The proposed mechanism of the inhibited active transport in proximal tubules after
CDME loading was intracellular ATP depletion because a dramatic decrease of ATP was
measured after CDME loading [Ben-Nun et al. 1993, Coor et al. 1991, Foreman et al. 1995]. Later it
was shown that cystine loading caused a reduction of intracellular phosphate. The main-
tenance of intracellular phosphate prevented ATP depletion due to CDME loading and
preserved proximal tubular transport [Bajaj et al. 1996]. As most proximal tubular transport
is sodium coupled, less fuel for Na-K ATPase on the basolateral membrane, resulting in
lower electrochemical gradient for sodium, would inhibit the transport across the apical
membrane [Baum 1998]. Consistent with this theory, cystine-loaded LLC-PK1 cells, a cell
line with characteristics of proximal tubular cells, had increased intracellular sodium and
decreased intracellular potassium concentrations compared to the control cells, indicat-
ing decreased activity of Na-K ATPase [Ben-Nun et al. 1992]. Recently, electrophysiological
studies on immortalized human proximal tubular epithelial cell line (IHKE-1), loaded
with CDME, demonstrated that CDME acutely altered basal membrane voltage of IHKE-
1 cells and inhibited at least 3 Na+-dependent transporters: Na+-alanine cotransporter,
Na+/H+ exchanger and NaPi transporter [Cetinkaya et al. 2002]. As NaPi transporter was
inhibited to the highest extent, it was suggested, consistent with the animal studies, that
intracellular phosphate and ATP depletion play the key role in subsequent inhibition of
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active transport [Cetinkaya et al. 2002]. The presence of Fanconi syndrome in patients with
mitochondrial disorders also favors the role of intracellular ATP depletion in proximal
tubular cell dysfunction in patients with cystinosis. Thus far this mechanism has not been
demonstrated in human cystinotic material.
The role of intracellular phosphate depletion remains uncertain, as patients with
hypophosphatemic rickets, having pronounced decrease in serum phosphate, develop no
other symptoms of Fanconi syndrome.
One should realize that CDME loading does not exactly mimic the situation in
cystinotic patients. In this experimental situation, cystine, accumulating in the lyso-
somes, is normally transported into the cytoplasm by cystinosin. Furthermore, it is not
excluded that fast increase in intracellular cystine in cells due to CDME loading causes a
decrease of the intracellular ATP, while gradual cystine accumulation in patient’s tissues
alters intracellular functions in a different fashion. Whether ctns-/- mice exhibit ATP
depletion remains to be investigated.
Increased apoptosis
Another pathologic mechanism possibly involved in cystinosis is an altered regulation of
cell survival and death due to enhanced apoptosis.
A recent study has demonstrated that the rate of apoptosis was increased in fibroblasts
of patients with nephropathic cystinosis and in renal proximal tubular epithelial cells
loaded with CDME compared to normal cells [Park et al. 2002]. The mechanism linking cys-
tine accumulation and enhanced apoptosis remains speculative and has to be elucidated
[Park et al. 2005]. Interestingly, increased apoptotic cell death has been demonstrated in
some other lysosomal storage diseases and in a mouse model of tyrosinemia developing
Fanconi syndrome [Finn et al. 2000, Huang et al. 1997, Jatana et al. 2002, Simonaro et al. 2001, Sun et al.
2000]. Whether apoptotic or necrotic cell death is enhanced in ctns-/- mice has not yet
been investigated and studies of apoptosis in biopsies of patients with cystinosis are lack-
ing.
Altered glutathione metabolism
Glutathione (GSH) is the most abundant cellular thiol, functioning as an important
redox buffer. Cysteine together with glutamate and glycine are needed for GSH synthe-
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sis. Theoretically, defective cystine exodus out of the lysosomes in cystinosis can lead to
cysteine deficiency in the cytosole, where cystine is reduced to cysteine [Gahl et al. 2001].
Cysteine deficiency could be a rate-limiting factor for GSH synthesis. GSH serves as a
cofactor for the GSH peroxidase family of enzymes, which metabolize H2O2 and lipid
peroxides, defending cells against reactive oxygen metabolites [Uhlig et al. 1992]. Increased
reactive oxygen damage due to altered glutathione defense would make cells prone to
apoptotic cell death. Furthermore, glutathione depletion results in alteration of mito-
chondrial ATP synthesis [Meister et al.1995, Han et al. 2003]. Therefore, disturbances in glu-
tathione metabolism could be the missing link between ATP depletion and increased
apoptosis as a basis of cellular dysfunction in cystinosis.
Rizzo et al.[1999] made an interesting observation in three cystinotic patients, who had
an increased excretion of pyroglutamic acid (5-oxoproline), that normalized with cys-
teamine therapy, pointing to the disturbances of glutathione metabolism in cystinosis. This
abnormality was not present in patients with an idiopathic Fanconi syndrome. The fact that
in fibroblasts of patients with glutathione synthetase deficiency the concentration of cys-
teine is increased, illustrates the importance of the pathway from cysteine to glutathione
[Ristoff et al. 2002]. As 5-oxoprolinuria was also demonstrated in patients without defects in
γ-glutamyl cycle, but having another inborn error of metabolism [Mayatepek et al. 1999], the
meaning of this finding in cystinotic patients needs further study.
Mechanism of chronic interstitial damage 
Not only low molecular weight proteins but also albumin excretion is increased in
cystinotic patients. The reabsorption of the excessively filtered proteins may contribute
to the renal interstitial injury observed in patients by the release of profibrogenic factors
[Abbate et al. 1999, Hirschberg et al. 2005, Zandi-Nejad et al. 2004]. Search for the presence of bioac-
tive peptides in urine of cystinotic patients, as has been done in Dent’s disease and Lowe
syndrome, could contribute to the explanation of chronic interstitial damage [Cutillas et al.
2003, Norden et al. 2004].
Diagnosis of cystinosis
Cystinosis should be suspected in all patients with failure to thrive and signs of renal
Fanconi syndrome as it is the most common cause of inherited Fanconi syndrome in
children. Some patients may present with a Bartter-like phenotype (hypokalemic meta-
bolic alkalosis, hyponatremia, high plasma renin and aldosteron) [Pennesi et al. 2005].
However, the presence of symptoms of proximal tubular dysfunction such as
CHAPTER 1
22
bw.levtchenko  12-02-2006  15:13  Pagina 22
aminoaciduria, glucosuria and phosphaturia should not allow missing the diagnosis of
cystinosis. The detection of elevated intracellular cystine content is the corner stone for
the diagnosis of cystinosis as pathognomonic cystine crystals in the cornea become
apparent only after the age of 1 year. Bone marrow aspiration was used in the past for the
early diagnosis of cystinosis showing hexagonal cystine crystals which were obviously
present under crossed polarizing prisms [Schneider et al. 1969]. However, this invasive
method is not used anymore as cystine determination in blood cells allows the accurate
and early diagnosis in most of the patients. The methods for cystine determination dif-
fer depending on the cell type: mixed leukocyte preparation or polymorphonuclear
leukocytes and the method used for cystine measurement: either cystine-binding assay,
amino acid chromatography or high performance liquid chromatography, making it dif-
ficult to compare the results of the different laboratories [de Graaf-Hess et al. 1999, Kamoun et
al. 1999, Oshima et al. 1974]. The addition of N-ethylmaleimide to isolated cells prior to thaw-
ing and lysis is essential in order to prevent the oxidation of intracellular cysteine leading
to a false increase of cystine concentration [de Graaf-Hess et al. 1999]. Cystine concentrations
expressed as nmol of cystine per mg protein in polymorphonuclear leukocytes of normal
controls, obligate heterozygotes and patients at diagnosis, measured by HPLC are pre-
sented in table 1. The advantages of HPLC method for cystine determination are: its
lower price and no need for radioactive materials such as in cystine-binding assay and its
higher sensitivity, compared to amino acid chromatography (detection limit  cystine 0.15
µmol/l). Cystine binding assay remains the most sensitive method for cystine determina-
tion, requiring lowest amount of blood (3 ml compared to 5-10 ml needed for HPLC
determination), however, it’s high price and the use of radioactive cystine-binding pro-
tein, derived form E.Coli, limits it’s use in some laboratories [Smith, Furlong et al. 1987].
Tandem mass spectrometry is a new sensitive method and might be used in the future for
cystine determination in cystinosis [Wear et al. 2005].
Molecular analysis of the cystinosis gene allows an early diagnosis and can be used for
prenatal diagnosis on cultured amniocytes or chorionic villi. Previously prenatal diagno-
sis of cystinosis was performed by measurement of [35S] cystine accumulation in amnio-
cytes or chorionic villi cells [Dumoulin et al. 1999].
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Treatment
Symptomatic therapy
The aim of symptomatic therapy in patients presenting with Fanconi syndrome is the
maintenance of fluid and electrolyte balance, good nutrition and prevention of rickets.
The dose of potassium, sodium, bicarbonate and phosphate varies substantially and shall
be regularly adapted according to serum values. 1,25-dihydroxycholecalciferol should be
used beginning in early childhood [Gahl et al. 2001, Loirat et al. 1999]. The excessive adminis-
tration of phosphate, 1,25-dihydroxycholecalciferol and bicarbonate may result in severe
nephrocalcinosis or renal stone formation [Loirat et al. 1999, Theodoropoulos et al. 1995].
Calcium supplementation is generally not indicated. Carnitine replacement normalizes
plasma and muscular carnitine levels, however, it is not established whether carnitine
administration results in a clinical improvement [Gahl, Bernardini et al. 1988, Gahl et al. 1993].
No cases of cardiomyopathy related to carnitine deficiency in patients with cystinosis
have been reported so far.
Poor appetite, vomiting and oral motor dysfunction often require nasogastric tube or
gastrostomy feeding especially in young children [Elenberg et al. 1998, Trauner et al. 2001].
Treatment with growth hormone improves the growth in children with cystinosis, allow-
ing them to catch-up and to maintain normal growth [Wuhl et al. 1998]. As cystine-deplet-
ing agent cysteamine improves growth in patients with cystinosis, it is possible that
patients treated with cysteamine starting from the early age would not need exogenous
growth hormone at all.
Levothyroxin is indicated in patients with hypothyroidism, insulin in case of diabetes
and testosterone may be considered in male patients with hypogonadism.
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Intracellular cystine content of polymorphonuclear cells, measured by HPLC.
Cystine content (median, range)
nmol cystine/mg protein
)21.0-40.0( 1.0)8=n( slortnoc yhtlaeH
)36.0-90.0( 2.0)51=n( setogyzoreteh etagilbO
Untreated patients with infantile cystinosis (n=5) 1.47, 1.68, 2.79, 3.79, 4.89
Table 1  Intracellular cystine content of polymorphonuclear cells, measured by HPLC.
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Whether albuminuria in cystinosis is responsive to the administration of angiotensin-
converting enzyme (ACE) inhibitors has not been investigated. If it would be the case,
ACE inhibitors could postpone the development of chronic interstitial damage as it has
been demonstrated in diverse proteinuric disorders.
Specific treatment with cysteamine
The amino thiol cysteamine depletes lysosomal cystine content by a disulfide exchange
reaction with cystine resulting in the formation of cysteine-cysteamine mixed disulfide
and cysteine. Cysteine-cysteamine mixed disulfide exits lysosomes via a lysine carrier and
cysteine via a cysteine carrier [Gahl et al. 1985]. The administration of cysteamine at 40-90
mg per kg (1.3-1.9 g/m2) in 4 daily doses drastically lowers cystine content of the lyso-
somes, postpones or even prevents the deterioration of renal function and the develop-
ment of extra-renal complications [Kimonis et al. 1995, Markello et al. 1993, Kleta et al. 2004].
Furthermore, cysteamine improves growth of cystinotic patients [Gahl et al. 1987].
The side effects of cysteamine are mostly restricted to gastrointestinal discomfort due to
the stimulation of H+ secretion in the stomach, mediated by cysteamine-induced gastrin
release [Shiratori et al. 1997] and bad breath and sweat odor. Allergic reactions, fever, seizures
and neutropenia are also reported, especially when the dose of the drug is abruptly
increased [Corden et al. 1981]. Gastric acid hypersecretion and ulcerogenity of cysteamine
can be improved by the administration of proton pump inhibitors [Dohil et al. 2003]. As the
target tissue cystine levels necessary to prevent the progression of renal disease and the
occurrence of extra-renal complications is unknown, the 0.9 percentile of heterozygote
values in the polymorphonuclear cells is recommended as an upper cystine limit before
the next dose of cysteamine is given (<0.5 nmol cystine per mg protein) [Middleton et al.
2003]. The regular measurements of cystine in polymorphonuclear leukocytes are
required in order to adjust cysteamine dose.
Topical 0.5 % cysteamine eye drops are indicated, as systemic cysteamine therapy has
no effect on corneal cystine crystals. These drops are highly effective and when adminis-
tered 6 to 12 times daily are able to dissolve completely corneal cystine crystals within 8
to 41 months [Gahl et al. 2000]. The attempts to develop a new topical cysteamine formu-
lation, stable at room temperature, until now were not successful as they were less effec-
tive compared to the standard formulation [Tsilou et al. 2003].
Unfortunately, in the majority of the patients cysteamine can not reverse Fanconi syn-
drome and only postpones the development of renal failure. Urinary loss of cysteamine
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in patients with Fanconi syndrome might be responsible for the irreversibility of renal
Fanconi syndrome.
As leukocyte cystine content returns to the initial high levels 6 hours after cysteamine
administration [Belldina et al. 2003], the drug should be taken every 6 hours including the
night. Non-compliance with the strict cysteamine dose regimen is another plausible
explanation of the inefficiency of cysteamine treatment and development of renal failure
and extra-renal complications in the majority of cystinosis patients.
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Aim and outline of the thesis
The aims of this thesis concern two main directions:
1 Improving medical care of cystinosis patients
2 Obtaining new insights into the pathogenesis of cystinosis.
Improving medical care
Diagnosis of cystinosis
The diagnosis of cystinosis is based on the measurement of elevated cystine content in
white blood cells in a suspected patient, most often presenting with renal Fanconi syn-
drome. Because in blood cystine preferentially accumulates in polymorphonuclear
leukocytes and not in the lymphocytes, it is logic that polymorphonuclear leukocytes
should be used for cystine determination instead of mixed leukocyte preparations.
However, worldwide most of the laboratories use mixed leukocyte preparations for cys-
tine determination because mixed leukocytes are easier to isolate from whole blood com-
pared to polymorphonuclear leukocytes. In chapter 2 we explored whether cystine
should be measured in polymorphonuclear leukocytes and not in mixed leukocytes.
To our opinion cystinosis should be confirmed in all patients as this diagnosis has a
great impact on the patient and the family and requires life-long treatment with cys-
teamine. Before the cystinosis gene CTNS was cloned, we used cultured primary skin
fibroblasts for the determination of the elevated cystine content for the confirmation of
the diagnosis. In chapter 3, we describe a simplified PCR method for the detection of a
common European 57kb deletion, which was present in 60% of tested Dutch alleles.
Molecular analysis of CTNS gene is currently used in The Netherlands for the confirma-
tion of diagnosis in all patients with cystinosis.
Treatment of cystinosis 
Longer survival of cystinosis patients due to successful renal replacement therapy, allows
these patients to reach an adult age. Growing into adulthood cystinosis patients experi-
ence the common problem of patients suffering from rare disorders. Children with cysti-
nosis are mainly treated in a limited number of university pediatric nephrology units.
After the transition to the adult care providers, adult cystinosis patients are spread
between numerous adult nephrology departments, which due to a small amount of cysti-
nosis patients are generally not experienced with treatment of this rare disorder. In chap-
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ter 4 we evaluated clinical care of adult Dutch cystinosis patients and provided the rec-
ommendations for the adult nephrologists.
Treatment with  ACE inhibitors of cystinosis patients with proteinuria could possibly
slow the deterioration of the renal function in these patients. The effectiveness of ACE
inhibitors in cystinosis is described in chapter 5.
Irreversibility of Fanconi syndrome and deterioration of the renal function in the
majority of the patients despite cysteamine therapy, might be explained by urinary cys-
teamine loss in patients with Fanconi syndrome. This hypothesis was tested in the study
described in chapter 6. Another possible explanation of incomplete efficiency of cys-
teamine therapy is a non-compliance with a strict dose regimen. This was investigated in
a study described in chapter 7.
New insights into the pathogenesis of cystinosis
Cystine accumulation in cystinosis starts already prenatally and continues after birth.
Interestingly, full-blown Fanconi syndrome develops starting from the age of 6 months.
Understanding of gradual appearance of signs of proximal tubular dysfunction, demon-
strated in chapter 8, would provide new insights into the pathogenesis of cystinosis.
Based on CDME loading model of cystinosis, the alteration of mitochondrial ATP
synthesis, resulting in the inhibition of Na,K ATP-ase was proposed to be an underlying
pathogenetic mechanism of the disease. In chapter 9 we describe an extensive study of
mitochondrial energy generative capacity and the activity of Na,K ATP-ase in cultured
human cystinotic fibroblasts.
Searching for a possible link between lysosomal cystine accumulation and inhibited
mitochondrial ATP generating capacity, we hypothesized that altered glutathione metab-
olism could play a role. In a study described in chapter 10 we investigated glutathione
metabolism in cultured cystinotic fibroblasts and polymorphonuclear cells.
Study of renal disease in cystinosis is hampered by unavailability of human renal
cystinotic material. This problem has been overcome by developing of proximal tubular
cell lines derived from urine of cystinosis patients. Study of intracellular ATP content and
glutathione status in cystinotic proximal tubular cells is described in chapter 11.
A general discussion and summary of this thesis is provided in chapter 12.
CHAPTER 1
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CHAPTER 2
________________________________________________________________
Comparison of cystine determination in
mixed leukocytes vs polymorphonuclear
leukocytes for diagnosis of cystinosis and
monitoring of cysteamine therapy
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Abstract
Background: Cystinosis is a rare inborn error of cystine transport, leading to accumula-
tion of cystine within the lysosomes. To diagnose cystinosis and to monitor treatment
with cysteamine, adequate measurements of intracellular cystine content are required.
Historically, cystine has been measured in mixed leukocyte preparations (ML), although
it preferentially accumulates in phagocytic blood cells (polymorphonuclear leukocytes
(PMN) and monocytes). Therefore we have switched from cystine determinations in ML
to PMN cells and compared the differences in intracellular cystine content in these two
cell preparations.
Methods: ML and PNM were isolated form freshly drawn blood. Cystine was measured
as cysteine after reduction with sodium borohydride and derivatization with monobro-
mobimane, followed by separation with automated HPLC.
Results: Mean intracellular cystine content (nmol cystine/mg protein) was lower in ML
compared to PMN cells in obligate heterozygotes (0.07 versus 0.27, p<0.001) and patients
treated with cysteamine (0.15 versus 0.94, p<0.001). At the time of diagnosis cystine val-
ues of ML in two patients were within the reference interval, while it was clearly elevated
in PMN and in cultured fibroblasts. After the switch from ML to PMN the dose of cys-
teamine had to be increased in 80% of patients under cysteamine therapy.
Conclusions: We demonstrate that cystine must be measured in PMN leukocytes and not
in ML preparation because using ML can lead to dismiss or delay of the diagnosis of
cystinosis and inadequate adjustment of cysteamine dose.
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Introduction
Cystinosis is a rare autosomal recessive disorder caused by mutations of cystinosis gene
(CTNS; chromosome 17p13), which encodes the lysosomal cystine carrier. The continu-
ous accumulation of cystine in the lysosomes leads to intracellular crystal formation
throughout the body. Patients with the common infantile form of cystinosis develop
renal Fanconi syndrome 3–6 months after birth and end-stage renal failure before the age
of 10 years. Treatment with the aminothiol cysteamine depletes intralysosomal cystine
via a disulfide exchange reaction with formation of cysteine-cysteamine mixed-disulfides
and cysteine; these exit the lysosomes via lysosomal carriers for lysine and cysteine,
respectively [Gahl et al. 2001]. When started at an early age, cysteamine treatment prevents
or postpones the deterioration of renal function and the occurrence of extrarenal com-
plications such as hypothyroidism, diabetes mellitus, retinopathy, encephalopathy, and
myopathy [Gahl et al. 2001].
Accurate measurement of intracellular cystine content is obligatory for the diagnosis
of cystinosis as well as for the monitoring of treatment with cysteamine. Historically, cys-
tine has been measured in mixed leukocyte (ML) preparations, despite the fact that it
preferentially accumulates in polymorphonuclear leukocytes (PMN) and monocytes
[Schulman et al. 1970]. We therefore compared intracellular cystine content in ML prepara-
tions and in PMN cells of healthy controls, obligate heterozygotes, and patients at diag-
nosis and under cysteamine therapy. Because the isolation of PMN may pose practical
problems in some laboratories, we also investigated whether preservation of whole blood
at room temperature influenced intracellular cystine content. If the cystine concentration
remains constant, it would allow the shipping of whole-blood samples.
Materials and methods
MLs were isolated exactly as described by de Graaf-Hess et al. [1999]. All solutions were
kept at 4 °C. PMN cells were isolated from 10 mL of blood by addition of 2 mL of dex-
tran solution (50 g/L dextran T500, 15 g/L EDTA, 7g/L NaCl, pH 7.4) in a 15-mL glass
tube. After gentle mixing and ~ 1 h on ice, the clear upper solution was divided between
two 15-mL screw-cap polypropylene tubes, brought up to a total volume of 8 mL with
phosphate-buffered saline (PBS), and mixed gently. To the bottom of the tubes we care-
fully added 7 mL of Ficoll (Ficoll-Paque 1077; Amersham-Pharmacia) via a syringe with
a 15-cm long needle; the tubes were then centrifuged at 500g for 20 min at 4 °C in a swing
Cystine determination in ML and PMN cells
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out rotor with no braking. After centrifugation, the interphase containing the lympho-
cytes and the two liquid layers were completely removed. The pellet, containing PMN
cells and some erythrocytes, was resuspended in 1 mL of PBS, and 3 mL of cold water was
added for hypotonic lysis of the erythrocytes. After exactly 1.5 min on ice, 1 mL of 36 g/L
NaCl solution was added; the solution was then mixed and centrifuged at 600g for 10 min
at 4 °C. The cells were washed with 5 mL of PBS and centrifuged again. Finally, the pel-
let was resuspended in 0.5 mL of PBS, transferred to a 1.5-mL screw-cap Eppendorf tube,
and centrifuged at 1000g for 5 min at 4 °C. The pellet was then frozen immediately in liq-
uid N2 and stored at - 80 °C until the cystine was measured. The differential counts of
ML and PMN preparations were determined automatically (Advia; Bayer®).
To determine whether blood samples can be preserved at room temperature, we col-
lected fresh whole blood (2 x 10 mL per patient) in tubes containing 1.5 mL of acid-cit-
rate-dextrose solution (ACD). PMN cells were isolated immediately and after 24 h of
preservation at room temperature.
Cystine was measured by HPLC as described previously [de Graaf-Hess et al. 1999].
Results
ML preparations (n = 17) contained, mean (SD), 37 (15)% PMN cells, 39 (11)% lym-
phocytes, and 5 (7)% monocytes.
The mean (SD) intracellular cystine content (nmol/mg of protein) was lower in ML
compared with PMN cells in obligate heterozygotes (n = 15; 0.07 (0.03) vs 0.27 (0.17)
nmol/mg of protein; p < 0.001) and in patients treated with cysteamine (n = 12; 0.15
(0.08) vs 0.94 (0.58) nmol/mg of protein; p < 0.001; Figure 1). In two patients at the time
of diagnosis (one with the infantile form and one with the late-onset form), the ML cys-
tine content was within the reference interval, whereas it was increased in PMN cells
(0.49 and 1.47 nmol/mg of protein, respectively) and in cultured fibroblasts (1.6 and 1.44
nmol/mg of protein, respectively).
Because of the switch from ML to PMN preparations, the dose of cysteamine had to
be increased in 12 of 15 of patients under cysteamine therapy because their cystine con-
centrations measured in PMN cells were clearly above the desired concentration of 0.5
nmol cystine/mg of protein (90th percentile value of cystine concentration in PMNs of
heterozygotes in our laboratory).
The mean (SD) cystine content of ML in obligate heterozygotes (n = 15) was undis-
tinguishable from that of healthy controls (n = 8) but was clearly increased in PNM cells
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compared with the control values ((0.27 (0.17) vs 0.09 (0.03) nmol cystine/mg of pro-
tein; p < 0.05; Figure 1)).
PMN cells of blood samples stored in ACD tubes for 24 h at room temperature (n =
7) had increased mean (SD) cystine (0.95 (0.50) vs 0.59 (0.46) nmol/mg of protein; p <
0.05; Figure 2).
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Figurie 1  Cystine (nmol/mg of protein) in ML preparations and PMN cells.
(A), healthy controls (n = 8); (B), obligate heterozygotes (n = 15); (C), patients at diagnosis (n = 4); (D),








Figure 2  Cystine content (nmol/mg protein) in
PMN (n=7).
(A), isolated immediately; (B), after 24 hours storage
at room temperature.
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Discussion
Detection of increased intracellular cystine is required for the diagnosis of cystinosis in
patients presenting with Fanconi syndrome. After the diagnosis of cystinosis, intracellu-
lar cystine should be measured regularly to evaluate the cysteamine dose. Estimation of
the optimum leukocyte cystine concentration to be achieved under therapy is conjectur-
al because it is not known whether cystine accumulation in blood cells is representative
of the storage in other tissues. Generally, it is recommended to strive for a ML cystine
concentration < 0.5 nmol/mg of protein [Gahl et al. 2001]. This is also the upper limit of
cystine seen in heterozygotes, who do not develop nephropathy [Middleton et al. 2003].
Because we observed a clear difference between cystine content in ML preparations
and PMN cells, we suggest that each laboratory produces its own reference values based
on the upper cystine values found in heterozygotes.
In 1970 Schulman et al. [1970], showed that cystine accumulation in cystinotic leuko-
cytes is located primarily in phagocytic blood cells rather than in lymphocytes. Cystine
measurement in purified PMN preparations improved the sensitivity of the method. Our
results were comparable to those of Smolin et al. [1987], who used a cystine-binding assay
for cystine determination. They also found lower cystine in MLs compared with PMNs
in heterozygotes, in one untreated patient, and in patients undergoing cysteamine thera-
py. In our laboratory, the mean intracellular cystine content of healthy controls did not
differ between MLs and PMNs, possibly because the low cystine concentrations in
healthy persons are close to the detection limit of the HPLC method.
To our knowledge, no missed diagnosis of cystinosis as a result of low cystine concen-
trations in ML preparations has been reported previously. In our laboratory, the diagno-
sis of cystinosis could have been missed in two patients if cystine had been measured only
in MLs. In one patient, treatment with cysteamine was delayed for 6 months because the
cystine concentration in the MLs remained within the reference interval. Later the diag-
nosis of cystinosis in both patients was confirmed by clearly increased cystine in fibrob-
lasts and mutational analysis of the CTNS gene.
The possible reasons for falsely low cystine in MLs, especially in young children, could
be the overrepresentation of lymphocytes in ML preparations, typical for the first year of
life. Furthermore, variations in the differential count of MLs in individual patients can
lead to unreliable variations in measured cystine because it is expressed per milligram of
protein in the total cell preparation.
As described by Kamoun et al. [1999], for storage experiments, we also used ACD tubes
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for blood collection. In our laboratory, the storage of blood at room temperature for 
24 h led to increases in intracellular cystine content. Thus, the shipping of whole-blood
samples for cystine determinations is not advisable.
In summary, we recommend measurement of cystine in PMNs and not in ML prepa-
rations because the recommended approach increases the sensitivity of cystine detection
for the diagnosis of cystinosis and provides a better target concentration during the mon-
itoring of cysteamine treatment.
Cystine determination in ML and PMN cells
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Abstract
Infantile nephropathic cystinosis, an inborn error of metabolism with an autosomal
recessive inheritance pattern, is characterized by lysosomal storage of the amino acid cys-
tine due to an impaired transport of cystine out of the lysosomes. Initial clinical features
consist of the renal Fanconi syndrome and crystals in the cornea. Oral therapy with cys-
teamine lowers the intracellular cystine content. Recently, the gene coding for the integral
membrane protein cystinosin, which is responsible for membrane transport of cystine
(CTNS), was cloned. Mutation analysis of the CTNS gene of Caucasian patients revealed
a common 57-kb deletion, and several other mutations spread throughout the entire
gene. In the present study, we developed an improved screening method for the detection
of the common 57-kb deletion. By use of this method we detected the 57-kb deletion in
59% of the examined Dutch alleles. The remaining alleles were screened for other muta-
tions by genomic sequencing of the different exons, revealing three previously described
mutations. Furthermore, we studied a possible genotype- phenotype relation of the
homozygous deleted patients, which could not be demonstrated in our study population.
Next to biochemical determination of cystine in leukocytes or fibroblasts, molecular
genetic analysis enables prenatal diagnosis and facilitates identification of carriers.
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Introduction
Infantile nephropathic cystinosis, a rare inborn error of metabolism with an autosomal
recessive inheritance pattern, is characterized by lysosomal accumulation of the amino
acid cystine due to a defect in the transport of cystine across the lysosomal membrane.
Infantile nephropathic cystinosis is characterized in particular by renal tubular dysfunc-
tion and the presence of crystals in the cornea [Gahl et al. 1986]. At birth, almost no symp-
toms are present. In the first year of life, the renal Fanconi syndrome becomes manifest,
which is characterized by failure to thrive, dehydration, anorexia, polyuria, polydipsia
and hypophosphataemic rickets [Gahl et al. 1986]. Even with treatment renal function pro-
gressively decreases and renal replacement therapy has to start at an age of approximate-
ly 10 years, usually followed by renal transplantation. After transplantation of the kidney,
cystine continues to accumulate in other organs, resulting in a multisystem disease [Gahl
et al. 1986]. Other characteristics are decreased pigmentation of the hair, eyes and skin,
hypothyroidism [Chan et al. 1970], and impaired ability to sweat [Gahl et al. 1986].
Oral therapy with cysteamine lowers the intralysosomal cystine content by converting
cystine to cysteine and cysteine-cysteamine mixed disulphide, which are transported across
the lysosomal membrane by a mechanism independent of the defective cystine carrier [Gahl
et al. 1987, Gahl et al. 1985]. Biochemical diagnosis is made by the measurement of the accu-
mulated cystine in leukocytes or fibroblasts by HPLC [de Graaf-Hess et al. 1999].
Recently, the gene coding for the lysosomal cystine transporter cystinosin (CTNS) was
cloned [Town et al. 1998]. This CTNS gene is mapped to the short arm of chromosome 17
(17p13) and consists of 12 exons. The mRNA of the CTNS gene is 2.6 kb and codes for a
367 amino acid cystine transporter with 7 transmembrane domains [Town et al. 1998].
Mutation analysis of the CTNS gene of cystinosis patients revealed a common 57-kb
deletion in Caucasian patients, and several other mutations spread throughout the entire
gene [Town et al. 1998, Shotelersuk et al. 1998, Attard et al. 1999, Forrestier et al. 1999, Thoene et al. 1999].
In the present study, we developed an improved screening method for the common 
57-kb deletion, which enables accurate discrimination between the different genotypes.
By this method we examined the prevalence of the common 57-kb deletion in the Dutch
population. Alleles not carrying the 57-kb deletion were sequenced to reveal other muta-
tions present in the coding region (including the intron-exon boundaries) of the CTNS
gene.
Furthermore, we studied a possible genotype-phenotype correlation by comparing
the phenotype of homozygous deleted patients with the phenotype of other genotypes.
Molecular basis of cystinosis in the Netherlands
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Material and Methods
Patients
We studied 11 Dutch patients with early-onset nephropathic cystinosis. Biochemical
diagnosis was made by the measurement of the intracellular cystine levels of leukocytes
or fibroblasts [de Graaf-Hess et al. 1999]. The severity of the phenotype was determined on
the basis of three parameters.
First, age of diagnosis was used, which correlates with the severity of the phenotype.
Secondly, age of thyroid-stimulating hormone (TSH) production was measured, show-
ing the increase of TSH as a response to the decline of thyroid function [Chan et al. 1970].
The third parameter used was reduction of creatinine clearance, reflecting the deteriora-
tion of kidney function.
Mutation Analysis
DNA was extracted from whole blood according to Miller et al. [1988]. The obtained DNA
samples were subjected to mutation analysis of the CTNS gene.
57-kb Deletion Screening; an Improved Method. The common 57-kb deletion was
screened for in 11 Dutch cystinosis patients, by PCR amplification across the deletion,
using the LDM1 forward and reverse primers [Anikster, Lucero et al. 1999]. To discriminate
between heterozygous and homozygous deleted patients, we also screened the patients
for the presence of the D17S829 marker, which is situated in intron 3 of the CTNS gene
(located in the deletion interval) [Town et al. 1998]. As an internal control we used primers
for the housekeeping gene ß-actin, amplifying a product of 635 bp. Two separate multi-
plex PCRs were performed, one with primers for the deletion and for ß-actin and the sec-
ond PCR with the primers for the D17S829 marker and for ß-actin (Figure 1a, b).
Multiplex PCR was carried out in a total volume of 50 µl on a Perkin- Elmer 9600
thermocycler (PE Biosystems, The Netherlands) containing 5 ng ß-actin primers and 50
ng of the other forward and reverse primers (LDM1 or D17S829 primers), 200 µM
dNTPs, 10 mM Tris-HCl buffer (pH 8.3), 1.0 mM MgCl2 and 0.5 unit Taq polymerase (all
from Life Technologies, The Netherlands). PCR parameters were as follows: 92°C/120 s
(initial denaturation) followed by 35 cycles of 92°C/30 s (denaturation), 54°C/30 s
(annealing), 72 ° C/30 s (elongation) followed by a final elongation step of 7 min by 
72° C. The obtained PCR products of both PCRs, one to detect the presence of the dele-
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tion (LDM primers) and the other one to detect the absence of the deletion (D17S829
marker), were separated on a 2% agarose gel. In presence of the deletion, next to the
internal control fragment ß-actin of 635 bp, a fragment of 423 bp is amplified with the
LDM1 primers (Figure 1a). In the other PCR reaction also the internal control fragment
ß-actin must be present, next to a band of 266 bp of the D17S829 primers, when the dele-
tion is not present (Figure 1b).
Sequencing of the CTNS Gene. The remaining alleles that did not carry the 57-kb dele-
tion were sequenced to reveal possible other mutations in the CTNS gene. Therefore,
intronic primers were designed based on the published sequences (Genbank accession
Nos Y15922–Y15933, and table 1). PCR was performed according to the above-described
conditions using 50 ng of forward and reverse primers.
Molecular basis of cystinosis in the Netherlands
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Figure 1 Multiplex PCR to screen for the 57-kb deletion. a Gel electrophoresis pattern of multiplex PCR
with primers for ß-actin and the 57-kb deletion (LDM1 primers). Each lane shows a band of 635 bp of
the internal control fragment of ß-actin. The LDM1 primers only generated a fragment of 423 bp when
the deletion was present (lanes 1 and 2). b Gel electrophoresis pattern of multiplex PCR for marker
D17S829 and ß-actin. Again the product of 635 bp of ß-actin is present in each lane. The D17S829
primers, which are located in the deletion interval, only created a fragment of 266 bp when the deletion is
not present (lanes 2 and 3). Samples in both a and b are from a homozygous deleted patient (lane 1), a
heterozygous deleted patient (lane 2) and a nondeleted patient (lane 3). Lane 4 shows a negative control.
M1 and M2 represent the size markers of respectively pUCHaeIII and Ï-PstI.
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After PCR, the products were automatically sequenced on the ABI Prism 377 automated
sequencer using the ABI Prism BigDye Terminator cycle sequencing kit according to the
instructions of the manufacturer (PE Biosystems, The Netherlands).
Results
Mutation Analysis
To reveal the molecular basis of Dutch cystinosis patients, we performed mutation analy-
sis of the CTNS gene. First, we screened 11 Dutch patients for the presence of the com-
mon 57-kb deletion. For this purpose, we developed an improved method to examine the
presence of the 57-kb deletion on different alleles. In this way, we were able to discrimi-
nate between homozygous or heterozygous deleted patients. Figure 1a shows the results
of the PCR detecting the presence of the 57-kb deletion and figure 1b shows the results
of the PCR for the D17S829 marker, which is situated in the deletion interval. In both fig-
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1 According to Town et al. [1998].
Table 1 Primer sequences used to sequence the different exons of the CTNS gene.
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ure 1a and b, lanes 1, 2 and 3 represent different cystinosis patients, lane 4 is a negative
control and M1 and M2 represent respectively pUC-HaeIII and Ï-PstI molecular weight
markers. In both figure 1a and b the control fragment of ß-actin of 635 bp is present in
each lane.
Figure 1a shows that in lanes 1 and 2 the deletion is present on one or two alleles and in
lane 3 the deletion is not present. In figure 1b it is seen that lane 1 contains no band for
the D17S829 marker (situated in the deletion interval) and lanes 2 and 3 do show a band
for this marker, meaning that the deletion is not homozygously present in lanes 2 and 3
(Figure 1b). Combining the results of both PCRs gives the following results, lane 1 is a
patient who is homozygous for the 57-kb deletion, lane 2 represents a patient who is het-
erozygously deleted and lane 3 is a patient who does not carry the deletion at all.
Of the 22 Dutch cystinosis alleles, the 57-kb deletion was detected in 13 alleles (59%), 5
patients were homozygous and 3 were heterozygous for the deletion (table 2).
Patients without the deletion or those who carried the 57-kb deletion on one allele, were
submitted to genomic sequencing of the different exons to reveal possible other muta-
tions in the CTNS gene. In 4 of the remaining 6 patients, another previously reported
mutation was found [Anikster, Shotelersuk et al. 1999]. Two of them are homozygous for the
922insG, 1 patient is heterozygous for the 198del21 bp and carries the 57-kb deletion on
Molecular basis of cystinosis in the Netherlands
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198 del 21 bp
922 ins G
922 ins G
       ?
del 67-73 (in frame)1
S310Q (stop AA 364)
S310Q (stop AA 364)
T7F (stop AA 13)
1     amino acid change due to allele 2
2, 3 siblings
Table 2 CTNS mutations of Dutch cystinosis patients
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the other allele. The fourth patient carries the 18delGACT in heterozygous state and so
far no second mutation has been detected in this patient. In summary, all patients show
mutations in the CTNS gene, although in 3 patients only one heterozygous mutation has
been found (table 2).
Genotype-Phenotype Correlation
Next to mutation analysis, we studied a possible genotype- phenotype correlation, com-
paring the phenotype of the homozygous deleted patients with the phenotype of the
other genotypes. The age of diagnosis seems to be earlier in homozygotes for the 57-kb
deletion compared to the other genotypes (17.4 vs. 32.0 months respectively) but signif-
icance was not reached (p = 0.10, Student’s t test). Furthermore, a comparison between
the genotype and the age of reduction in creatinine clearance (GFR < 50 ml/min) was
made (51.3 vs. 58.5 months for 57-kb homozygotes vs. others), and no significant differ-
ence was observed (p = 0.61, Student’s t test). Increase of TSH is only detected in patients
2 and 9, again not indicating a genotype-phenotype relation (data not shown).
Discussion
Infantile nephropathic cystinosis is a rare inborn error of metabolism, which causes renal
failure due to the accumulation of cystine in the lysosomes. Mutation detection in the
Dutch population revealed the presence of the common 57-kb deletion in 59% of the
alleles. The allele frequency of the Dutch population is somewhat lower than the
European average (76%) but is still in line with the hypothesis that this deletion arose in
Europe and that it is probably due to a founder effect [Shotelersuk et al. 1998].
Performing a multiplex PCR to detect both the 57-kb deletion and the D17S829 mark-
er in one tube gave in some cases false negative results, which is also reported by others
[Anikster, Lucero et al. 1999]. Performing both PCRs separately (not in one tube) may also give
false negative results, due to failing of the PCR by inhibition or manual mistakes.
Therefore, we developed an improved screening method for accurate detection of the
common 57-kb deletion. In contrast to previously reported PCR-based detection meth-
ods [Forestier et al. 1999], we chose to perform two separate multiplex PCRs for the detec-
tion of the 57-kb deletion or the D17S829 marker. In both PCRs we applied primers for
an internal control fragment of ß-actin, which amplify a larger fragment than the frag-
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ments of 423 and 266 bp of the LDM1 and D17S829 primers respectively. When the band
of ß-actin of 635 bp is present, the other fragment (LDM1 or D17S829) must also be
amplified by PCR, because smaller fragments are in general better amplified than larger
ones. In this way, we are certain that every genotype is correctly determined, and that no
false negative results could be obtained. Hereby, we developed an improved, accurate and
reproducible procedure for the detection of the common 57-kb deletion, which enables
proper discrimination between the different genotypes of the 57-kb deletion.
In 3 patients only a mutation was found on one allele in the coding region (including
intron-exon boundaries) of the CTNS gene, indicating that a second mutation must be
present. The presence of the second mutation may be located in the 3´-UTR or intronic
sequences of the CTNS gene causing instability of the RNA or interruption of the splic-
ing mechanism. Another possibility is the presence of mutations in the 5´-UTR or the
promoter region of the CTNS gene, which can alter the expression of the gene.
Recently, Attard et al. [1999] showed a correlation between the form of cystinosis and
the genotype. The infantile form, which is the most severe form of cystinosis, is associat-
ed with major DNA changes (deletions, insertions) or changes in important parts of the
protein, whereas the other forms of cystinosis (late-onset, nonclassical) are associated
with minor DNA changes in less important parts of the CTNS protein [Thoene et al 1999,
Anikster, Shotelersuk et al 1999, Anikster et al 2000]. In this study, we investigated the infantile form
of cystinosis and found next to the 57-kb deletion, three other mutations present in the
CTNS gene. The first one is an insertion of guanine at DNA position 922, present in
homozygous state in 2 patients. This insertion causes a frameshift, resulting in a prema-
ture stop codon at amino acid position 364, thereby disrupting the lysosomal target motif
[Hunziker et al. 1996]. This motif regulates the transport of the protein to the lysosomal
membrane.
The second mutation found is a heterozygous deletion of GACT at DNA position 18,
which results in a premature stop codon at amino acid position 13. The last mutation
found is a deletion of amino acids 67–73, which results in an in-frame deletion of seven
amino acids of the protein. This deletion is located in the part of cystinosin that is pre-
sent in the lysosomal lumen and results in loss of an N-glycosylation site [Attard et al. 1999].
This latter mutation may not completely destroy the transport function of cystinosin and
is therefore expected to cause a milder form of cystinosis [Attard et al. 1999]. On the other
hand, this study shows that presence of the 57-kb deletion next to the deletion of amino
acids 67–73 likely causes the infantile form of cystinosis.
In summary, all mutations found in the Dutch infantile cystinosis patients are major
DNA changes located in functionally important parts of the protein, or are mutations
Molecular basis of cystinosis in the Netherlands
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that contribute to the severity of the phenotype next to a truncating mutation. These
findings support recent published data on genotype-phenotype correlations of cystinosis
patients [Attard et al. 1999, Anikster, Shotelersuk et al. 1999].
Several other genes seem to be located in the 57-kb deletion interval [Touchman et al.
2000]. Absence of these genes next to the CTNS gene could contribute to the phenotype
of cystinosis.
Furthermore, the presence of the 57-kb deletion results in no protein expression at all,
which may result in a more severe phenotype compared to other mutations present in the
CTNS gene. Based on this hypothesis, we compared the phenotype of the homozygous
form of this 57-kb deletion with other genotypes. This relatively small study shows that
patients who are carrying the 57-kb deletion on both alleles did not have statistically dif-
ferent parameters compared to the other patients, although, the age of diagnosis seems
earlier in patients who are homozygous for the 57-kb deletion. However, the alertness of
the physician is an important factor that might influence the age of diagnosis. To study
this relation, larger patient groups are necessary. The results from this study show that it
is not presumable that other genes located in the 57-kb deletion region contribute exten-
sively to the phenotype of cystinosis.
Screening for the 57-kb deletion will resolve about 45% (5 out of 11 patients) of the
molecular basis of cystinosis in Dutch Caucasian patients. To reveal mutations present on
the remaining alleles of cystinosis patients, it is necessary to perform sequencing analysis
of the whole CTNS gene.
Early treatment is of vital importance for cystinosis patients. The sooner the diagno-
sis can be made, the earlier treatment can be initiated and the better the life expectancy
of these children becomes. Molecular analysis facilitates prenatal diagnosis and identifi-
cation of carriers and thereby genetic counselling.
CHAPTER 3
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________________________________________________________________
Follow-up and treatment of adults with
cystinosis in the Netherlands
Joyce Geelen, Leo Monnens and Elena Levtchenko
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Abstract
Background: Cystinosis is a rare autosomal recessive disease, caused by intracellular cys-
tine accumulation due to a defect in the lysosomal cystine carrier.
Treatment with cysteamine favours the transport of cystine out of the lysosomes, dimin-
ishes organ damage, and postpones the progression of renal failure. The extra-renal
deposition of cystine continues after renal transplantation, leading to later complica-
tions. The objective of this study was to evaluate the follow-up, the occurrence of late
complications, the social status, and the adequacy of cysteamine treatment in adult
patients with cystinosis.
Methods: The medical histories of 10 adult cystinosis patients aged 19–36 years were
studied. The impairment of thyroid function, central nervous system, endocrine pan-
creas, and ocular manifestations, as well as treatment with cysteamine were evaluated.
Results: Eight patients received in total 12 renal grafts, one patient was dialysed and one
received conservative treatment for chronic renal failure. Extra-renal complications were
noted in six patients, loss of visual acuity in four, hypothyroidism in three, diabetes mel-
litus in one, cerebral atrophy and epilepsy in one, and swallowing difficulties in two
patients. Ophthalmic control was not performed in two patients, thyroid function was
not controlled in two and glycaemia not controlled in two patients. Seven patients
received 2100–4000 mg cysteamine per day in 2 (n=2), 3 (n=1), 4 (n=3), or 6 (n=1)
doses. Cystine concentration in leukocytes was measured once or twice a year in eight
patients and was within the recommended range only in three patients.
Conclusion: A high rate of extra-renal complications in adults with nephropathic cysti-
nosis was found. Optimizing the cysteamine therapy may attenuate these complications.
Better communication between paediatric and ‘adult’s’ nephrologists is needed to
improve follow-up and treatment of grown-up cystinosis patients.
CHAPTER 4
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Introduction
Cystinosis, a rare autosomal recessive disease, caused by intracellular cystine accumula-
tion due to a defect in the lysosomal cystine carrier, occurs in approximately 1 in
100,000–200,000 live births [Gahl et al. 2001]. The cystinosis gene, CTNS, identified by posi-
tional cloning strategy, has been mapped to the short arm of chromosome 17.
This gene encodes a protein, named cystinosin, with features of a lysosomal mem-
brane protein [Town et al. 1998]. Renal Fanconi syndrome, an early clinical manifestation of
the infantile form of nephropathic cystinosis, generally becomes apparent 3–6 months
after birth. Untreated patients usually develop end-stage renal disease (ESRD) before the
age of 10 years, with a wide range up to 20 years [Niaudet et al. 1999]. Late-onset form of
cystinosis generally appears at the age of 12–14 years, often does not presents with com-
plete Fanconi syndrome, but may progress to ESRD within a few years of diagnosis [Gahl
et al. 2001]. An aminothiol, cysteamine, depletes intralysosomal cystine content by reacting
with cystine to form cysteine–cysteamine mixed disulphide and cysteine, which can leave
lysosomes via lysosomal lysine and cysteine carriers respectively. However, cysteamine
does not reverse Fanconi syndrome and only postpones the commencement of renal-
replacement therapy. After renal transplantation, the ongoing accumulation of cystine
causes multi-organ damage: photophobia and loss of visual acuity due to corneal cystine
crystals and retinopathy, bradykinesia, dementia, convulsions or spasticity due to cere-
bral atrophy, basal ganglia and periventricular calcifications or ischaemic lesions, muscle
weakness and swallowing difficulties due to vacuolar myopathy, hypothyroidism,
exocrine pancreas deficiency and diabetes mellitus [Kaiser-Kupfer et al. 1986, Broyer et al. 1996,
Sonies et al. 1990, Kimoniset al. 1995, Fivush et al. 1988, Gahl et al. 1987]. Growth retardation, delayed
puberty, hypogonadism and male infertility are frequent [Winkler et al. 1993, Tête et al. 1999].
These serious late complications require the continuation of cysteamine treatment
after renal transplantation in order to diminish extra-renal cystine accumulation [Almond
et al. 1993]. Regular measurement of intracellular cystine is indicated to control the effica-
cy of cysteamine treatment in pre- and post-transplant patients [Kamoun et al. 1999].
The aim of the study was to evaluate the follow-up, the occurrence of extra-renal com-
plications, the social status, and the adequacy of cysteamine treatment in adult patients
with nephropathic cystinosis in the Netherlands.
Follow-up and treatment of adults with cystinosis
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Subjects and methods
A retrospective analysis of case histories of 10 adult cystinosis patients who were followed
in five Dutch university hospitals was performed. The diagnosis of cystinosis was based
on the evidence of cystine corneal crystals and/or elevated leukocyte cystine level. The
impairment of thyroid function, central nervous and muscular system, endocrine pan-
creas and ocular manifestations, the social status of the patients, and treatment with cys-
teamine (dose, frequency, and cystine measurements in leukocytes) were evaluated.
Cystine leukocyte content was measured by HPLC in the same laboratory [de Graaf et al.
1999].
Results
Characteristics of the patients
The patient’s age range was 19–36 years, there were six male and four female patients.
Cystinosis was diagnosed during the first decade of life in all patients. At presentation, all
patients had renal Fanconi syndrome and cystine corneal crystals. The median age at
diagnosis was 3 years.
Renal replacement therapy (RRT) was initiated at median age of 12 years. Eight
patients received in total 12 renal grafts, one patient dialysed and one had chronic renal
failure and received conservative treatment.
Among the transplanted patients, six had well functioning renal grafts and two had
pre-terminal graft failure due to chronic rejection (Table 1). Renal graft loss was not
related to the cystinosis and was caused by arterial bleeding after the graft biopsy in
patient no. 2, acute rejection (first graft), renal-artery stenosis and chronic rejection (sec-
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Extra-renal organ involvement (Table 1)
No patient died. Six patients suffered from major extra-renal complications. Two patients
had multiple extra-renal organ involvement.
Visual acuity
Four patients had loss of visual acuity due to excessive cystine corneal accumulation,
retinopathy at fundus examination in patients nos 1 and 5, and band keratopathy in
patient 10. Two patients received no ophthalmic control.
Endocrine complications
One patient had insulin dependent diabetes mellitus, three had hypothyroidism and
required thyroid hormone treatment. The thyroid gland function was not controlled in
two patients. The glycaemic control was not performed in three patients and only occa-
sionally in three other patients. Gonadal function was not assessed in any patient.
Central nervous system and muscle involvement.
Patient no. 8 had epilepsy with evidence of periventricular calcifications and cerebral
atrophy on computer tomography of the brain. Two patients had swallowing difficulties
due to myopathy. Patient no. 1 had mild dysphagia. In patient no. 10, swallowing prob-
lems appeared at the age of 22 years, predominantly during the passage of food through
the pharynx, and were not progressive. At the age of 31 years he presented with com-
plaints of dyspnoea. The evaluation revealed no heart involvement, but decreased force
of respiratory muscles. Lung function examination showed a restrictive respiratory dys-
function. He was advised to stop smoking, which resulted in short reduction in com-
plaints. Later, dyspnoea increased and was a cause of severe disability.
Growth
The median length of male patients was 164.50 cm (–3.70 SD) and of female patients
157.50 cm (–2.50 SD).
CHAPTER 4
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Social status, education, and integration
Three patients did not complete any professional study, two were still occupied with low
and intermediate professional education, and five received low or intermediate education
and were working (Table 1).
Patients nos 8 and 10 have a stable relationship.
Cysteamine treatment (Table 2)
Median age at start of cysteamine therapy was 14 years (range 3–25). At the time of eval-
uation, seven patients were receiving oral cysteamine treatment. The dose varied from 40
to 70 mg/kg cysteamine base per day in 2 (n=2), 3 (n=1), 4 (n=3) or 6 (n=1) doses. Three
patients were not treated with cysteamine: one because of the patient’s refusal (no. 5),
and two patients did not receive a prescription from their physicians. Patient 4 was obvi-
ously not compliant with the prescribed medication.
In two patients no measurements of cystine levels in the leukocytes were done. In eight
patients cysteamine was measured at least once a year; at last measurement median cys-
tine content was 0.35 with a range of 0.072–3.00 nmol/mg protein. Only three patients
had leukocyte cystine content within the recommended range (< 0.2 nmol/mg protein).
No information about the interval between the last cysteamine dose and the time of
blood examination was available.
Cysteamine eye drops were not administered in four patients.
Relation between cysteamine treatment and the occurrence of late complications
Among the three untreated patients, one (no. 5) had a severe course of the disease with
multiple complications, including diabetes mellitus, epilepsy, and retinopathy. Patient no.
6 had impaired thyroid function, but patient no. 7 has not yet any extra-renal organ
involvement.
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Discussion
Renal transplantation and the availability of cysteamine treatment have transformed
cystinosis from a fatal paediatric disease into a treatable one with which patients can sur-
vive into adulthood.
The evaluation of 36 adult American cystinosis patients, aged 17–34 years revealed a
high rate of mortality and morbidity [Theodoropoulus et al. 1993]. Seven patients died at ages
between 18 and 34 years from aspiration, pseudobulbar palsy, uraemia, or unexplained
sudden death. Twenty-two per-cent of the patients were blind or had severely impaired
vision, 86% required thyroid hormone replacement, 30% had distal myopathy, and more
than 60% had swallowing difficulties. Only 11 of 36 patients received an adequate cys-
teamine treatment [Theodoropoulus et al. 1993].
Adult cystinosis patients are generally followed up by nephrologists, who pay major
attention to the renal function, risks of renal osteodystrophy, hypertension, and other
symptoms shared by all nephrological patients. The purpose of this study was to evalu-
ate the adequacy of the follow-up and treatment of adult cystinosis patients, as they suf-
fer from additional complications related to cystinosis and require specific cysteamine
treatment.
Case histories of all Dutch adult cystinosis patients, followed in five University hospi-
tals, were studied.
Despite the fact that the diagnosis of cystinosis was made before the age of 10 years
and all patients had Fanconi syndrome at presentation, this series of patients was not
homogenous. Patients 1, 6 and 10 reached ESRD at the age of 17–18 years, which is later
than classically described in patients with an infantile form of cystinosis. Cysteamine
treatment was not likely to explain the late onset of ESRD as it was either not adminis-
tered or was administered late. Surprisingly, patients 1 and 2, who are siblings, developed
terminal renal failure at the ages of 10 and 18 years respectively. The data from European
Dialysis and Transplant Association Registry showed the median age at the start of renal
replacement therapy to be 9.5 years, with a wide range of 1–20 years. No information on
cysteamine therapy or clinical presentation was available in this database [Rigden et al.
1999].
Patient no. 8 presented at the age of 9 years with Fanconi syndrome and cystine crys-
tals in the cornea.
Cysteamine was administered only at the age of 17 years. However, at the age of 30 he
still did not require renal replacement therapy, which prevents him being classified as
having an infantile form of cystinosis.
Follow-up and treatment of adults with cystinosis
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Attard et al. [1999] also described two patients, presenting at early age with classical
infantile cystinosis, who did not develop renal failure at the age of 18 and 22 years. DNA
analysis showed that these patients had at least one mutation, presumably permitting the
production of some functional protein, which could account for their milder phenotype
[Attard et al. 1999]. We did not perform mutation analysis in our studied patients, but
believe that the diversity of genotype could explain their different clinical courses.
The morbidity of Dutch cystinosis patients, with an exception of visual impairment,
was lower than in the American series, possibly due to the amelioration of cystinosis
treatment during the last decade. A milder course of the disease in some patients could
be another explanation for this lower morbidity 
Seven of 10 Dutch adult patients were treated with cysteamine compared to 30%
Americans; however, only three of 10 patients had the recommended leukocyte cystine
level. Cystine was measured in the mixed leukocyte preparation by the HPLC method in
the same biochemical laboratory, which excluded methodological differences in the
determination.
According to the laboratory guidelines, blood for cystine determination has to be
taken before the next cysteamine dose. However, we were not able to determine whether
this recommendation was always followed. Measured by the HPLC method, cystine value
in healthy controls (n=15) was 0.04–0.013 and in the obligate heterozygotes (n=15)
0.03–0.2 nmol/mg protein. As the cystine leukocyte level necessary to prevent the pro-
gression of renal disease and the occurrence of extra-renal complications is unknown, the
upper heterozygote value was recommended as an upper limit of cystine before the next
dose of cysteamine is given. We have recently changed from measuring cystine in mixed
leukocytes to the granulocyte preparations, as cystine preferentially accumulates in the
granulocytes. Heterozygote value was significantly higher when measured in the granu-
locytes (0.11–0.63). However, as all previous measurements have been done in the mixed
leukocyte preparations, we used the last cystine leukocyte value to evaluate the current
status of the patients.
No uniform follow-up and treatment strategy was applied by Dutch nephrologists.
While renal function and arterial hypertension were assessed at each ambulatory visit,
the extra-renal organ involvement relating to cystinosis was evaluated only occasionally
or not at all. Two nephrologists did not prescribe any cysteamine treatment. Even when
the measured cystine leukocyte content was above the recommended level, the dosage of
cysteamine was not systematically adapted. Three patients received cysteamine in 2–3
doses, which is insufficient as the leukocyte cystine content returns to its original levels
as early as 4–6 h after the cysteamine dose [Schneider et al. 1995].
CHAPTER 4
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Cysteamine eye drops are effective in reducing photophobia and density of corneal
crystals in cystinosis patients; however, four patients did not receive this treatment. The
effectiveness depends on the concentration and the number of daily instillations: a dose
of 0.5% at 5–6 times a day is recommended [Dureau et al. 1999].
We have no information on compliance with the cysteamine therapy, except in patient
no. 4, who was obviously non-compliant. Non-compliance also could be suggested in
patient no. 10, who had a high leukocyte cystine content despite adequate cysteamine
prescription. Non-compliance with cysteamine treatment is a difficult problem, as for
patients the potential later benefits of cysteamine do not always outweigh the more
immediate inconveniences such as an unpleasant odour or gastrointestinal discomfort.
In summary, the finding of a high incidence of extrarenal complications in adult
Netherlands cystinosis patients, and a rather unsystematic follow-up, indicate the neces-
sity of optimizing the care of these patients.
Better communication between paediatric and ‘adults’ nephrologists is required in
order to continue adequate follow-up and treatment of cystinosis patients growing into
adulthood. A minimum requirement would be an annual neurological examination,
including the evaluation of the strength of oropharyngeal and hand muscles, and an oph-
thalmologic examination, regular determination of plasma TSH, T3 and glycaemic con-
trol, as well as measurement of intracellular cystine content at least twice a year.
Follow-up and treatment of adults with cystinosis
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CHAPTER 5
________________________________________________________________
ACE inhibitor enalapril diminishes 
albuminuria in patients with cystinosis
Elena Levtchenko1, Henk Blom2, Martijn Wilmer1,2, Lambertus van den Heuvel1,2 and
Leo Monnens1
1Department of Paediatric Nephrology, 2Laboratory of Paediatrics and Neurology, Radboud University
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Abstract
Background/Aims: Cystinosis, a rare autosomal recessive disease, manifests with renal
Fanconi syndrome during the first year of life. Interstitial damage is a major cause of
renal failure in patients with cystinosis. We presume that albuminuria contributes to the
development of renal failure in these patients. The aim of this study was to examine
whether the administration of ACE-inhibitor enalapril diminishes albuminuria in
patients with cystinosis.
Methods: Five patients with cystinosis aged 4-9 years were studied. All patients had
Fanconi syndrome and were treated with cysteamine. Median creatinine clearance was 48
ml/min/1.73 m2 (range 21-61). The excretion of albumin and α-1 microglobulin as well
as arterial blood pressure and serum creatinine were evaluated before and at 3 months on
oral administration of enalapril (0.15 mg/kg once daily).
Results: At three months on enalapril, albuminuria decreased in all patients (1042 vs 629
mg per 24 hrs, p<0.05). The median reduction of albuminuria was 43% (range: 4-72%,
p<0.05). Urinary excretion of α-1 microglobulin remained constant.
Systolic blood pressure decreased from median 110 to 100 mm Hg (p<0.05), while dias-
tolic blood pressure remained stable (median 60 mm Hg). Creatinine clearance decreased
from median 48 to 45 ml/min/1.73 m2 (p<0.05) and returned to previous values after the
discontinuation of enalapril.
Conclusion: ACE-inhibitor enalapril diminishes albuminuria in patients with cystinosis
and might be used in these patients in order to slow the progression of renal insufficien-
cy attributed to proteinuria.
CHAPTER 5
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Introduction
Cystinosis, a rare autosomal recessive deficiency of the lysosomal cystine carrier, result-
ing in lysosomal cystine accumulation, occurs in approximately 1 in 100,000-200,000 live
births [Gahl et al. 2001]. The cystinosis gene CTNS, encoding the lysosomal cystine carrier
protein, named cystinosin, has been mapped to the short arm of chromosome 17 [Town
et al. 1998].
Cystinosis is the most common cause of Fanconi syndrome in children, which gener-
ally becomes apparent 3-6 months after birth [Niaudet et al. 1999]. The excessive urinary loss
of low molecular weight proteins such as α−1 microglobulin in patients with cystinosis is
attributable to Fanconi syndrome. Albuminuria might occur due to increased glomeru-
lar filtration of albumin or diminished tubular re-absorption [Norden et al. 2001]. Untreated
patients develop end stage renal failure due to chronic interstitial damage before the age
of 10 years [Gretz et al. 1983, Gahl et al. 2002]. The aminothiol cysteamine depletes intra-lyso-
somal cystine content via a disulfide exchange reaction with cystine to form cysteine-cys-
teamine mixed disulfide and cysteine, which exit the lysosomes via lysosomal lysine and
cysteine carriers respectively [Gahl et al. 1987, Schneider et al. 1995]. However, cysteamine does
not reverse Fanconi syndrome and only postpones the start of renal replacement thera-
py [Markello et al. 1993].
The exposure of renal proximal tubules to an excessive amount of albumin changes
gene expression profile of proximal tubular cells and leads to interstitial inflammation
and fibrosis [Nakajima et al. 2002, Abbate et al. 1998]. The therapy with angiotensin converting
enzyme (ACE) inhibitors or angiotensin II receptors blockers diminishes albuminuria
and slows the decline of renal function in different chronic nephropathies [Ruggenenti,
Perna et al. 1998, Lewis et al. 1993, Ruggenenti, Mosconi et al. 1998]. As albuminuria has been shown
to be an important factor in renal disease progression, we hypothesised that it might also
contribute to the development of renal failure in patients with cystinosis and can be
treated by ACE inhibitors.
The aim of this study was to examine whether the administration of the ACE-
inhibitor enalapril could diminish albuminuria in patients with cystinosis by reducing
the glomerular leakage.
Enalapril diminishes albuminuria in cystinosis
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Patients and methods
Five patients with Fanconi syndrome due to cystinosis, aged 4-9 years, were studied. All
patients had homozygous mutations of CTNS gene: four - homozygous 57 kb deletion
and one - homozygous 922insG. All of them were on regular cysteamine treatment (50-
100 mg/kg divided in 4-5 daily doses), started at median age of 14 months (range 7-22
months). Median creatinine clearance was 48 ml/min/1.73 m2 (range 21-61). Urinary
excretion of albumin and α-1 microglobulin (α-1 MG) as well as arterial blood pressure,
serum creatinine and creatinine clearance were evaluated before and at 3 months on oral
administration of enalapril (0.15 mg/kg once daily). Creatinine clearance was also con-
trolled 3 months after the discontinuation of enalapril. Blood pressure was measured in
supine position by Dinamap (Criticon, Tampa, FL). The lowest value of 3 consecutive
readings was used for further analysis. Wilcoxon signed-rank test was applied for statis-
tical analysis. Differences were considered statistically significant at p<0.05.
Results
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Table 1 Influence of enalapril on blood pressure, the excretion of albumin, α-1 microglobulin and  creati-
nine clearance of cystinotic patients with Fanconi syndrome.
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Albuminuria diminished in all patients. The median reduction of albuminuria was 43%
(range: 4-72%, p<0.05) (Figure 1a). The urinary excretion of α-1 MG statistically
remained unchanged (Figure 1b).
Systolic blood pressure decreased from median 110 to 100 mm Hg (p<0.05), while dias-
tolic blood pressure remained stable (median 60 mm Hg). Two patients had complaints
related to the lowed blood pressure such as fatigue and dizziness.
Creatinine clearance decreased from median 48 ml/min/1.73 m2 (range 21-61) to 45
ml/min/1.73 m2 (range 15-55) (p<0.05). The most apparent rise in serum creatinine
occurred in patients 1 and 2 with creatinine clearance below 25 ml/min/1.73 m2. After
the discontinuation of enalapril creatinine clearance returned to the base line in all
patients (median: 51, range: 21-68).
Discussion
It is established that the intervention in the renin angiotensin system reduces proteinuria
and slows the progression of renal insufficiency independently of blood pressure correc-
tion [Ruggenenti et al. 2001]. Although it is presumed that anti-proteinuric effect of ACE
inhibitors reflects changes in intraglomerular haemodynamics, the influence of these
drugs on nephrin expression may be important for the reduction of glomerular hyper-
permeability [Benigni et al. 2001, Kelly et al. 2002, Davis et al. 2003].































Figure 1 In patients with cystinosis, influence of enalapril on
a. albuminuria excretion; b. α-1 microglobulin excretion
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This issue as far as we know has never been addressed in patients with cystinosis. As
albuminuria is constantly found in urine of patients with cystinosis, we hypothesised that
it might contribute to the development of the chronic interstitial inflammation and
fibrosis, leading to renal failure [Gubler et al. 1999], even on cysteamine therapy. Although
it is unknown to which degree albuminuria contributes to the development of intersti-
tial fibrosis in cystinotic patients, the reduction of albuminuria could mitigate the loss of
kidney function in these patients.
Our study shows that albuminuria was significantly decreased in all patients 3 months
on the administration of the ACE-inhibitor enalapril. Interestingly, only a slight decline
(4%) was observed in patient 5 with the highest creatinine clearance (61 ml/min/1.73
m2) and lowest albumin excretion, indicating that the contribution of glomerular albu-
minuria is probably low in this patient. The fact that albuminuria decreases, while the
excretion of low molecular proteins remains stable, favours an effect of enalapril on the
glomerular leakage of albumin.
A strong association exists between acute increase of serum creatinine of up to 30%
within first months on ACE therapy and long-term preservation of renal function in
patients with diabetic and non-diabetic renal disease [Bakris et al. 2000]. The most common
course of this acute rise in serum creatinine level is a decreased effective arterial blood
volume, obviously present in cystinotic patients, having sodium loss and polyuria. In our
group, creatinine rise was most obvious in 2 patients with creatinine clearance below 25
ml/min/1.73 m2. These changes were transient and the discontinuations of enalapril
resulted in return to the base line in all patients. Even a low dose of enalapril should be
used with caution in normotensive patients with cystinosis, especially in those with a
severe degree of renal insufficiency, warranting frequent monitoring of serum creatinine.
We can speculate whether the administration of angiotensin II (ATII) receptor block-
er would result in less hypotensive effect in this patient’s group. In pre-clinical studies
ACE-inhibitors and ATII receptor blocker were shown to have similar effect on glomeru-
lar capillary pressure  [Lafayette et al. 1992]. In clinical settings it was suggested that ACE-
inhibitors have a slightly more hypotensive effect [Gansevoort et al. 1999].
In summary, we have demonstrated that the ACE-inhibitor enalapril diminishes albu-
minuria in patients with cystinosis and might be used in these patients in order to slow
the progression of renal insufficiency attributed to proteinuria.
CHAPTER 5
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Negligible urinary cysteamine loss in 
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Abstract
Background/Aims: Cystinosis is an inborn error of lysosomal cystine transporter, result-
ing in cystine accumulation in lysosomes of all cells. Renal Fanconi syndrome is an early
sign of kidney involvement in cystinosis patients. Cysteamine, a small amino thiol,
depletes intralysosomal cystine content and reduces organ damage. However, it does not
reverse renal Fanconi syndrome and only postpones the progression to renal failure. We
examined whether cysteamine could be lost in urine of cystinosis patients with Fanconi
syndrome, which may explain the inefficiency of treatment. Urinary cysteamine loss was
studied in cystinosis patients with and without Fanconi syndrome.
Patients and methods: Urine of 6 cystinosis patients was collected during 6 hours fol-
lowing a morning gift of cysteamine. Four patients had renal Fanconi syndrome, 2
patients were transplanted and had no Fanconi syndrome. Each urine sample was exam-
ined for cysteamine,α-1 microglobulin and creatinine. Cysteamine was determined, after
reduction of all disulfides with dithioerythriol and sodiumboriumhydrate, by HPLC.
Results: The administered morning doses of cysteamine ranged 150-1000 mg (40-150
mg/kg/day). All four patients with renal Fanconi syndrome had high alpha-1 microglob-
ulin excretion. One transplanted patient had a normal α-1 microglobulin excretion. In
all patients urine cysteamine excretion ranged 0.9-7.2 mg/portion, which was less that
1% of the ingested dose.
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Introduction
Cystinosis is an autosomal-resessive defect of the lysosomal cystine carrier, resulting in
accumulation of free amino acid cystine in lysosomes [Gahl 1986]. Renal Fanconi syn-
drome is an early sign of kidney involvement in cystinosis. Long-term therapy with the
amino-thiol cysteamine depletes intralysosomal cystine content and reduces organ dam-
age, the rate of progression to renal failure and improves growth [Gahl et al. 1985, Schneider
et al. 1995]. However, treatment with cysteamine does not reverse the renal Fanconi syn-
drome in cystinosis patients. Cysteamine is a small amino-thiol with a molecular weight
of 77.14, which could be lost in urine of cystinosis patients with renal Fanconi syndrome,
resulting in insufficient cystine depletion in proximal tubular cells.
The aim of this study was to estimate urinary cysteamine loss in cystinosis patients
with and without Fanconi syndrome, treated with cysteamine.
Patients and methods
Urine of 6 cystinosis patients, 6-13 years old, was collected during 6 hours following
morning gift of phosphocysteamine or cysteamine bitartrate (Cystagon®). Four patients
had renal Fanconi syndrome, 2 transplanted patients had no Fanconi syndrome: one with
well functioning renal graft and the other with pre-terminal renal failure. Each urine
sample was examined for cysteamine, alpha-1 microglobulin and creatinine content.
Cysteamine was determined according to Fiskerstrand et al. [1993] with some modi-
fications [de Graaf-Hess et al. 1999]. In short, all disulfides are reduced by dithioerythri-
ol  and sodiumboriumhydrate. Next all free thiol groups are derivatized by Thiolyte,
resulting in fluorescent compounds which are separated by HPLC with reverse-phase
column and quantified by a fluorometer. Figure 1 shows the typical HPLC elution pat-
terns.
Creatinine was measured by a standard procedure. α-1 microglobulin was measured
by a immunonephelometry.
Negligible urinary cysteamine loss in cystinosis
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Results
Data of the patients are presented in a table 1. The orally administered morning doses of
the cysteamine ranged 150-1000 mg (40-150 mg/kg/day). All four patients with renal
Fanconi syndrome had high α-1 microglobulin excretion. One transplanted patient had
normal α-1 excretion. Urine cysteamine excretion ranged 12.7 - 99.5 µmol/l. Knowing
the molecular weight of cysteamine and urine volume during 6 hours collection, we cal-
culated cysteamine excretion per 6 hours, which was 0.9-7.2 mg, which was less than 1%
of ingested morning doses. The highest cysteamine excretion was observed in a patient
KK, who has well functioning renal graft.
Discussion
Cysteamine treatment of cystinosis patients does not restore the renal Fanconi syndrome
and in most patients only postpones the development of renal failure. Theoretically, oral-
ly ingested cysteamine could be lost in urine of patients with Fanconi syndrome and
resulted in insufficient cystine depletion in proximal tubular cells.
CHAPTER 6
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Figure 1 HPLC chromatograms of thyolyte derivatized thiols in urine of patient SE. Cysteamine peak at
10.15 min
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Our patients received recommended dose of cysteamine [Gahl 1999], which was adjust-
ed to leukocyte cystine content 4 times/year. We found that less than 1% of ingested cys-
teamine was excreted in urine. Our data confirms those of Jonas Schneider et al. [1982],
who measured 24 hours cysteamine excretion in 5 cystinosis patients, receiving an aque-
ous solution of cysteamine, which is less stable than phosphocysteamine or cysteamine
bitartrate, administered in our patients. They applied an indirect method for cysteamine
measurement, using the binding of cysteamine in patients plasma or urine with radiola-
beled cystine thiosulfonate [Jonas et al. 1981].
It was shown that plasma cysteamine is less than 20 % protein bound [Smolin et al.
1988]. This fraction could be lost in urine bound to albumin as in 4 cystinosis patients
with Fanconi syndrome an  increased albumin excretion (0.173-2.7g/24 hour) was found
(own unpublished data). However, using our method, total urine cysteamine could be
determined, which excludes that  protein-bound fraction was missed.
Finally, we may conclude that negligible urinary cysteamine loss occurs in cystinosis
patients with and without Fanconi syndrome.
CHAPTER 6
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CHAPTER 7
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Strict cysteamine dose regimen is 
required to prevent nocturnal cystine 
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Abstract 
Cystinosis is an autosomal recessive disorder, caused by mutations in the lysosomal cys-
tine carrier cystinosin, encoded by the CTNS gene. The disease generally manifests with
Fanconi syndrome during the first year of life and progresses towards end stage renal dis-
ease before the age of 10 years. Cysteamine depletes intralysosomal cystine content, post-
pones the deterioration of renal function and the occurrence of extra-renal organ dam-
age. Based on the pharmacokinetic data, patients with cystinosis are advised to use cys-
teamine every 6 h. The aim of this study was (1) to evaluate the cysteamine dose regimen
in Dutch patients with cystinosis and (2) to determine morning polymorphonuclear
(PMN) leukocyte cystine content 6 h vs 9 h after the last evening cysteamine dose. Only
5/22 of Dutch cystinosis patients ingested cysteamine every 6 h. Morning (8 a.m.) PMN
cystine content in 11 examined patients was elevated 9 h after 12.5–15 mg/kg evening
cysteamine dose compared to the value 6 h after the ingestion of the same dose (0.73±
0.81 nmol vs 0.44 ± 0.52 nmol cystine/mg protein, p=0.02). In conclusion, only the
minority of Dutch cystinosis patients follows the recommended strict cysteamine dose
regimen. We provide evidence that cysteamine has to be administered every 6 h, includ-
ing the night, as it has much better effect for maintaining low PMN cystine levels.
CHAPTER 7
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Introduction
Cystinosis is a rare autosomal recessive disorder caused by a defect in the lysosomal cys-
tine carrier cystinosin, encoded by the CTNS gene [Kalatzis et al. 2001, Town et al.1998]. Cystine
accumulation due to impaired cystine exit from the lysosomes in all tissues causes a
multi-organ disease, with kidneys being clinically first affected. In general patients with
cystinosis manifest with poor growth and generalized proximal tubular dysfunction
(Fanconi syndrome) during the first year of life and develop end stage renal disease
before the age of 10 years. Longer survival of these patients due to renal transplantation
reveals extrarenal organ damage, such as hypothyroidism, diabetes mellitus, hypogo-
nadism, peripheral and central neuropathy, distal myopathy and retinal blindness, usual-
ly becoming apparent after the first decade [Gahl et al. 2001, Gahl et al. 2002].
In 1976 Thoene et al. demonstrated that the aminothiol cysteamine lowered leukocyte
cystine content in cystinosis patients [Thoene et al. 1976]. Cysteamine depletes intralysosomal
cystine via disulfide exchange reaction with cystine resulting in a formation of cysteine and
cysteine-cysteamine mixed disulfide, which exit the lysosomes via cysteine and lysine carri-
ers, respectively, therefore bypassing the defective cystine carrier [Pisoni et al. 1985] (Figure 1).
Cysteamine dose regimen in cystinosis  
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Figure 1 Disulfide exchange reaction between cysteamine and cystine, resulting in for-
mation of free cysteine and cysteine-cysteamine mixed disulfide, exiting the lysosome
via cysteine and respectively lysine carriers
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To diagnose cystinosis and to monitor cysteamine treatment, cystine determination in
the leukocytes is mandatory. Although cystine content of leukocytes might not com-
pletely reflect the accumulation in the other organs, the levels below 1 nmol 1/2 cys-
tine/mg protein (= 0.5 nmol cystine/mg protein) are considered to reflect an adequate
cysteamine dose [Gahl et al. 2001, Gahl et al. 2002, Kleta et al. 2005]. Cysteamine treatment slows
the deterioration of renal function, improves growth and should be continued also after
renal transplantation, in order to postpone the occurrence of extrarenal damage [Gahl et
al. 2001, Gahl et al. 2002, Kleta et al. 2005, Markello et al. 1993, Sonies et al. 2005]. Unfortunately, renal
Fanconi syndrome generally remains irreversible, and some of the patients still develop
renal insufficiency and extrarenal complications, despite cysteamine treatment.
Because intracellular leukocytes’ cystine content decreases to the minimal levels about
2 h after cysteamine ingestion and then returns to pre-dose levels 6 h after the drug
intake, the adequate cysteamine dose regimen implies the administration of the drug
every 6 h [Smolin et al. 1988, Belldina et al. 2003]. This dose regimen, however, is extremely dif-
ficult to follow, especially at night. We assumed that the nocturnal cystine accumulation
might be partially responsible for the ineffectiveness of cysteamine therapy in some
patients and, therefore, we evaluated the current cysteamine dose schedule in a Dutch
cohort of cystinosis patients. Additionally, we compared morning polymorphonuclear
(PMN) leukocyte cystine content after 6 h vs 9 h night pause following the last evening
cysteamine ingestion. PMN leukocytes were used instead of mixed leukocyte prepara-
tions, as cystine preferentially accumulates in these cells and not in the lymphocytes
[Smolin et al. 1987, Levtchenko et al. 2004].
Patients and methods
Questionnaire
Twenty-two patients aged 14.7 ± 9.7 years, 14 males, filled out the questionnaire con-
cerning the schedule of cysteamine bitartrate (Cystagon®) intake. The diagnosis of cysti-
nosis was made in all patients, presenting with renal Fanconi syndrome, by determina-
tion of elevated PMN cystine content and finding of corneal cystine crystals.
CHAPTER 7
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Comparison of morning polymorphonuclear cystine content 9 h vs 6 h night pause
after evening cysteamine intake
In 11 compliant patients, after signing informed consent, 12.5–15 mg/kg cysteamine
bitartrate was administered four times daily:
1. During the first week at 8 a.m., 2 p.m., 8 p.m., and 2 a.m.
2. During the second week at 8 a.m., 1 p.m., 6 p.m. and 11 p.m.
At the end of each week, blood samples were taken at 8 a.m. for PMN cystine dosage prior
to the ingestion of the first morning cysteamine dose.
Intracellular cystine content of PMN cells was determined by high-performance liq-
uid chromatography (HPLC) as described previously and expressed in nmol cystine/mg
protein (cystine concentration x 2 = 1/2 cystine concentration) [Levtchenko et al. 2004, de
Graaf et al. 1999].
Statistical analysis
Data are presented as mean ± SD. To compare data between patients following strict
(every 6 h) Cystagon® dose schedules and those not taking the drug during the night,
unpaired student t-test was applied. To compare morning intracellular PMN cystine val-
ues 6 h versus 9 h night pause after the last evening Cystagon® dose, paired student t-test
was applied. Values were considered statistically significant at p<0.05.
Results
Questionnaire
Five patients (23%) followed the strict Cystagon® dose regiment (group 1). Seventeen
patients (group 2) received Cystagon® only during the wake time. Patients of group 1
were younger compared to those of group 2 (7.5± 2.7 years vs 15.8± 9.2 years, p=0.004).
Daily Cystagon® dose was not different between the two groups. The night pause
between the last evening/night and the first morning Cystagon® ingestion was signifi-
cantly longer in patients from group 2 (8.9± 2.0 h vs 6.1± 0.7 h, p=0.001). Mean PMN
cystine content (the average of all determinations during 2004), determined 5–6 h after
Cysteamine dose regimen in cystinosis  
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Cystagon® ingestion, was significantly higher in patients of group 2 compared to group
1 (0.6± 0.3 nmol vs 0.37± 0.13 nmol cystine/mg protein, p=0.02) (Table 1). No relation
between the age of the patients and mean PMN cystine content could be detected.
Intracellular PMN cystine content was determined four times yearly in all patients of
group 1. In patients of group 2 it was determined four times yearly in eleven, three times
in two and two times in four patients.
Comparison of morning polymorphonuclear cystine content 9 h vs 6 h after
evening cysteamine intake
In 11 examined patients, morning PMN cystine content after 9 h night pause following
the evening cysteamine dose (12.5–15 mg/kg) was significantly elevated compared to the
PMN content 6 h after the ingestion of the same dose (0.73 ± 0.81 nmol vs 044 ± 0.52
nmol cystine/mg protein, p=0.02) (Figure 2).
Discussion
Cysteamine is the only available cystine-depleting drug, postponing the deterioration of
the renal function, improving growth and delaying the occurrence of extrarenal compli-
cations in patients with cystinosis. To achieve the maximal effectiveness of the treatment,
the following recommendations have to be followed [Kleta et al. 2005, Schneider 2004]:
1. Starting cysteamine as early in life as possible (target dose 60–90 mg/kg/day or





Table 1  Clinical data on Dutch patients following strict (every 6 hours) Cystagon®dose regiment (Group 1)
and patients receiving Cystagon® only during the wake time (Group 2).
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2. Administering cysteamine every 6 h
3. Frequent monitoring of leukocyte cystine content
4. Obtaining blood for cystine determination 5–6 h after cysteamine ingestion
The most difficult recommendation to follow is to administer cysteamine every 6 h,
which means that at least one cysteamine dose should be taken during the night. The
nocturnal accumulation of cystine in patients who do not follow the strict 6 h dose reg-
imen might be responsible for the relative ineffectiveness of the treatment.
In this study, we evaluated actual cysteamine treatment schedule in 22 Dutch patients
with cystinosis. The medical advice to administer cysteamine every 6 h was respected
only by the minority of the patients (23%). In patients following the strict cysteamine
dose regimen, average PMN cystine content was significantly lower compared to the
other patients, despite the fact that their daily cysteamine doses were comparable.
Despite the evident pharmacokinetic data [Smolin et al. 1988, Belldina et al. 2003], many
patients and even many physicians do not realize that 2–3 h extra night pause may cause
a significant cystine accumulation. Our study demonstrates that the administration of
the same daily cysteamine dose distributed equally during 24 h results in significantly
lower morning PMN cystine content, compared to the “only wake-time” regimen,
applied by the majority of the patients.
Although it is unknown whether leukocyte cystine content reflects cystine accumula-
tion in the other tissues, it can be suggested that in patients ingesting cysteamine only
during the wake time, nocturnal accumulation of cystine may occur in the other organs.
Well preserved creatinine clearance in two siblings 15 years and 8 years old with infan-

























Figure 2 Morning polymorphonuclear
cystine content (mean+SD) in 11 exa-
mined patients 6 h vs 9 h night pause
following the last evening/night
Cystagon® ingestion
bw.levtchenko  12-02-2006  15:13  Pagina 77
tile cystinosis adequately treated with cysteamine, starting from early age, supports the
idea that a dose regimen of every 6 h is necessary for the preservation of renal function
[Kleta et al. 2004].
All well-treated patients from our Dutch cohort were relatively young, meaning that
their parents were responsible for the compliance with therapy. During puberty, it often
becomes difficult to convince the patient to continue with the strict cysteamine dose reg-
imen, especially taking into account the annoying side effects of the drug, such as bad
breath odor and gastrointestinal discomfort. The latter side effect, caused by an increased
secretion of gastric acid after cysteamine ingestion, can be successfully treated by proton-
pump inhibitors [Dohil et al. 2003]. Some breath odor improving drugs such as chlorophyll
or essential oils (Breath Assure®) are used by some cystinosis patients, helping to improve
their compliance.
Interestingly, in all patients following a strict dose regimen, PMN cystine determina-
tion was performed four times per year compared to the less frequent measurements in
7/18 of the other patients, suggesting better awareness and responsibility of the physi-
cians treating these patients.
In conclusion, cysteamine treatment is effective in reducing cystine accumulation in
cystinosis when taken on a regular basis. We have provided additional evidence that cys-
teamine has a much better effect in maintaining low PMN cystine levels when taken every
6 h, including during the night.
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Abstract
Cystinosis, an autosomal recessive disorder due to a defective cystine exit out of the lyso-
somes, is a major cause of inherited Fanconi syndrome in childhood. The causative gene
CTNS (17p13) encodes the lysosomal cystine carrier cystinosin. The pathogenesis of
cystinosis is poorly understood and ATP depletion is suggested based on the studies of
proximal tubules loaded with cystine dimethyl ester.
We describe a patient with cystinosis from the age of 3 weeks who demonstrated grad-
ual development of Fanconi syndrome during the first 6 months of life. The absence of
complete Fanconi syndrome and cystine content of white blood cells within the het-
erozygote range led to a delay of the diagnosis of cystinosis. Gradual deterioration of
proximal tubular dysfunction contrasts an immediate appearance of transport defects
after cystine dimethyl ester loading and therefore in our opinion contradicts the hypoth-
esis of ATP depletion being a central player in the pathogenesis of cystinosis. Further
studies are required to explain differential sensitivity of proximal tubular transporters to
cystine accumulation. Additionally, we would like to stress that treatment with cystine
depleting agent cysteamine, should be started as soon as possible as full-blown Fanconi
syndrome is not present at birth and might be prevented.
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Introduction
Cystinosis is an autosomal recessive lysosomal storage disease due to a defect of CTNS
gene (17p13) encoding the lysosomal membrane protein cystinosin [Gahl et al. 2002]. While
the function of cystinosin has been elucidated [Kalatzis et al. 2003], the explanation of the
clinical symptoms of cystinosis remains enigmatic. It is generally accepted that the lyso-
somal accumulation of cystine induces in some way a decrease in intracellular ATP, which
would diminish sodium-coupled transport in the proximal tubular cells. Renal proximal
tubules loaded with cystine dimethyl ester displayed an impaired oxidative phosphoryla-
tion and reduction of intracellular ATP [Foreman et al. 1987, Coor et al. 1991, Baum 1998]. A
direct proof for ATP depletion as a keystone in the pathogenesis of cystinosis is lacking.
The clinical symptoms observed in cystinotic patients do not directly underpin this
hypothesis. We investigated the renal function of a patient with proven defect in CTNS
during the first 6 months of life, demonstrating gradual development of proximal tubu-
lar dysfunction.
Case report
A male sibling of a patient with cystinosis, born after an uneventful pregnancy with a
birth weight of 3720 gram, presented at the age of 3 weeks at the outpatient clinic with a
weight of 4210 gram in a perfect clinical condition. Laboratory investigations showed
normal values for serum creatinine, potassium, phosphate and bicarbonate (table 1) and
mild aminoaciduria (table 2). The mixed leukocyte cystine content was within the het-
erozygote range 0.15 nmol/mg protein (normal 0.09±0.03). Cystine measurement in
polymorphonuclear leucocytes, a superior method [Levtchenko et al. 2004], was not per-
formed. At the age of 6 months he weighted 8260 gram and his serum concentrations of
phosphate and bicarbonate were decreased. The cystine content in the mixed leukocyte
was 0.14 nmol/mg protein. As the tubular abnormalities became more severe, a skin
biopsy was performed to determine cystine content in skin fibroblasts, demonstrating
clearly an elevated value: 1.6 nmol/mg protein (normal 0.10±0.07). The diagnosis of
cystinosis was made and cysteamine treatment was started. Molecular analysis demon-
strated a homozygous 57kb deletion of CTNS gene, confirming the diagnosis. Actually he
is 8 years old, has a creatinine clearance 75ml/min/1.73 m2 and a persistent Fanconi syn-
drome.
The clinical and laboratory data are presented in tables 1-3.
Development of Fanconi syndrome in cystinosis
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Table 1. Clinical and laboratory data of the patient.
*References values from N. Webb & R. Postlethwaite ed.  “Clinical paediatric nephrology” 3rd
edition, Oxford, 2003, p. 494-503
** Reference value from Lehrnbecher et. al. Pediatr Nephrol 1998; 12: 290-292
Table 2. Amino acid excretion (mmol/mmol creatinine)
ecnerefeRshtnom 6shtnom 3skeew 3egA
04-91224292eniditsihlyhtem-3
7-05182etarytubonima-a























Table 1  Clinical and laboratory data of the patient.
Table 2  Amino acid excretion (mmol/mmol creatinine).
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Discussion
As far as we know this is the first detailed report, demonstrating gradual appearance of
Fanconi syndrome in an infant with cystinosis.
Excellent reports of Brodehl et al. previously demonstrated a disturbed phosphate
reabsorption and hyperaminoaciduria already at the age of 4 1/2 months [Brodehl et al. 1965,
Hagge et al. 1965]. Reznik et al. [1991] described proximal tubular dysfunction in 3 infants
with cystinosis 6-8 months old both having decreased phosphate and amino acid reab-
sorption. These studies, however, did not provide longitudinal data on the development
of Fanconi syndrome during infancy.
In our patient full-blown Fanconi syndrome developed gradually during the first 
6 months of life as reflected by the lowering of serum bicarbonate, a defect in the reab-
sorption of phosphate and more pronounced aminoaciduria and glucosuria. Gradual
deterioration of proximal tubular function can be related to progressive morphologic
changes of proximal tubules in cystinotic patients. While no significant changes were
observed in the fetus [Gubler et al. 1999], typical proximal tubular atrophy called “swan
neck” deformity was demonstrated by serial biopsies of 2 cystinotic patients only after the
age of 6 months [Mahoney et al. 2000].
Although this is a single case, our observation indicates differential sensitivity of api-
cal proximal tubular transporters to cystine accumulation. Gradual development of
Development of Fanconi syndrome in cystinosis
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Table 3. Monosaccharides and polyoles excretion (mmol/mmol creatinine)
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Fanconi syndrome during the first 6 months of life contrasts with the rapid appearance
of disturbed tubular transport after loading of proximal tubules with cystine
dimethylester (CDME). CDME loading during 10-30 minutes caused a pronounced
inhibition of proximal tubular transport and a drastic inhibition of mitochondrial ATP
production [Foreman et al. 1987, Coor et al. 1991], suggesting that CDME might have a direct
unrelated to cystine accumulation effect on mitochondria. Interestingly, 10 minutes
incubation of isolated mitochondria with CDME resulted in a significant inhibition of
mitochondrial oxygen consumption with glutamate and not with succinate, possibly
reflecting an inhibitory effect on the respiratory chain complex I, as succinate enters res-
piratory chain beyond complex I [Foreman et al. 1995]. A detailed study of energy metabo-
lism in human cystinotic tissues is required to answer the question whether mitochon-
drial ATP synthesis is disturbed in cystinosis. Furthermore, recently proposed alternative
pathogenetic mechanisms such as enhanced apoptosis [Park et al. 2002] and altered glu-
tathione metabolism [Levtchenko et al. 2005] should be further investigated. A new technique
of proximal tubular cell culture from urine of cystinotic patients allows obtaining these
cells for metabolic research [Laube et al. 2005].
Another intriguing observation, requiring explanation, is the specific excretion pat-
tern of sugars and polyols in this patient. While urinary concentration of glucose, galac-
tose, myo-inositol and erythriol were elevated, the excretion of the other monosaccha-
rides remained normal (table 3). ATP dependent, Na-coupled transport of glucose, galac-
tose and myo-inositol should be altered in this patient, while the non-Na-coupled trans-
port of fructose is probably not affected [Wright et al. 2004].
Probably the most important message of this report is the possibility of missing the
diagnosis of cystinosis in a young infant. Naturally because our patient was a sibling of a
known patient with cystinosis and had already at the age of 3 weeks signs of mild proxi-
mal tubular dysfunction, the diagnosis of cystinosis was highly suspected. However, total
white blood cell cystine content being within the heterozygote range did not allow mak-
ing the diagnosis. The other possible explanations of aminoaciduria such as galac-
tosemia, vitamin D deficiency, UTI, Lowe syndrome were all excluded. Finally the diag-
nosis of cystinosis was made at the age of 6 months due to the determination of the ele-
vated cystine content in cultured fibroblasts, and was confirmed later by molecular analy-
sis of CNTS gene. Delayed diagnosis of cystinosis in this case motivated a study compar-
ing cystine determination in total white blood cell preparations and polymorphonuclear
cells, which demonstrated that polymorphonuclear cells should be preferentially used for
the diagnosis of cystinosis and for monitoring of cysteamine therapy [Levtchenko et al. 2004].
Early diagnosing of cystinosis is extremely important for the immediate initiation of
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treatment with cystine depleting agent cysteamine. Cysteamine should be started as soon
as possible as it may prevent the deterioration of glomerular filtration rate, improves
growth, protects the impairment of extra-renal organs [Gahl et al. 2002] and in some
patients can even diminish renal tubular dysfunction [da Silva et al. 1985, Kleta et al. 2004].
In conclusion, gradual development of Fanconi syndrome in an infant with cystnosis
requires further studies explaining a differential sensitivity of proximal tubular trans-
porters to cystine accumulation. Furthermore, in suspected patients we recommend
immediate cystine determination in polymorphonuclear cells.
Development of Fanconi syndrome in cystinosis
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Abstract
Cystinosis is an autosomal recessive lysosomal storage disorder caused by a defect in the
lysosomal cystine carrier cystinosin. Cystinosis is the most common cause of inherited
Fanconi syndrome leading to renal failure, in which the pathogenesis is still enigmatic.
Based on studies of proximal tubules loaded with cystine dimethyl ester, altered mito-
chondrial ATP production was proposed to be an underlying pathological mechanism.
Thus far, however, experimental evidence supporting this hypothesis in humans is lack-
ing. In this study, energy metabolism was extensively investigated in primary fibroblasts
derived from eight healthy subjects and eight patients with cystinosis. Patient’s fibroblasts
accumulated marked amounts of cystine (median, range: 4.3 (2.7-5.5) versus 0.2 (0.1-
0.3) nmol/mg protein, p<0.001). Moreover, they displayed a significant decrease in intra-
cellular ATP content (median, range: 37.3 ( 26.9-55.0) versus 51.5 (44.7-58.5) nmol/mg
protein, p<0.05). Remarkably, however, overall energy generating capacity, activity of res-
piratory chain complexes, ouabain-dependent rubidium uptake, reflecting Na,K-ATPase
activity, and bradykinin-stimulated mitochondrial ATP production were all normal in
these cells.
In conclusion, the data presented demonstrate that mitochondrial energy generating
capacity and Na,K-ATPase activity are intact in cultured cystinotic fibroblasts, thus ques-
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Introduction
Cystinosis is an autosomal recessive lysosomal storage disorder caused by a defect in the
lysosomal cystine carrier cystinosin, encoded by the CTNS gene (17p13) [Kalatzis et al.
2001]. Intralysosomal accumulation of cystine virtually in all tissues leads to a multi-
organ disease with kidneys being clinically first affected. Patients with cystinosis mostly
present with generalized proximal tubular dysfunction (Fanconi syndrome) during the
first year of life and, when untreated with the cystine depleting agent cysteamine, devel-
op end stage renal disease before the age of 10 years [Gahl et al. 2002].
Because proximal tubular cells are highly metabolic active [Klahr et al. 1992], the appear-
ance of Fanconi syndrome as a first clinical sign in cystinosis points to disturbances in
energy metabolism in these patients. This idea is substantiated by the occurrence of
Fanconi syndrome in patients with mitochondrial disorders [Niaudet et al. 1996].
Although lysosomal accumulation of cystine in cystinosis was demonstrated already
in the 60s [Schulman et al. 1969], studies on the pathogenesis of this disease were initially
hampered by the absence of a proper in vitro model of lysosomal cystine accumulation.
This issue was solved with the introduction of dimethyl esters of amino acids, which
readily passed the lysosomal membrane and, once inside the organelle, were rapidly
degraded by lysosomal hydrolases to yield free amino acid and methanol thus allowing
amino acid loading of the lysosomes [Goldman et al. 1973, Reeves 1979]. Cystine dimethyl ester
(CDME) loading of intact leukocytes, cultured lymphoblasts and fibroblasts established
defective cystine exodus from the lysosomes as basic defect in cystinosis [Gahl, Tietze et al.
1982, Jonas, Smith et al. 1982, Pisoni et al. 1985].
Subsequently, CDME loading of proximal tubular cells was used for studying the
pathogenesis of Fanconi syndrome in cystinosis. Foreman et al. demonstrated that incu-
bation of rat cortical tubules with CDME increased intracellular cystine concentrations
to values comparable to those measured in patients with cystinosis and inhibited active
amino acid and glucose transport [Foreman et al. 1987]. CDME loading of rabbit proximal
tubules perfused in vitro resulted in decreased transepithelial potential difference and
inhibition of volume absorption, active glucose and bicarbonate transport, mimicking
renal Fanconi syndrome in cystinosis [Salmon et al. 1990].
ATP depletion was postulated to be responsible for inhibition of active transport in
proximal tubular cells as dramatic decreases in ATP content and mitochondrial respira-
tion rate were demonstrated after CDME loading [Coor et al. 1991, Baum 1998]. Because most
proximal tubular transport is sodium coupled, less fuel for the Na,K-ATPase on the baso-
lateral membrane will lower the sodium electrochemical gradient thus inhibiting trans-
ATP metabolism in cystinotic fibroblasts
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port across the apical membrane. Consistent with this idea, cystine-loaded porcine
epithelial tubular cells (LLC-PK1) showed a diminished activity of Na,K-ATPase, demon-
strated by reduced rubidium uptake, leading to increased sodium and decreased potassi-
um concentrations inside the cells [Ben-Nun et al. 1993].
Although ATP depletion as a keystone for the pathogenesis of cystinosis is well docu-
mented in the CDME loading model, it has not yet been proved in human cystinotic tis-
sues. Furthermore, the possible link between intralysosomal cystine accumulation and
ATP depletion is still unknown.
Cultured cystinotic skin fibroblasts are known to accumulate cystine [Guillet et al. 1998]
and are easily available via skin biopsy in patients with cystinosis. Because a metabolic
defect caused by cystine accumulation has to be present in all body tissues, we used
cystinotic fibroblasts to investigate the energy metabolism in cystinosis. The latter was
done by determining total intracellular ATP content, overall mitochondrial energy gen-
erating capacity, activity of mitochondrial respiratory chain complexes I, II, III and IV ,
maximal bradykinin-stimulated mitochondrial ATP production and ouabain-dependent
rubidium uptake in primary skin fibroblasts derived from patients with cystinosis com-
pared to control fibroblasts.
Subjects and methods
Patients
The study was approved by the Institutional Review Board. Skin biopsies were performed
after obtaining informed consent in 8 patients with cystinosis prior to starting of cys-
teamine therapy and in 8 healthy subjects. In all patients cystinosis manifested with renal
Fanconi syndrome at the age of 6-18 months. The diagnosis of cystinosis was made by
measuring an elevated cystine content in polymorphonuclear cells (>0.5 nmol cys-
tine/mg protein) and was confirmed by molecular analysis of CNTS in all patients.
Fibroblast’s cell culture, isolation of polymorphonuclear leukocytes and 
intracellular cystine measurements
Skin fibroblasts were cultured in custom made M199 medium with Tween-20 (5mg/L,
Gibco) supplemented with fetal calf serum (10%), penicillin (100 U/ml, Gibco) and
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streptomycin (100U/ml, Gibco). Polymorphonuclear leukocytes were isolated as
described previously [Levtchenko et al. 2004]. Intracellular cystine was determined by high
performance liquid chromatography (HPLC) and expressed as nmol cystine/mg protein
[Levtchenko et al. 2004].
Measurement of total intracellular ATP content
Cystinotic and control fibroblasts were grown to confluence in 75 cm2 tissue culture
flasks (approximately 1.0x106 cells) and detached using trypsin. After washing in PBS cell
pellets were divided into two portions for duplo experiments, shock frozen in liquid N2
and stored at -80°C until use. Prior to ATP determination, pellets were resuspended on
ice in 0.5 ml cold PBS. A 25-fold diluted fraction (25µl) of the suspension was transferred
to a transparent microtiter plate and ATP was measured using ATP Bioluminescence
Assay Kit HSII (Roche®) according to the instructions of the manufacturer. The residue
of the undiluted cell suspension was used for protein determination using the method of
Lowry. Data are represented as mean of two separate experiments in nmol ATP/mg pro-
tein.
Analysis of metabolic origin of intracellular ATP
To investigate the metabolic origin of intracellular ATP in cultured fibroblasts, we mea-
sured the total intracellular ATP content after specific inhibition of glycolysis or the
oxidative phosphorylation pathway. To inhibit glycolysis, fibroblasts were incubated for
5hr at 37°C with 0.3mM sodium-iodoacetate (SIA), an inhibitor of glyceraldehyde-3-
phosphate dehydrogenase or 50mM 2-deoxyglucose (2-DOG), a competitor of glucose.
Glycolytic activity was determined in a 96 well plate assay by lactate production and was
more then 80% decreased by SIA and 2-DOG compared to the control conditions with-
out the inhibitors [Yang et al. 2004]. The inhibition of mitochondrial ATP production was
achieved by incubating fibroblasts for 5hr at 37°C with 1µM rotenone, which is a specif-
ic inhibitor of complex I, or with 1µg/ml antimycin A, a specific inhibitor of complex III,
inhibiting both succinate and NADH-dependent respiration [Dickman et al. 1990]. The via-
bility of the cells after the inhibition of glycolysis or mitochondrial ATP production was
assessed in a fluorescence assay using resazurin (0,01%) as a marker [Yang et al. 2004].
Following incubations with each of the inhibitors and with vehicle controls, intracellular
ATP content was determined.
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Measurement of overall oxidative phosphorylation (OXPHOS) activity in intact 
mitochondria
Intact mitochondria were isolated from fresh cultured fibroblasts (approximately 20x106
cells) according to Bentlage [Bentlage et al. 1996] and suspended in SEF buffer (0.25 M
sucrose, 10 mM KPi, 2 mM EDTA, pH 7.4). Overall energy generating capacity was deter-
mined by measuring 14CO2 production rates from oxidation of 14C labeled substrates
([1-14C]-pyruvate, [U-14C]-malate, [1,4-14C]-succinate and [1-14C 2-oxoglutarate) in
combination with several co-substrates. Oxidation rates were normalized against citrate
synthase (CS) activity and expressed as nmol 14CO2/h [Trijbels et al. 2004].
Measurement of the activity of respiratory chain complexes (I-IV) in intact
mitochondria 
Intact mitochondria were isolated as described above, aliquoted for separate measure-
ments of the respiratory chain complexes and stored at –80°C. With slight modifications,
complex I (NADH:Q1 oxidoreductase) activity was determined spectrofotometrically by
monitoring NADH oxidation at 340nm as described by Fischer [Fischer et al. 1986]. Activity
of complex III (Coenzyme Q10: cytochrome C oxidoreductase) was determined by mea-
suring the reduction of cytochrome C at 550 nm with reduced decylubiquinone as an
artificial substrate according to Bentlage et al. Complex II+III (succinate:cytochrome C-
oxidoreductase, SCC) activity was determined spectrofotometrically at 550nm by mea-
suring reduction of cytochrome C using succinate as a substrate in the presence of
rotenone and KCN to inhibit complex I activity and eliminate re-oxidation of
cytochrome C, respectively [Fischer et al. 1985]. Complex IV (cytochrome C oxidase, COX)
activity was determined by the method described by Cooperstein and Lazarow
[Cooperstein et al. 1951]. Mitochondrial citrate synthase (CS) activity was measured by a
method described by Srere [Srere et al. 1963] and expressed as mU/mg protein. Activities of
complexes I, II, III are expressed as mU/ U COX after normalization of the activity of
complex IV against that of CS.
Luminescence monitoring of bradykinin stimulated mitochondrial ATP production in
intact fibroblasts
To monitor mitochondrial ATP production, ~25,000 fibroblasts were seeded on a 13mm2
glass coverslip and cultured for 24 h. Cells were then infected with a baculovirus con-
taining the cDNA for mitochondria targeted luciferase generated as described by Visch
[Visch et al. 2004]. The cDNA was kindly provided by dr. G.A. Rutter [Ainscow et al. 2001]. After
48h of culture in the presence of 1.75 mM Na-butyrate, the coverslip was placed in the
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thermostated (37ºC) luminometer and perfused (3 ml/min) with a Hepes-Tris medium
(132 mM NaCl, 4.2 mM KCl, 1 mM MgCl2, 5.5 mM D-glucose, 10 mM Hepes, 1 mM
CaCl2, pH 7.4) containing beetle 5 µM luciferin (Promega). Luciferase luminescence was
monitored continuously using a custom build setup that consisted of a light shielded
low-noise photomultiplier tube (PMT) with a built-in H7360-1 amplifier-discriminator
(Hamamatsu Photonics K. K., Shizuoka-Ken, Japan). PMT output was monitored in time
using a PCI-6601 photon counting board (National Instruments, Austin, USA) coupled
to an IBM-compatible computer using custom written software (Drs. S.P. Srinivas and W.
van Driessche, Laboratory of Physiology, K.U. Leuven, Belgium). Light output was
recorded at 2 s intervals, after which the traces were smoothed off-line by using a 3-point
moving average (Origin pro 6.1, OriginLab Corporation, Northampton, MA, USA).
Typically, light output from a coverslip of fibroblasts expressing mitochondrial luciferase
was 500-1,500 counts/s with a background of 15 counts/s. At the indicated time, 1 µM
bradykinin was included in the perfusion medium for maximal stimulation of mito-
chondrial ATP production. Bradykinin releases Ca2+ from the endoplasmic reticulum
leading to a rapid increase in cytosolic and consequently intramitochondrial Ca2+ con-
centration, which, in turn, leads to an increase in activity of the pyruvate dehydrogenase
system, 2-oxoglutarate dehydrogenase and isocitrate dehydrogenase [Jouaville et al. 1999].
Results are expressed as the percentage increase in luciferase luminescence.
Measurement of the activity of Na,K- ATPase by Rb+ influx
86Rubidium (86Rb+), a congener of K+, uptake was measured to determine Na,K-ATPase
activity in cystinotic and control fibroblasts as previously described [Munzer et al. 1994].
Briefly, cells were grown to 40-60% confluence in 24 well plates, washed 3 times with
Rb+-transport medium (140mM choline choride, 6mM NaCl, 0.5mM MgCl2, 5mM glu-
cose, 4mM Na-Tris (pH 7.4)) and pre-incubated in 180µl of this  medium with or with-
out 10mM ouabain, a specific Na,K-ATPase inhibitor, for 5 min at 37°C. Uptake was
started by adding 20µl of a mixture of KCl (5mM) and 15µCi /ml 86Rb+ (8.6µM), fol-
lowed by 30 min of incubation at 37°C. Then, the medium was removed and cells were
washed 3 times with ice-cold Rb-transport medium. After solubilisation in 0.5ml NaOH
(0.2M) for 40 min, 0.4ml was used for liquid scintillation counting (Packerd). Ouabain
sensitive 86Rb+ uptake was expressed in nmol/mg protein/h. Control experiments with
10µM bumetanide (inhibitor of Na+,K+,2Cl- cotransport) showed no significant
ouabain-insensitive uptake (data not shown).
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Statistical analysis
Mann-Whitney U test was used for the comparison of values from cystinotic and control
cells. The correlation between two variables was estimated by a Spearman rank correla-
tion method. The differences were considered statistically significant at p<0.05.
Results
The intracellular cystine content was significantly elevated in cystinotic fibroblasts
(median, range: 4.3 (2.7-5.5) versus 0.2 (0.1-0.3) nmol/mg protein, p<0.001).
Data on intracellular ATP content, activity of mitochondrial respiratory chain enzyme
complexes I, II, III and IV and Na,K-ATPase activity are presented in Table 1.
Total intracellular ATP content and metabolic origin of intracellular ATP
The total ATP content in fibroblasts derived from patients with cystinosis was decreased
compared to the healthy controls (median, range: 38.8 (26.9-72.1) versus 51.5 (44.7-58.5)
nmol/mg protein, p<0.05). No significant correlation could be detected between intra-
cellular cystine accumulation and intracellular ATP content (Figure 1).
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Table 1 Intracellular cystine and ATP content (nmol/mg protein), activity of respiratory chain enzyme
complexes I, II, III (mU/mU COX), IV (mU/U CS) and activity of Na,K- ATPase (nmol/mg protein/ h) in
cultured skin fibroblasts.
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Additionally we determined intracellular ATP content in polymorphonuclear leukocytes
isolated directly from patients with cystinosis (n=15), treated with cysteamine (40-60
mg/kg/day), and compared the values with those derived from control subjects (n=18).
As in cultured cystinotic fibroblasts we detected a significant decrease of intracellular
ATP content in cystinotic versus control cells (median, range: 317 (149-1141) versus 557
(207-1101) nmol/mg protein, p<0.05) and no correlation between the intracellular cys-
tine and ATP content (Figure 2).
In order to investigate the relative contribution of glycolysis and mitochondrial oxidative
phosphorylation for ATP synthesis in cultured fibroblasts, we determined the intracellu-
lar ATP content after incubation of the cells with the inhibitors of glycolysis (SIA, 2-
DOG) and respiratory chain complexes (rotenon and antimycin A). Prior to determina-
tion of intracellular ATP content a cell viability test was performed showing that under
the used conditions the majority of cells (>90%) remained viable (data not shown).























Figure 1 Intracellular cystine and ATP
content in fibroblasts of patients with























Figure 2  Intracellular cystine and ATP
content in PMN cells of patients with
cystinosis (n=15, r=-0.02, p=0.9).
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As demonstrated in Figure 3, inhibition of the glycolysis resulted in a remarkable
decrease (>80%) of intracellular ATP content compared to vehicle control in both
cystinotic and control fibroblasts. After the inhibition of complex I by rotenone or com-
plex III by antimycin, less than 30% decline of initial intracellular ATP content was
observed in cystinotic and control fibroblasts. Cystinotic fibroblasts exhibited a slightly
more pronounced decline of intracellular ATP content due to the inhibition of respira-
tory chain complexes, but the difference with controls did not reach statistical signifi-
cance (Figure 3).
Overall energy generating capacity and activity of respiratory chain complexes of
isolated mitochondria and ATP production rate in intact cells
As shown in Table 2, comparable overall oxidation rates of [1-14C]-pyruvate, [1-14C]-
2-oxoglutarate, [U-14C]-malate and [1,4-14C]-succinate in isolated mitochondria were
detected in cystinotic (n=4) and control fibroblasts (n=4).
The activity of individual mitochondrial respiratory chain complexes did not differ
between cystinotic and control cells (Table 1).
Furthermore, maximal bradykinin-induced increase of mitochondrial ATP produc-
tion measured in intact cells by intramitochondrial luciferase probe was not different





























Figure 3  Decrease of intracellular ATP con-
tent (mean, SD) after inhibition of glycolysis
(sodium-iodoacetate: SIA; 2-deoxyglucose:
DOG) and respiratory chain complexes (I:
rotenon (ROT); III: antymicin A (ANT)) in
control (n=5) and cystinotic (n=4) fibrob-
lasts cell lines (p > 0.05)
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Na,K-ATPase activity
Although the activity of Na,K-ATPase, measured by ouabain-sensitive Rb influx, was
slightly decreased in cystinotic cells (50.8 (32.1-67.0) versus 60.5 (45.6-95.0) nmol/mg
protein/h, this difference was not statistically significant (Table 1).
Discussion
Cystinosis is the most frequent cause of inherited Fanconi syndrome, leading to renal
failure, in which the pathogenesis is still unknown. Based on the studies of rat and rab-
bit proximal tubular suspensions or cultured proximal tubular cells loaded with CDME,
intracellular ATP depletion with subsequent decrease of Na,K-ATPase activity has been
proposed to be the underlying biological mechanism of cellular dysfunction in cystinosis
ATP metabolism in cystinotic fibroblasts
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Figure 4  Maximal bradykinin-induced
increase in mitochondrial ATP production
(mean, SD) in control (n=4) and cystinotic
(n=3) fibroblast cell lines (p>0.05).
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[Salmon et al. 1990, Coor et al. 1991, Baum 1998, Ben-Nun et al. 1993]. Inhibited energy metabolism,
however, has not yet been demonstrated in human cystinotic material. Here, for the first
time, we attempted to confirm such an alteration of intracellular ATP status and oxida-
tive phosphorylation in cystinosis by an extensive study of the energy metabolism in
human cystinotic fibroblasts. Intracellular ATP content was decreased in fibroblasts
derived from patients with cystinosis compared to the controls. As the metabolism of cul-
tured cells could be influenced by ex-vivo growth and regarding the overlap of ATP
ranges between cystinotic and control cells, we additionally determined intracellular ATP
content in polymorphonuclear leukocytes immediately isolated from freshly drawn
blood. Interestingly, in agreement with the fibroblast data, intracellular ATP was also
decreased in PMN cells of the patients compared to the controls, despite the fact that
their cystine values were decreased compared to the fibroblasts due to cysteamine treat-
ment.
Intracellular ATP is produced by cytosolic glycolysis and mitochondrial OXPHOS. In
vivo studies demonstrated that energy of mammalian kidneys is mostly derived from the
oxidative metabolism. The activity of glycolytic enzymes in proximal tubules is minimal
[Klahr et al. 1992]. In contrast, the contribution of oxidative phosphorylation for ATP pro-
duction is limited in cultured skin fibroblasts [Robinson 1996], which was confirmed in this
study. Cystinotic fibroblasts were, however, chosen as the subject of our study since they
accumulate cystine in vitro and therefore will exhibit the metabolic consequences there-
of. Secondly, cultured fibroblasts from patients with mitochondrial disorders have been
successfully used to demonstrate reduced ATP production and deficient OXPHOS activ-
ity [Visch et al. 2004, Loeffen et al. 2000, Ugalde et al. 2004]. Additionally, an inhibited activity of
Na,K-ATPase after CDME loading has been demonstrated in cultured LLC-PK1 cells
[Ben-Nun et al. 1993], despite the fact that these cells are also predominantly glycolytic [Felder
et al. 2002].
Several approaches were used to investigate mitochondrial ATP generating capacity of
cystinotic and control fibroblasts. Initial experiments were performed in isolated mito-
chondria. Overall mitochondrial energy generating capacity as well as the activity of indi-
vidual mitochondrial respiratory chain complexes (I, II, III, IV) was comparable between
cystinotic and control cells, providing evidence that intracellular cystine accumulation
did not cause a mitochondrial defect.
Assuming that the presence of high lysosomal cystine content in the cell is obligatory
for the alteration of oxidative phosphorylation, additional experiments were performed
in intact cells to study bradykinin-stimulated intramitochondrial ATP production. These
experiments, however, did not reveal any difference between cystinotic and control
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fibroblasts. In summary, altered mitochondrial ATP generating capacity was not respon-
sible for decreased ATP content in cystinotic fibroblasts.
The slightly more pronounced decline of intracellular ATP after the inhibition of the
respiratory chain complexes in cystinotic fibroblasts might indicate the inhibition of gly-
colytic activity or a relative higher contribution of the OXPHOS system. Elevated ATP
consumption could be an alternative explanation of decreased ATP content in cystinotic
cells; however, this possibility was not examined in this study.
Finally, we examined whether intracellular ATP decrease in cultured fibroblasts caused
a functional inhibition of the activity of Na,K-ATPase. The conditions of rubidium
uptake experiments (low sodium and physiologic potassium concentrations in the medi-
um) were carefully selected to stimulate the maximal activity of Na,K-ATPase, which was
found to be comparable in cystinotic and control cells. This might be different in proxi-
mal tubular cells, because Na,K-ATPase activity in fibroblasts is trivial compared to prox-
imal tubular cells in vivo [Klahr et al. 1992].
How to reconcile our findings with the results obtained in proximal tubules loaded
with CDME? It is not excluded that CDME loading can provoke effects different from
those attributed to cystine accumulation in cells with a deficient lysosomal cystine carri-
er. In concordance with this idea, recent work on human IHKE-1 cells demonstrated that
CDME itself had an acute (within 1 minute) effect on the basal membrane potential (an
initial depolarization followed by a more pronounced repolarization). This effect was
distinct from those on Na+ dependent alanine transporter, which was inhibited after at
least 30 minutes of incubation with CDME. As the hyperpolarization induced by CDME
could be blocked by Ba 2+, the authors concluded that CDME activated a K+ conductance
[Cetinkaya et al. 2002].
It is also possible that CDME can directly affect the mitochondrial respiration as the
incubation of isolated mitochondria with CDME resulted in reduced mitochondrial O2
consumption with glutamate as substrate, but not with succinate, which electrons enter
the electron transport chain beyond complex I at the level of Coenzyme Q10, suggesting
the direct inhibition of complex I by CDME [Foreman et al. 1995].
An increase in intracellular cysteine concentration was demonstrated in vivo in rats
after 4 days of intraperitoneal CDME injections and in rabbit proximal tubules loaded
with CDME in vitro probably as a result of reduction of cystine to cysteine in the cytosol
[Foreman et al. 1987]. To determine whether cystine or its breakdown product cysteine was
responsible for alterations in proximal tubular transport, the effect of cysteine dimethyl
ester loading was studied. Strikingly, cysteine ester could indeed inhibit volume absorp-
tion, glucose and bicarbonate transport in rabbit proximal tubules in a concentration-
ATP metabolism in cystinotic fibroblasts
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dependent manner, while methyl esters of leucine and tryptophan had no effect on these
parameters [Salmon et al. 1990]. In contrast to CDME, cysteine ester loading, however, did
not effect the O2 consumption rate, despite a remarkable increase in intracellular cysteine
concentration [Sakarcan et al. 1994].
More research is required for the understanding of the pathogenesis of cystinosis.
This research should further explore already introduced alternative pathogenic mecha-
nisms of the disease as enhanced apoptosis and possibly increased reactive oxygen cell
damage [Park et al. 2002, Chol et al. 2004, Levtchenko et al. 2005]. New techniques such as micro
arrays and proteomics applied in human in vitro models of cystinosis might help to cre-
ate new ideas for the future studies. Human proximal tubular cells from cystinotic
patients can be cultured in vitro [Laube et al. 2005] and possibly represent an excellent
model for studying the pathogenesis of the disease. However, the metabolism of these
cells can be influenced by ex-vivo growth. In addition, cultures from urine might contain
other than proximal tubular epithelial renal cells, including glomerular podocytes, which
can be exfoliated to urine. This would mean that prior to the transport and metabolic
studies, the cells from urine should be cloned in order to obtain a pure proximal cell cul-
ture.
In conclusion, intracellular ATP depletion in cultured human cystinotic fibroblasts is
not caused by the alteration of mitochondrial oxidative phosphorylation and does not
result in a functional inhibition of Na,K-ATPase activity. Study of proximal tubular cells
derived from patients with cystinosis is required to explain the discrepancy of our results
with those obtained in CDME loading model of cystinosis.
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Abstract
Background: Cystinosis is an autosomal recessive disorder, caused by mutations of the
lysosomal cystine carrier cystinosin, encoded by the CTNS gene (17p13).
The concomitant intralysosomal cystine accumulation leads to multi-organ damage,
with kidneys being the first affected. Altered mitochondrial oxidative phosphorylation
has been demonstrated in animal proximal tubules loaded with cystine dimethyl ester,
mimicking cystine accumulation in cystinosis, but has not been confirmed in cells of
patients with cystinosis.
Furthermore, the link between cystine accumulation and mitochondrial damage is
also missing. We hypothesized that cytosolic cysteine deficiency resulting in intracellular
glutathione (GSH) shortage might be involved in cellular dysfunction in cystinosis.
Methods: Components of the γ-glutamyl cycle were measured in cultured skin fibroblasts
(n=9) and polymorphonuclear (PMN) leukocytes (n=15) derived from patients with
cystinosis and compared with the values in cultured fibroblasts (n=9) and PMN cells
(n=18) of healthy controls.
Results: Cystine content in cystinotic fibroblasts and PMN cells was significantly elevat-
ed compared with the controls, consistent with the lysosomal cystine accumulation in
these cells. Although no reduction of total intracellular GSH content was found in
cystinotic cells, it inversely correlated with cystine levels. Furthermore, GSH disulfide
(GSSG) was elevated in cystinotic cells, resulting in an increased GSSG/total GSH (%)
ratio. No relationship between intracellular cystine and GSH was found in control
fibroblasts and PMN cells.
Conclusion: An elevated GSSG/total GSH (%) ratio might indicate increased oxidative
stress present in cystinotic cells. Inverse correlation between cystine accumulation and
intracellular GSH content indicates that under stress conditions such as intensive energy
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Introduction
Cystinosis, affecting 1:200 000 newborns annually, is a lysosomal cystine storage disease
caused by a defect in a lysosomal cystine carrier cystinosin, encoded by the CTNS gene
(17p13). Patients with the most severe infantile form of cystinosis develop renal Fanconi
syndrome during the first year of life and end-stage renal disease before the age of 10.
Longer survival of cystinosis patients due to the success of renal transplantation reveals
later extra-renal complications such as hypothyroidism, diabetes mellitus, hypogo-
nadism, and musculo-, neuro- and retinopathy. The cystine depleting drug cysteamine
postpones the deterioration of renal function, improves growth and diminishes extra-
renal organ damage in cystinosis. Patients with late-onset or juvenile cystinosis generally
have less pronounced proximal tubular dysfunction, but may develop severe proteinuria
and renal failure. Extrarenal organs are also involved in patients with late onset form. The
third very rare ocular form of cystinosis is characterized by photophobia due to accu-
mulation of cystine crystals in the cornea and the absence of renal or extra-renal disease
[Gahl et al. 2001]. Mutations in CTNS have been demonstrated in all three clinical forms of
cystinosis [Attard et al. 1999].
Although the molecular basis of cystinosis is elucidated, the link between intralyso-
somal accumulation of cystine and cellular dysfunction is not yet clarified.
Altered ATP synthesis has been demonstrated in rabbit and rat proximal tubules
loaded with cystine dimethylester, mimicking cystine accumulation in cystinosis [Baum et
al. 1998]. However, this pathogenic mechanism has not been confirmed in cells of patients
with cystinosis. Assuming that ATP deficiency is indeed the cause of cellular damage in
cystinosis, it still has to be explained how cystine accumulation alters ATP synthesis.
Several theoretical considerations and experimental findings indirectly point to distur-
bances in glutathione (GSH) metabolism. In normal cells, proteins are degraded within
lysosomes to amino acids, which are transported to the cytosol. Cystine is carried by
cystinosin to the cytosol where it is reduced to cysteine by cytosolic reducing systems
[Gahl et al. 2001].
Theoretically, the intralysosomal cystine accumulation in cystinosis can result in the
cytosolic deficit of cysteine. Cysteine together with glutamate and glycine is needed for
GSH synthesis (Figure 1), requiring two successive enzymatic reactions, both consuming
one ATP molecule per enzymatic cycle. The first and ratelimiting reaction couples gluta-
mate and cysteine and is catalysed by γ-glutamylcysteine synthetase (γ-GCS), resulting in
the formation of γ-glutamylcysteine (γ-GC). The second reaction couples γ-GC with
glycine and is catalysed by GSH synthetase (GSH-S). Humans with deficient GSH-S
Altered status of glutathione and its metabolites in cystinotic cells
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accumulate and excrete elevated amounts of 5-oxoproline, due to diminished conversion
of 5-oxoproline to glutamate by 5-oxoprolinase (Figure 1) [Larsson et al. 2000]. The elevat-
ed 5-oxoproline excretion has also been demonstrated in cystinotic patients with Fanconi
syndrome, untreated with cysteamine, suggesting an alteration in GSH synthesis in these
patients [Rizzo et al. 1999]. Additionally, the presence of aminoaciduria and metabolic aci-
dosis in patients with a deficiency of γ-GCS suggests that GSH deficiency might result in
renal proximal tubular dysfunction [Larsson et al. 2000].
GSH is the most abundant cellular thiol, functioning as an important redox buffer.
GSH serves as a cofactor for the GSH peroxidase family of enzymes, which metabolize
H2O2 and lipid peroxides, defending cells against reactive oxygen metabolites.
Glutathione reductase, using the NADPH oxidase system, is necessary to regenerate GSH
[Uhlig et al. 1992].
GSH depletion results in mitochondrial dysfunction in several cellular and animal
models [Meister et al. 1995, Han et al. 2003] and therefore might affect ATP synthesis in cysti-
nosis. Interestingly, increased glutathionylation of the mitochondrial complex I due to
elevated mitochondrial glutathione disulfide (GSSG) has been shown recently to increase
superoxide production [Taylor et al. 2003]. An increased superoxide production has been
demonstrated by chemiluminescence assay in isolated polymorphonuclear (PMN) cells
and mononuclear phagocytes from cystinotic children [Pintos et al. 1985].
GSH has also a role in maintaining the intracellular pool of cysteine via the reaction






















Figure 1  Á-Glutamyl cycle.
1: Á-glutamylcysteine synthetase, (Á-GCS);
2: glutathione synthetase (GSH-S);
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Taking these considerations together, we suggested that GSH deficiency might link
intralysosomal cystine accumulation and mitochondrial dysfunction in cystinosis.
To test this hypothesis, we investigated total, reduced and oxidized intracellular GSH,
cysteine and total γ-glutamyl-cysteine and cysteinyl-glycine levels in cultured fibroblasts




The age of the patients (n=15) at the time of the study was 5–40 years (median 17); there
were nine males. The diagnosis of cystinosis was made at the age 6–28 months by demon-
strating an elevated intracellular cystine content in PMN leukocytes (>0.5 nmol cys-
tine/mg protein) and the presence of corneal cystine crystals, and was confirmed by mea-
surements of elevated cystine content in cultured skin fibroblasts in nine patients and
mutational analysis of the CTNS gene in 14 patients. Seven patients had renal Fanconi
syndrome with a glomerular filtration rate (GFR) between 28 and 84 ml/min/1.73m2
(median 57) and eight patients had a functioning renal graft (GFR 20–160
ml/min/1.73m2, median 84). All patients were treated by cysteamine (Cystagon®) 40–80
mg/kg /day.
Cell preparations
Skin fibroblasts culture. Skin fibroblasts were obtained by skin biopsies after receiving
informed consent from nine patients with cystinosis prior to the start of cysteamine
treatment and in nine healthy controls, followed by culturing in custommade M199
medium with Tween-20 (5 mg/l, Gibco) supplemented with fetal calf serum (10%), peni-
cillin (100 U/ml, Gibco) and streptomycin (100 U/ml, Gibco) as described previously
[Levtchenko et al. 2004]. Approximately 5x106 cells were grown for each assay to confluency
and detached using trypsin. After washing twice in phosphate-buffered saline (PBS;
Gibco), cells were centrifuged and pellets were shock-frozen immediately in liquid N2
and stored at - 80 °C.
Altered status of glutathione and its metabolites in cystinotic cells
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Polymorphonuclear leukocytes.
PMN leukocytes of 15 cystinotic patients and 18 adult healthy controls were isolated
immediately from 10 ml of freshly drawn blood as described previously, frozen in liquid
N2 and stored at - 80 °C [Levtchenko et al. 2004].
Determination of thiol-amino acids and small thiol-peptides
Preparation of cell extracts was performed as described previously [Levtchenko et al. 2004].
Briefly, frozen cell pellets were resuspended on ice in sodium phosphate buffer (pH 7.2)
with 1mM N-ethylmaleimide (NEM) (resulting in determination of oxidized thiols) or
without NEM (resulting in total thiols measurement) followed by sonication. NEM binds
to all free -SH groups. Our method  does not allow us to distinguish between cytosolic
disulfides and thiols bound to intracellular proteins.
The homogenates were centrifuged at 14, 000 g for 10 min at 4 °C. The supernatants
were used for measurements of protein concentrations by the Lowry method and for
determination of intracellular cystine and total cysteine, GSSG and total GSH, total 
γ-glutamyl-cysteine and total cysteinyl-glycine by using high-performance liquid chro-
matography (HPLC) [de Graaf-Hess et al. 1999]. Free cysteine content was calculated as the
difference between total cysteine and oxidized cysteine.
Cystine was measured as cysteine (1/2 cystine) after addition of NEM and expressed
as nmol cystine/mg protein (as some centres express cystine as 1/2 cystine/mg protein, we
provide a conversion factor: 1/2 cystine/mg protein = 2 x cystine/mg protein). A modifi-
cation of our method was using an elution buffer with pH 3.34 instead of pH 3.88 to
obtain a better separation of the components. Values were expressed as median and
range.
Statistical analysis
Non-parametrical Mann–Whitney U-test was used for the comparison of values from
cystinotic and control cells.
The correlations between two variables were estimated by a Spearman rank correla-
tion method. The differences were considered statistically significant at p<0.05.
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Results
Thiol compounds in cultured skin fibroblasts
The median intracellular cystine content in cystinotic fibroblasts was elevated compared
with normal (4.3 (2.7–5.5) vs 0.2 (0.1–0.3) nmol/mg protein, p<0.001), consistent with
lysosomal cystine accumulation in these cells. Intracellular free cysteine and total GSH
values did not differ between cystinosis and controls. GSSG was elevated in cystinotic
fibroblasts (0.7 (0.5–1.7) vs 0.3 (0.2–0.9) nmol/mg protein, P<0.05). The GSSG/total
GSH ratio (%) was also significantly elevated (Table 1).
The direct precursor of GSH, γ-glutamyl-cysteine, was detectable neither in cystinot-
ic nor in control fibroblasts, as its concentration was under the detection limit of our
assay (<0.5 mmol/l).
Intracellular cysteinyl-glycine content was elevated in cystinotic fibroblasts (median
0.5 (0.1–0.6) vs 0.1 (<0.1–0.2) nmol/mg protein) (Table 1).
Thiol compounds in polymorphonuclear cells
As all examined cystinosis patients were treated with the cystine-depleting drug cys-
teamine, the intracellular cystine content of PMN cells was elevated to a lesser extent
compared with cystinotic fibroblasts, confirming the efficacy of cysteamine therapy.




Table 1  Thiol compounds (median, range) in cultured skin fibroblasts (nmol/mg protein)
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However, it was still significantly increased compared with the control subjects (0.5
(0.3–0.8) vs 0.1 (0.09–0.2) nmol/mg protein, p<0.001). As in cystinotic fibroblasts, intra-
cellular free cysteine and total GSH contents did not differ between patients and controls
in PMN cells.
GSSG was significantly elevated (median 0.9 (0.3–1.8) vs 0.3 (0.2–0.4) nmol/mg pro-
tein, p<0.05), resulting in an elevated GSSG/total GSH ratio (Table 2).
No relationship between intracellular GSH content and the age, GFR and the presence or
absence of Fanconi syndrome in our group of patients could be demonstrated.
Theoretically, the increased GSSG in PMN cells of the patients treated with cys-
teamine may have been influenced by cysteamine treatment. Therefore, we have mea-
sured GSSG in two cystinotic patients untreated with cysteamine, whose PMN cystine
content was 1.58 and 1.97 nmol/mg protein, respectively. In these patients, GSSG was 1.1
(within the range of treated patients) and 2.8 nmol/mg protein (above the range of treat-
ed patients), respectively, opposing a possible role for cysteamine treatment in the eleva-
tion of GSSG in PMN cells.
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Relationship between intracellular cystine accumulation and glutathione content
Although total GSH content was not different between cystinotic and control cells, we
observed a significant inverse correlation between cystine accumulation and intracellular
GSH content in cystinotic fibroblasts. In PMN cells, this correlation was less pronounced
probably due to the lower cystine content in patients treated by cysteamine (Figure 2).
In control fibroblasts and PMN cells, no relationship between intracellular cystine and
GSH could be demonstrated (data not shown).
Discussion
We found increased GSSG and GSSG/total GSH ratio in cultured skin fibroblasts and
PMN leukocytes derived from patients with cystinosis. Strikingly, in fibroblasts of
patients with cystinosis, intracellular cystine accumulation was inversely correlated with
their total GSH content. This relationship was not present in fibroblasts and PMN cells
of controls.
Cultured cystinotic fibroblasts accumulated cystine to a higher extent compared with
PMN cells of the patients treated with cysteamine, and therefore fibroblasts may be a bet-
ter model for studying the pathogenesis of the disease. However, the metabolism of cul-
tured cells could be influenced by ex vivo growth, which is not the case for PMN cells
immediately derived from patients with cystinosis or healthy controls.














Figure 2  Intracellular cystine (nmol/mg protein)
and total GSH (nmol/mg protein) in PMN cells
(n=15) (open circles) (r= - 0.31, p=0.3) and in
cultured skin fibroblasts (n=9) (filled circles) 
(r= - 0.82, p<0.01) of patients with cystinosis.
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Interestingly, the trends found were comparable in both cell types.
The hypothesis of alterations in intracellular glutathione and cysteine levels in cysti-
nosis was first tested >30 years ago. Comparably with our results, these early studies
demonstrate no difference in absolute glutathione and cysteine contents between
cystinotic and normal fibroblasts [Schulman et al. 1972, States et al. 1977]. A direct and sensitive
HPLC method with and without the use of NEM allowed us to determine not only total
GSH, but also GSSG, which was elevated in cystinotic fibroblasts and PMN cells com-
pared with the controls. Our data, however, are distinct from the results of States et
al.,[1977] who found decreased GSSG in cystinotic fibroblasts. The possible reason for
this discrepancyis the deproteinization of samples prior to thiol detection by States et al.,
which would eliminate the detection of GSH bound in disulfides to protein.
In contrast to the recent findings of Chol et al.[2004] who detected a modest decrease
of GSH in three cystinotic conditionally immortalized fibroblast cell lines compared with
three controls [Chol et al. 2004], we were not able to demonstrate any reduction of total
intracellular GSH in a larger study population. Although in our opinion the data of Chol
et al. should be interpreted with caution due to their rather small number of observa-
tions, the measurements of intracellular thiols during the different phases of the cell cycle
could be an additional explanation of this difference. Chol et al. found decreased intra-
cellular GSH content during the phase of exponential cell growth, while we determined
intracellular thiol components in cells grown to confluency. This also explains the high-
er fibroblast cystine content in our study (4.3 vs 0.88 nmol cystine/mg protein, respec-
tively), which is closer to cystine accumulation in tissues in vivo (for example in kidney:
>25 nmol 1/2 cystine/mg wet weight) [Gahl et al. 2001].
Deficient cytosolic cysteine resulting in impaired intracellular glutathione synthesis,
due to the altered exit of cystine out of the lysosomes, was our starting hypothesis which
could not be directly confirmed in this study. Equal free cysteine content in cystinotic and
control cells was found in both cultured fibroblasts and PMN cells. Comparably with our
results, no difference in cysteine content between cystinotic and control fibroblasts could
be demonstrated earlier by Shulman et al. [1972]. However, the intracellular cysteine con-
tent measured by their group was almost 30 times lower compared with our data. More
recent studies, using direct determination by HPLC, in fibroblasts are in line with our
measurements of intracellular cysteine content [Ristoff et al. 2002]. The cysteine content in
the cells, however, do not necessary reflect the dynamic process of cysteine formation,
consumption and transport into and out of the cells. The normal cysteine content in
cystinotic cells might be maintained via increased import of this amino acid or from
increased degradation of GSH.
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Although we do not have a clear explanation for the increased cysteinyl-glycine in
cystinotic fibroblasts, it might be speculated that these cells use GSH degradation more
extensively to replenish their cytosolic cysteine pool, especially as this amino acid is
essential for the growth of human fibroblasts in culture [Eagle et al. 1961]. The inverse cor-
relation between cystine accumulation and total intracellular GSH content demonstrat-
ed in our study indicates that under stress conditions such as intensive cell proliferation
or increased oxidative stress, cystinotic cells may become GSH depleted. In these situa-
tions, cysteine deficit due to a defective exit of cystine out of the lysosomes might limit
GSH synthesis. As tissue cystine levels measured in patients with cystinosis are much
higher compared with those detected in cultured fibroblasts [Gahl et al. 2001], GSH defi-
ciency might occur in vivo. To obtain more insights into GSH synthesis in cystinotic cells,
studies with stable isotopes at rest and under stress conditions are required in order to
investigate the activities of individual enzymes of the γ-glutamyl cycle.
Probably the most important finding of this study is significantly increased GSSG and
concordantly GSSG/total GSH ratio, present in both cystinotic fibroblasts and PMN cells,
which reflects a changed redox potential in the studied cells. The redox regulation of gene
expression and intracellular communication is just emerging as a vital mechanism in
health and disease [Cadenas et al. 2004]. As mitochondria are important sources of intracel-
lular reactive oxygen species (ROS), it is tempting to speculate that cystinotic cells are less
protected from mitochondrial free radical production.
Mitochondrial superoxide is converted to H2O2 by inducible Mn-superoxide dismu-
tase (Mn-SOD) and, when released to the cytoplasm, can change the redox state to the
rest of the cell [Cadenas et al 2004]. Increased free radical production can be responsible for
increased apoptosis, demonstrated in cystinotic fibroblasts and renal tubular epithelial
cells [Park et al. 2002, Imai et al. 2004]. In agreement with this hypothesis, increased activity of
SOD, used as an index of superoxide overproduction, has been demonstrated in cystinot-
ic fibroblasts by Chol et al. [2004]. Increased oxidative stress might be the missing link
between cystine accumulation within the lysosomes and two other proposed pathogenic
mechanisms of cystinosis such as mitochondrial dysfunction and apoptosis.
In conclusion, although no depletion of absolute GSH and cysteine contents is found
in cystinotic fibroblasts and PMN cells, we demonstrate an inverse correlation between
cystine accumulation and intracellular GSH content. In addition, the elevated GSSG
might indicate the presence of increased oxidative stress, which can be responsible for cell
damage in cystinosis. An increased peroxidation in, for example, proximal tubular cells
could have striking results on the signal transduction in these cells [Imai et al. 2004]. The
study of the mitochondrial GSH content and ROS production in cystinotic cells in rest
Altered status of glutathione and its metabolites in cystinotic cells
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conditions and in conditions of intensive energy demand and increased oxidative stress
are in our opinion promising directions for future research.
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Abstract
Cystinosis, the most frequent cause of inborn Fanconi syndrome, is characterized by the
lysosomal cystine accumulation, caused by mutations in the CTNS gene. To elucidate the
pathogenesis of cystinosis, we cultured proximal tubular cells from urine of cystinotic
patients (n = 9) and healthy controls (n = 9), followed by immortalization with human
papilloma virus (HPV E6/E7). Obtained cell lines displayed basolateral polarization,
alkaline phosphatase activity, and presence of amino
p
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patients and nine healthy controls, and evaluated for the first time intracellular ATP lev-
els and intracellular glutathione status in human cystinotic proximal tubular cells.
Methods
Study population
Urine was collected from nine patients with cystinosis aged 5–15 years. In all patients,
cystinosis manifested with renal Fanconi syndrome at the age of 6–18 months. The diag-
nosis of cystinosis was made by determining elevated cystine content of polymorphonu-
clear cells (>0.5 nmol cystine/mg protein) and was confirmed in eight patients by mole-
cular analysis of CTNS gene.
Urine of 48 healthy subjects (4–13 years old) was used for obtaining control proximal
tubular cells.
Cell culture and immortalization
Urine was collected and within 5 h centrifuged (223g) for 5 min, at room temperature.
After washing in phosphate-buffered saline (PBS) and a second centrifugation step, urine
sediment was resuspended in 3 ml PTEC culture medium (DMEM– HAM_s F12;
Cambrex Biosciences) containing FCS (10%), penicillin (100 U/ml, Gibco), streptomycin
(100 U/ml, Gibco), insulin (5 µg/ml), transferrin (5 µg/ml), selenium (5 ng/ml), hydro-
cortisone (36 ng/ml), epithelial growth factor (10 ng/ml), and tri-iodothyronine (40
pg/ml) [Detrisac et al. 1984]. The suspension was transferred to 25 cm2 tissue culture flask
and placed at 37 °C in a 5% CO2 incubator. The medium was changed every 2–3 days.
To maintain proliferation, cells at passage number 4 or less were transfected with plas-
mid DNA, containing the HPV 16 E6/E7 genes, using the amphotropic packaging cell
line PA 317 [Ryan et al. 1994].
Characterization of proximal tubular epithelial cells
As a positive control, commercially available human HK-2 HPV E6/E7 cell line (HK-2)
was used (ATCC) [Ryan et al. 1994]. As a negative control undifferentiated human podocyte
CHAPTER 11
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cell line immortalized with Simian virus containing t-sensitive allele (SV40-ts58), kindly
provided by Dr. M. Saleem [Saleem et al. 2002], was used.
Light and electron microscopy
To demonstrate the characteristic cobblestone morphology of primary cultures, phase
contrast microscopy (Axiolab) was applied. Transmission electron microscopy (TEM)
was used to show ultrastructural morphology of proximal tubule cells. After immortal-
ization and growing to confluence, cells were gently scraped from flasks, fixed, dehydrat-
ed, and embedded in Epon 812 (Merck) as described previously [de Graaf et al. 2004].
Semithin (1 µm) and ultrathin sections were cut on an ultratome, Reichert Ultracut S
(Leica Microsystems). The semithin slices were stained with toluidine blue and examined
using light microscopy. The ultrathin specimens were contrasted with 4% uranyl acetate
and lead citrate before examination by electron microscopy (Jeol 1200 EX2).
Enzymatic studies
To confirm proximal tubular origin of cultured cells, activity of BBM alkaline phos-
phatase was measured in cell suspensions (approximately 0.1x106 cells) in at least two
independent experiments using BM Chemiluminescence ELISA substrate (AP) kit
(Roche) according to instructions of the manufacturer. To quantify activity, a standard
curve was made with dilutions of Shrimp Alkaline Phosphatase (Amersham Biosciences).
Protein levels were determined using a method of Lowry.
Immunological studies
The presence of aminopeptidase N (CD-13) on the membrane of cultured cells
(0.25x106) as an indication of their proximal tubular origin was determined by flow
cytometry analysis (Coulter XL) with monoclonal mouse-anti-human CD13-FITC anti-
body (Dako) with a 1:100 dilution in PBS. Unlabeled cell suspensions were used as neg-
ative controls to evaluate positive staining profile.
The presence of PTEC specific protein megalin was examined using monoclonal anti-
body 6C5, which was a kind gift of Dr. W.S. Argraves (Charleston SC, USA) [Kounnas et al.
1993]. Cells were cultured to semi-confluence on cover slides and fixed using
paraformaldehyde (2%). After incubation with anti-megalin for 1 h, cells were washed
and incubated for a second hour with goat-anti-mouse-FITC conjugate (Dako). Slides
were examined by immunofluorescence microscopy.
Lectins staining pattern specific for proximal tubular cells was examined with Sophora
japonica agglutinin (aggl) (SJA, Vector Laboratories), Lotus tetragonolobus aggl (LTA,
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Sigma), and Erythrina cristagalli aggl (ECA, Vector Laboratories) by incubating cells with
each of the lectins (75 µg/ml) labeled with FITC (LTA and ECA) or rhodamine (SJA) for
1 h at room temperature [Grupp et al. 2001].
Determination of thiol-amino acids and small thiol-peptides
Preparation of cell extracts and measurement of intracellular thiols (total GSH, oxidized
glutathione (GSSG), cystine, and cysteine) using HPLC were performed as described pre-
viously [Levtchenko et al. 2005]. GSSG is glutathione present in disulfides.
Measurement of total intracellular ATP content
Cystinotic and control cell cultures were grown to confluence in 75 cm2 tissue culture
flasks (approximately 5.0x106 cells) and detached using trypsin. After washing in PBS,
cell pellets were shock frozen in liquid N2 and stored at - 80 °C until ATP determination.
Prior to ATP determination pellets were resuspended on ice in 0.5 ml cold PBS. A 25-fold
diluted fraction (25 µl) of the suspension was transferred to a white microtiter plate and
ATP was measured using ATP Bioluminescence Assay Kit HSII (Roche) according to the
instructions of the manufacturer. The residue of the undiluted cell suspension was used
for protein determination using the method of Lowry.
Statistical analysis
Data (mean, SD) are presented as a mean of two separate experiments. Unpaired t test
was used for statistical analysis.
Differences were considered statistically significant at p < 0.05.
Results
Immortalized exfoliated cells express PTEC phenotype
While colonies with a cobblestone morphology developed in all nine collected cystinotic
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urine samples within 2 weeks (Figure 1A), only nine out of 48 control urine samples
showed cell proliferation. After immortalization with HPV 16 E6/E7, obtained cell lines
exhibited the presence of microvilli and tight junctions, characteristic for PTEC, indicat-
ing that cultured cells develop apical and basolateral polarization, emphasized with the
toluidine blue staining (Figs. 1B and C). High activity of alkaline phosphatase (AP) was
detected in both cystinotic and control PTEC cultured from urine (11456 ± 7135 µU/mg
protein) (Figure 2). The activity of AP in cells derived from urine was about 100-fold
higher compared to commercially available HK-2 cell line (143 ± 309) and 1000-fold
higher compared to the podocytes (14 ± 13). Megalin (Figure 1D) and aminopeptidase
N (Figure 3) were present in all examined PTEC cultured from urine. Aminopeptidase N
was not detected on the podocytes. Furthermore, the staining with SJA, ECA, and LTA
lectins was all positive in obtained PTEC in concordance with their proximal origin (data
not shown).







Figure 1 (A) Phase contrast image of primary cultures showing cobblestone morphology (original magni-
fication 100x). (B) Light microscopy of cultured cells stained with methylene blue after scraping from tissue
culture flask showing bipolar orientation (original magnification 400x). (C) Transmission electron micro-
scopic image showing microvilli (black arrows), tight junctions (white arrow), and nuclei (asterisks) (orig-
inal magnification 3000x). (D) Immunofluorescence image showing positive staining with monoclonal anti-
megalin antibody 6C5 (original magnification 400).
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Cystinotic cell lines accumulate cystine and contain increased oxidized glutathione 
Cystine levels in cystinotic PTEC were significantly elevated compared to healthy control
cells (0.86 ± 0.95 nmol/ mg versus 0.09 ± 0.01 nmol/mg protein, p = 0.03), confirming
their cystinotic phenotype (Figure 4A).
Total GSH content was below the detection limit of 0.10 nmol/mg protein in three
cystinotic PTEC and four control PTEC. In the remaining cultures, cystinotic cells
demonstrated a significant increase of GSSG compared to healthy controls (1.16 ± 0.83
nmol/mg versus 0.29 ± 0.18 nmol/mg protein, p = 0.04) (Figure 4B). Total GSH (16.77 ±
5.48 versus 9.85 ± 9.25, p = 0.16) and free cysteine (11.45 ± 3.94 versus 11.38 ± 4.07,




   
   
   





   
   
   
   






   
   
   





   
   
   
   






Figure 3 Fluorescence intensity of mouse-anti-human CD-13-FITC (aminopeptidase N) antibody ana-
lyzed by flow cytometry. (A) Cultured PTEC cell lines derived from urine and (B) conditionally immortal-
ized podocytes. Unlabeled cells are presented in white, labeled cells in black.



























Figure 2 Alkaline phosphatase activity in
cell suspensions. Activities (mean values
of at least two independent experiments)
quantified using shrimp alkaline phos-
phatase. Data of control PTEC (#1 and
#2) and cystinosis PTEC (#3 and #4) are
representative for total study population.
PO, conditionally immortalized
podocyte.
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Total intracellular ATP contents are comparable between cystinotic and control cell lines
Total intracellular ATP content in the cultured cells did not differ between cystinotic and
control PTEC (3.49 ± 1.01 versus 4.03 ± 2.62, p = 0.558) (Figure 5). There was no corre-
lation between cystine and ATP contents and between ATP and glutathione contents in
cystinotic and control PTEC.
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Figure 5 ATP concentration in PTEC cultured
from urine of controls (n = 9) and cystinotic
patients (n = 9). Values are expressed as nmol/mg
protein, p > 0.05.
Figure 4 (A) Cystine content (nmol/mg protein) in control (n=9) versus cystinotic (n=9) PTEC cell lines,
p=0.03. (B) GSSG content in control (n=5) versus cystinotic (n=6) cell lines, p=0.04.
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Discussion
In the present study, we developed human proximal tubular epithelial cell lines from
urine of patients with cystinosis and healthy controls. This non-invasive approach is used
because no other in vitro or in vivo model for studying the pathogenesis of renal disease
in cystinosis is available.
In contrast to previous studies [Racusen et al. 1991, Racusen et al. 1995, Laube et al. 2005], we
immortalized proximal tubular cells with HPV E6/E7, allowing us to obtain sufficient
material for metabolic studies.
The presence of typical proximal tubular cell morphology, brush border enzyme AP
activity, positive staining with anti-CD13 and anti-megalin antibodies, and proximal
tubular specific lectin pattern confirmed proximal origin of obtained cell lines. These fea-
tures were not changed after the transfection.
Human podocytes conditionally immortalized with SV-40 ts 58 were used as a nega-
tive control to demonstrate that obtained cell lines were not podocytes, which also can be
exfoliated in urine [Vogelmann et al. 2003]. Anti-CD 13 antibody (anti-aminopeptidase N)
appeared to be an ideal marker to discriminate podocytes from proximal tubular cells, as
this marker was positive for all tested urinary PTEC cell lines but always negative for the
podocytes.
Culturing PTEC from urine of healthy controls was less successful compared to
patients with cystinosis (100% proliferation in cystinosis versus 19% in controls). A pos-
sible explanation could be that through increased mechanical stress in cystinotic patients
more viable cells are exfoliated.
Our present in vitro model is superior to CDME-loading method, which only mimics
lysosomal cystine accumulation, since the molecular defect in CTNS gene is naturally
present in cells derived from urine of cystinotic patients. Strikingly, in contrast to the
studies in CDME loaded proximal tubular cells [Salmon et al. 1990, Coor et al. 1991, Ben-Nun et
al. 1993, Foreman et al. 1995, Baum 1998, Cetinkaya et al. 2002], we found no significant difference in
intracellular ATP, questioning the hypothesis of ATP depletion being the cause of defec-
tive proximal tubular transport.
It might be suggested that higher cystine concentrations are necessary to cause ATP
depletion in cystinotic cells, as cystine accumulation in our in vitro model was lower
compared to cystinotic kidney: >15 nmol/mg wet weight [Gahl et al. 2001]. Further exten-
sive study of mitochondrial ATP synthesis in cystinotic proximal tubular cell lines is
required to answer the question whether decreased ATP production is responsible for cel-
lular dysfunction in cystinosis.
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In seven cell lines (three cystinotic and four controls), intracellular GSH was depleted
and could not be quantified because it was under the detection levels of the assay. A pos-
sible explanation of this observation is that not all obtained cell lines express glutathione
transporters [Lash et al. 2005].
The most important finding of this study is a significantly elevated GSSG content in
cystinotic PTEC, which might point to increased oxidative stress and altered redox sta-
tus, while total GSH was comparable in cystinotic and control cells. Increased GSSG was
already reported by our group in primary cystinotic fibroblasts and polymorphonuclear
cells, while total GSH and free cystine were within the normal range in all tested cell types
[Levtchenko et al. 2005]. Concordant with our data, Chol et al. [2004] have recently demon-
strated in conditionally immortalized cystinotic fibroblasts an increased activity of
superoxide dismutase, converting superoxide into H2O2, possibly indicating increased
oxidative stress. Interestingly, oxidized glutathione (GSSG) can activate pro-apoptotic
PKCd [Chu et al. 2003] and might play a role in increased apoptosis demonstrated in
cystinotic fibroblasts [Park et al. 2002]. Altogether these findings indicate that further
research should be focused on reactive oxygen species in cystinotic cells.
In conclusion, normal ATP content in cystinotic proximal tubular epithelial cell lines
questions the hypothesis of altered ATP synthesis as a keystone in the pathogenesis of
cystinosis. Elevated oxidized glutathione suggests increased oxidative stress, possibly
playing a role in cellular dysfunction in cystinosis.
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Cystinosis is a rare lysosomal storage disease whose hallmark is the accumulation of cys-
tine within the lysosomes. The disease generally manifests with proximal tubular dys-
function, known as Fanconi syndrome, and progresses towards end stage renal disease
(ESRD). Besides the kidneys, lysosomal cystine accumulation in virtually all tissues caus-
es multi-organ damage, making cystinosis a systemic metabolic disease. An amino thiol
cysteamine is the only available cystine depleting drug, which retards the deterioration of
the renal function and postpones the occurrence of extra-renal complications. In patients
with cystinosis, cysteamine therapy should be initiated as soon as possibly and must be
continued life-long. Even after renal transplantation cysteamine is required to protect the
extra-renal organs. Despite significant progress made in the last 3 decennia, most patients
with cystinosis, although delayed compared to untreated patients, still develop ESRD and
extra-renal complications. This could be partially related to the fact that intracellular
events downstream to lysosomal cystine accumulation remain unknown, thus hampering
therapeutic interference into the disease pathogenesis. Furthermore, non-compliance with
cysteamine treatment might be responsible for therapy failure in some patients.
In our work described in this thesis we primary aimed improving the clinical care of
cystinosis patients (Chapters 2-7). Next, we performed cell biological studies providing
new insights towards understanding the pathogenesis of cystinosis (Chapters 8-11).
Improving clinical care of cystinosis patients
Diagnosis of cystinosis
Cystine measurement
For the early initiation of cysteamine therapy the early diagnosis of cystinosis is manda-
tory. The detection of an elevated cystine content in patient’s tissue is obligatory for the
diagnosis. Corneal cystine crystals are a pathognomonic marker of the disease, but usu-
ally can be detected by an experienced ophthalmologist only after the first year of life.
Blood cells are easily available for cystine measurements and are generally used for
making the diagnosis. Accurate cystine measurements are also required for the monitor-
ing of cysteamine therapy. Cystine measurements might be used for the detection of the
heterozygotes mostly having a slightly elevated cystine content compared to healthy per-
sons. Historically cystine has been measured in mixed white blood cells (ML), despite the
fact that it preferentially accumulates in polymorphonuclear leukocytes (PMN) and
monocytes, but not in the lymphocytes [Schulman et al. 1970]. The reason for this is that ML
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are easier to isolate from whole blood. Because cystine content is expressed in nmol per
mg protein, values in ML, containing large amounts of lymphocytes, can be expected to
be lower compared to values measured in PMN. Additionally, any change in differential
count of white blood cell populations would influence the cystine value, making the
comparison between different measurements in the same patients less accurate. In
Chapter 2 we describe our study comparing cystine content of ML and PMN measured
simultaneously by HPLC in 4 patients at diagnosis, 12 patients undergoing cysteamine
therapy, 15 obligate heterozygotes and 8 healthy controls. As it could be theoretically pre-
dicted, intracellular cystine was significantly elevated in PMN compared to ML in
patients at diagnosis and under cysteamine therapy. Furthermore, the overlap between
heterozygotes and healthy controls was smaller when cystine was measured in PMN,
which was already demonstrated earlier [Smolin et al. 1987]. In controls ML and PMN val-
ues were comparable due to very low cystine content close to the detection limit of our
assay: 0.15 µmol/l cystine. In all patients under cysteamine therapy the dose of cys-
teamine had to be increased because their PMN cystine was above 0.5 nmol/mg protein
(90th percentile of cystine value measured in the heterozygotes, accepted as an upper
limit in patients under cysteamine therapy). In two patients at diagnosis cystinosis could
be missed due to cystine values in ML within the heterozygote range, while it was clear-
ly above the heterozygote range when measured in PMN. It could be expected that
patients whose therapy is monitored by cystine detection in PMN cells would have bet-
ter renal function survival compared to those whose cystine is measured in ML. Further
studies have to prove it.
In conclusion, we consider it essential to measure cystine in PMN and not in ML,
because it increases the sensitivity of cystine detection for the diagnosis of cystinosis and
provides better target concentration during the monitoring of the cysteamine treatment.
Molecular analysis of the cystinosis gene
In our opinion the diagnosis of cystinosis has to be confirmed in all patients with anoth-
er method than cystine detection in PMN. Inaccurate procedure of PMN isolation or
transport could result in false increase of cystine value due to the oxidation of intracel-
lular cysteine, which is ~100 times more abundant in the cytosole of white blood cells cell
compared to cystine [de Graaf-Hess et al. 1999]. Initially we used cystine detection in prima-
ry skin fibroblasts for the confirmation of the diagnosis, as molecular analysis of the
cystinosis gene (CTNS) was not available. In 1998 the CTNS gene, encoding lysosomal
cystine transporter, cystinosin was identified by positional cloning strategy and mapped
to the short arm of chromosome 17 (17p13) [Town et al. 1998]. In Chapter 3 we describe an
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improved double multiplex PCR method for the detection of the common in European
population 57-kb deletion spanning exons 1 to 10 plus a large amount of upstream
sequence. In all tested patients (n=11) 2 separate PCR were performed. The first one used
LDM1 forward and reverse primers up- and downstream the deletion [Anisker, Lucero et al.
1999]. In the presence of 57-kb deletion, the amplification with these primers resulted in a
fragment of 423 bp. To discriminate between heterozygous and homozygous deleted
patients a second separate PCR using primers to identify the presence of D17S829 mark-
er, which is situated in intron 3 of CTNS gene, located in the deletion interval, should be
performed. In the presence of D17S829, 266 bp band is produced. For both PCRs an
amplification of 635 bp fragment of the housekeeping gene β-actin was used as an inter-
nal control. Thus, patients with homozygous 57 kb deletion will have 423 and 635 bp PCR
products, patients having heterozygous 57 kb deletion: 266, 423 and 635 pb products and
patients without the deletion: 266 and 635 bp products. This simple and accurate method
allowed us to identify the 57 kb deletion in 59% (13/22) of all tested Dutch alleles, 5
patients were homozygous and 3 were heterozygous for the deletion. The resting alleles
were submitted to the genomic sequencing, which revealed other previously reported
mutations in all but 3 alleles. The unidentified mutations might be located in untested
regions of the gene such as the promoter or intronic sequences. In our small patient pop-
ulation no correlation between the genotype and the severity of the phenotype (age at
diagnosis, decline of renal function, age at start of thyroid hormone replacement) could
be detected. The analysis of larger patient’s groups revealed the correlation of the geno-
type with the clinical form of cystinosis: complete deletion or truncating mutations with
a loss of functional protein were generally detected in patients with most severe infantile
form of cystinosis, while patients with juvenile and ocular form had mutations allowing
residual cystinosin activity [Attard et al. 1999, Anikster et al. 2000, Thoene et al. 1999].
Actually molecular analysis of CTNS is used in all Dutch patients for the confirmation




Cystinosis is a multisystem disorder, initially affecting kidneys and cornea. When renal
replacement therapy was not available, patients with cystinosis generally died before the
age of 10 years and extra-renal organ involvement was largely unknown. Longer survival
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of cystinosis patients due to the possibility of renal transplantation revealed endocrine
organ damage (hypothyroidism, diabetes mellitus, male hypogonadism), muscular atro-
phy, retinopathy, central and peripheral neural system damage, hepatic and exocrine pan-
creas involvement, usually developing after the first decade [Gahl et al. 2002]. This means
that physicians treating older cystinosis patients (generally “adult” nephrologists) should
be aware of the extra-renal complications of cystinosis. Because cystinosis is a rare disor-
der (for example in the Netherlands there are in total 40 cystinosis patients and among
them 10 adults), nephrologists treating adult patients are not able to get experienced with
treatment of these patients. The situation is relatively different for paediatric patients
concentrated within few children university nephrological centres, each of them treating
at least 3-5 patients. To evaluate the clinical care of 10 Dutch adult patients with cysti-
nosis we reviewed their medical records (Chapter 4). Strikingly, ophthalmic control was
never performed in two patients, thyroid function was not checked in another two
patients and two more patients did not get glycemia control. Only seven Dutch adult
patients were treated with cysteamine (three of them received the drug in 2 or 3 doses
daily, while 4 times daily are obligatory). Cystine content in white blood cells was within
the recommended range only in three patients. Thus, rather inadequate medical care of
Dutch cystinosis patients was observed. This motivated us to organise a multidisciplinary
cystinosis outpatient clinic for all adult Dutch patients, functioning in UMC St Radboud
over the last 2 years. In one day the patients are examined by a physician experienced in
metabolic diseases, an ophthalmologist, a neurologist (for those with neurologic com-
plaints) and a clinical genetician (a single counselling per patient). Additionally an aid of
a social worker is proposed to all patients. Blood for cystine detection is taken 5-6 hours
after cysteamine ingestion and is proceeded immediately for PMN isolation. The recom-
mendations for medical care are provided for the nephrologists who remain responsible
for the medical care of their patients. During the last 2 years we have identified 2
unknown adult patients with cystinosis and one patient in whom the diagnosis of cysti-
nosis could be rejected after almost 20 years of cysteamine therapy.
Treatment of proteinuria
The deterioration of the renal function in patients with cystinosis is associated with the
progressive development of tubulo-interstitial lesions, including tubular atrophy and
interstitial fibrosis [Gubler et al. 1999]. The pathogenetic mechanisms by which cystine
accumulation leads to renal failure are enigmatic. Albuminuria invariably present in
patients with cystinosis might be one of the contributing factors. Whether albuminuria
in cystinosis originates from increased glomerular filtration, decreased proximal tubular
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reabsorption or the combination of both is unknown. In Chapter 5 we demonstrate in 5
patients with Fanconi syndrome that albiminuria could be decreased with ~ 40% under
treatment with angiotensin converting enzyme (ACE) inhibitor enalapril (0.15 mg/kg
once daily). Interestingly, treatment with enalapril did not change the increased urinary
excretion of low molecular weight protein α-1 microglobulin, supporting the glomeru-
lar origin of albuminuria. Decrease of albuminuria might improve the survival of the
renal function in cystinosis as it has been demonstrated in various other renal diseases
[Ruggenenti et al. 2001]. Not surprisingly, treatment with enalapril was accompanied by a
decrease of systolic blood pressure and complaints of hypotension in 2/5 patients.
Creatinine clearance diminished from median 48 to 45 ml/min/1.73 m2 and returned to
previous values after the discontinuation of enalapril. These side effects of enalapril indi-
cate that ACE inhibitors should be used with caution in patients with cystinosis, suffer-
ing from sodium losses and polyuria. It is not excluded that angiotensin II receptor
blockers, possibly having less pronounced hypotensive effect [Gansevoort et al. 1999], could
be better tolerated by cystinosis patients.
Improving the effectiveness of cysteamine therapy
Cysteamine can deplete white blood cell cystine content with 80-90%, but is unable to
prevent the deterioration of the renal function and the occurrence of extra-renal disease
in the majority of the patients. Two studies described in Chapters 6 and 7 aimed to
improve the effectiveness of cysteamine therapy.
Our first hypothesis was that cysteamine being a small molecule (MW 77.14) could be
lost in urine of cystinosis patients suffering from Fanconi syndrome. As shown in
Chapter 6 it was not the case as less than 1% of the ingested dose was excreted into urine.
Secondly, we suggested that inappropriate cysteamine administration might be
responsible for therapy failure in some patients (Chapter 7). To test this idea we asked
Dutch patients with cystinosis to fill in a questionnaire concerning their cysteamine dose
regimen. This questionnaire revealed that only 5/22 patients took the drug every 6 hours
as it is recommended according to the pharmacodynamic data. Most of the patients
ingested cysteamine only during the wake time resulting in a night pause (between the
last evening and the first morning dose) of ~ 9 hours. Subsequently, we investigated
whether morning cystine PMN value was elevated in patients after 9 hours night pause
compared to 6 hours night pause. In 11 compliants patients mean morning PMN cystine
value was indeed above the recommended value of 0.5 nmol/mg protein 9 hours after the
last evening cysteamine ingestion (0.73 nmol cystine/mg protein) versus  6 hours after
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the last evening cystemine dose (0.44 nmol cystine/mg protein, p<0.05). Although it is
unknown whether PMN cystine content adequately reflects cystine accumulation in the
other tissues, we strongly advise cystinosis patients to ingest cysteamine every 6 hours
including the night as it provides better metabolic control of cystinosis.
In summary, for optimal clinical care of cystinosis patients we recommend:
1. As early as possible diagnosis of cystinosis using cystine detection in PMN leuko-
cytes in order to initiate cysteamine treatment as early as possible.
2. Use of PMN leukocytes for the monitoring of cysteamine therapy (5 to 6 hours
after the last cysteamine dose PMN cystine value should be below 0.5 nmol cys-
tine/mg protein). ML should not be used.
3. Confirmation of the diagnosis of cystinosis by molecular analysis of the cystinosis
gene.
4. Multi-disciplinary approach for medical care of cystinosis patients, in particular
adults, suffering from extra-renal complications of the disease.
5. Administration of ACE inhibitors or angiotensin II receptor blockers in patients
with albuminuria under strict control of blood pressure and serum creatinine
(requires further study).
6. Administration of cysteamine treatment every 6 hours including the night.
New insights into the pathogenesis of cystinosis
The second major part of our work (Chapters 8-11) included cell biological studies
exploring pathogenic mechanisms involved in cellular dysfunction in cystinosis.
A case report described in Chapter 8 demonstrated a gradual deterioration of proxi-
mal tubular dysfunction starting with mild aminoaciduria detected at the age of 3 weeks
towards full-blown Fanconi syndrome at the age of 6 months. The differential sensitivi-
ty of apical proximal tubular transporters to cystine accumulation is in our opinion in
contrast to the generally accepted hypothesis of reduced ATP generation being a keystone
in the pathogenesis of cystinosis. This because in cystine dimethyl ester (CDME) loading
model of cystinosis immediate ATP depletion and direct inhibition of different trans-
porters was demonstrated [Baum 1998].
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Study of energy metabolism in cystinosis
Because no animal or cell model of cystinosis was previously available, others have stud-
ied the pathogenesis of the disease by loading proximal tubular cells with CDME. CDME
loading resulted in inhibition of proximal tubular transport, mimicking Fanconi syn-
drome in cystinosis. In this model a pronounced decrease of mitochondrial ATP synthe-
sis was demonstrated, which was postulated to be an underlying pathogenetic mecha-
nism in cystinosis [Foreman et al. 1987, Salmon et al. 1990, Coor et al. 1991, Ben-Nun et al. 1993, Sakarcan
et al. 1992, Foreman et al. 1995, Baum 1998]. Until now an altered energy metabolism has not
been confirmed in human cystinotic material.
We performed an extensive study of ATP metabolism in primary cultured fibroblasts
of patients with cystinosis with known genetic defects of the CTNS gene (Chapter 9).
The choice of fibroblasts was based on their relative easy availability by skin biopsy and
the extensive cystine accumulation in these cells. Furthermore, our group is experienced
in studying the pathogenesis of mitochondrial disorders in primary fibroblasts, display-
ing altered ATP production and deficient oxidative phosphorylation (OXPHOS) activity
[Visch et al. 2004, Loeffen et al. 2000, Ugalde et al. 2004]. Patient’s fibroblasts accumulated marked
amounts of cystine (median, range: 4.3 (2.7-5.5) versus 0.2 (0.1-0.3) nmol/mg protein in
controls, p<0.001), consistent with their cystinotic phenotype. Strikingly cystinotic
fibroblasts contained significantly decreased amount of intracellular ATP compared to
control fibroblasts (median, range: 37.3 (26.9-55.0) versus 51.5 (44.7-58.5) nmol/mg
protein, p<0.05).
To confirm the alteration of intracellular ATP status in cystinosis, we additionally
measured intracellular ATP content in PMN cells immediately derived from patients and
controls. Comparable to cystinotic fibroblasts, intracellular ATP was also decreased in
cystinotic versus control PMN cells (median, range: 317 (149-1141) versus 557 (207-
1101) nmol/mg protein, p<0.05).
Intracellular ATP content is the sum of ATP produced by cytosolic glycolysis and
mitochondrial OXPHOS minus intracellular ATP consumption as presented by a sim-
plistic equation: Cellular ATP content = (ATP production by OXPHOS + ATP produc-
tion by glycolysis) - ATP consumption.
Decreased ATP production, enhanced consumption or a combination of both would
result in diminished ATP content. We primary concentrated our efforts on studying the
mitochondrial ATP generating capacity because a possible alteration of mitochondrial
complex I was demonstrated in CDME model of cystinosis [Foreman et al. 1995].
Remarkably, overall energy generating capacity, activity of respiratory chain complex-
es in mitochondrial enriched cell fractions and bradykinin-stimulated maximal mito-
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chondrial ATP production in intact cells were all normal in cystinotic fibroblasts. The
reason for this observation could be the fact that cystinotic fibroblasts preferably use
cytosolic glycolysis to generate ATP, which was also observed in our study. Interestingly,
after the inhibition of the glycolysis by 2-deoxyglucose (DOG) or sodium iodoacetate
(SIA) no difference in intracellular ATP content between cystinotic and control fibrob-
lasts could be detected anymore, suggesting an alteration of the glycolytic pathway in
cystinosis.
Because PMN cells are also glycolytic, no study of mitochondrial ATP generation was
performed in PMN.
To investigate whether decreased ATP content had functional consequences in fibrob-
lasts, we studied the activity of Na,K ATP-ase by Rb+ influx in maximally stimulated con-
ditions. This study also revealed no differences between cystinotic and control cells,
meaning that despite decreased ATP levels in cystinosis, the ATP content was still suffi-
cient for normal Na,K ATP-ase pump function.
In conclusion, our study demonstrating diminished ATP content in cystinotic cells
failed to confirm the alteration of mitochondrial ATP generating capacity postulated in
CDME model of cystinosis. The questions whether deficient glycolysis or increased ATP
consumption were responsible for decreased ATP remain unanswered and should be fur-
ther investigated.
Study of glutathione metabolism
Next to altered ATP metabolism we searched for alternative pathogenetic mechanisms in
cystinosis.
Theoretical considerations and some clinical data indicated that a disturbed glu-
tathione metabolism might play a role [Rizzo et al. 1999]. Cystine is carried by cystinosin to
the cytosol where it is reduced to cysteine by cytosolic reducing systems [Gahl et al. 2001].
Theoretically the intra-lysosomal cystine accumulation in cystinosis can result in the
cytosolic deficit of cysteine, which together with glutamate and glycine are needed for
glutathione (GSH) synthesis. Cytosolic deficiency of cysteine might limit GSH synthesis.
In a clinical study, comparable to the patients with GSH synthetase deficiency [Larsson et
al. 2000], elevated 5-oxoproline excretion has been demonstrated in cystinotic patients
with Fanconi syndrome, untreated with cysteamine, in contrast to normal 5-oxoproline
excretion in patients with idiopathic Fanconi syndrome. Interestingly, urinary 5-oxopro-
line excretion normalized under cysteamine treatment. Thus, this observation suggests
disturbed GSH homeostasis, specific for cystinosis patients untreated with cysteamine
[Rizzo et al. 1999]. We studied intracellular GSH status in cultured cystinotic fibroblasts and
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PMN cells immediately isolated from blood (Chapter 10) and found that total GSH and
free cysteine were both normal in cystinotic cells. Strikingly, cystinotic fibroblasts and
PMN cells demonstrated a significantly elevated amount of glutathione disulfide (oxi-
dized GSH or GSSG) (median, range in fibroblasts: 0.7 (0.5-1.7) nmol/mg protein versus
0.3 (0.2-0.9) in controls; in PMN: 0.9 (0.3-1.8) nmol/mg protein versus 0.3 (0.2-0.4) in
controls). Subsequently elevated GSSG was also detected in proximal tubular cells
derived from urine of cystinotic patients (Chapter 11). The same change in GSH status
has been demonstrated in immortalized cystinotic fibroblast cell lines by Chol et al.
[2004]. Thus, increased GSSG is a consistent finding in 3 cystinotic cell types and might
reflect a pathogenetic mechanism in cystinosis. The explanation of altered GSH status is
speculative. GSH is the most abundant cellular thiol, functioning as an important redox
buffer. In addition, GSH defends cells against reactive oxygen species (ROS), serving as a
cofactor for the GSH peroxidase family of enzymes, which metabolize H2O2 and lipid
peroxides, resulting in the formation of GSSG. Glutathione reductase, using NADPH oxi-
dase system, is necessary to regenerate GSH [Uhlig et al. 1992]. Thus, elevated GSSG might
reflect aberrant ROS handling and altered redox status present in cystinotic cells.
Importantly, an increased superoxide production has been earlier demonstrated by
chemoluminescence assay in isolated polymorphonuclear cells and mononuclear phago-
cytes from cystinotic children [Pintos Morell et al. 1985]. GSH binds various toxic substances
to form GSH conjugates, that are subsequently exported out of the cells by specific trans-
porters [Lash 2005]. Inhibited transport in cystinotic cells can be responsible for the
decreased efflux of GSSG or GSH conjugates and might explain the altered GSH status in
cystinosis.
In our opinion altered ratios between total and oxidised GSH in cystinotic cells might
not only reflect increased oxidative stress and/or deficient GSSG transport, but itself can
cause further cell damage. Oxidised glutathion (GSSG) can activate pro-apoptotic pro-
tein kinase C δ [Chu et al. 2003] and might be a pro-apoptotic stimulus in cystinosis [Park et
al. 2002].
In conclusion, altered GSH status with increase of GSSG is demonstrated in cystinot-
ic fibroblasts, PMN and proximal tubular cells. Further studies should investigate the ori-
gin and the consequences of this observation.
Development of proximal tubular cell model of cystinosis
Cystinotic fibroblasts and PMN cells, although extensively accumulating cystine, do not
represent an ideal model for studying the pathogenesis of cystinosis for two reasons.
First of all, in patients with cystinosis fibroblasts and PMN cells display no overt signs
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of the disease. Secondly, these cell types in vivo and in vitro preferentially use anaerobic
glycolysis for ATP synthesis [Robinson 1996, Yang et al. 2004]. Cystinotic renal proximal tubu-
lar epithelial cells (PTEC), which are initially affected in cystinosis and in vivo dependent
on oxidative metabolism would be a  much better in vitro cell model for cystinosis
research. Generally renal tissue in cystinosis is unavailable as renal biopsy is not required
for the diagnosis. Therefore attempts have been made to cultivate renal cells exfoliated
into urine [Racussen et al. 1995, Laube et al. 2005].
We succeeded to obtain proximal tubular cell cultures from 9 patients with cystinosis
and 10 healthy controls (Chapter 11). As primary PTEC stop to proliferate after 4-6 pas-
sages, an immortalization step is required to obtain sufficient material for extensive
metabolic studies.
We used human papilloma virus E6/E7 genes, which was previously used for the
immortalization of well characterized human proximal tubular cell line HK-2 [Ryan et al.
1994]. Obtained cell lines demonstrated baso-lateral polarization, enzymatic activity of
alkaline phosphatase, positive staining with anti-aminopeptidase N and anti-megalin
antibody, confirming their proximal tubular origin. Unfortunately, immortalized
cystinotic PTEC accumulated cystine at a much lesser extent compared to cystinotic renal
tissue in vivo, probably due to continuous cell proliferation (0.8±0.9 nmol cystine/mg
protein versus 0.1±0.01 in controls (p<0.05) in contrast to >15 nmol cystine/mg wet tis-
sue in the patients).
Interestingly, immortalized cystinotic PTEC also displayed an increased GSSG con-
tent, which was found in cystinotic fibroblasts and PMN cells (1.2+0.8 nmol/mg protein
versus 0.3±0.2 in controls, p<0.05). Because intracellular ATP content was normal in
cystinotic PTEC, we performed no studies of energy generating capacity in these cells.
Our current understanding of the pathogenesis of the disease is summarised in Figure 1.
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Figure 1 Speculative mechanisms of cellular damage in cystinosis.
Defective cystine exit out of the lysosomes possibly disturbs cytosolic supply of cysteine, which is a limit-
ing step for GSH synthesis. Although GSH and cysteine deficiencies were not detected in our study in rest
conditions, it can occur in conditions of increased oxidative stress, when increased ROS production or
decreased ROS elimination would cause cell damage (stimulate apoptosis or necrosis). Increased GSSG
might be a consequence of increased ROS generation or diminished GSSG efflux out of the cells. Elevated
GSSG/GSH ratio reflects changed redox status in cystinotic cells which could influence gene expression
and stimulate apoptosis. Decreased ATP content in cystinotic cells might result from increased ATP con-
sumption (due to increased oxidative stress) or diminished glycolytic activity.
Abbreviations: GSH, glutathione; GSSG, glutathione disulfide or oxidized GSH; GCS, γ-glutamylcysteine
synthetase; GS, GSH synthetase; γ-glut-cys, γ-glutamylcysteine; MRP2/MRP4, multidrug resistance pro-
teins 2 and 4; OAT1/3, organic anion transporters 1 and 3; 2OG-, 2-oxoglutarate; SOD, superoxide dis-
mutase; SDCT-2, sodium-dicarboxylate transporter 2; ?↓, putative decrease; ?↑, putative increase; ?,
uncertain mechanism.
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Directions for future research
Due to our extensive efforts resulting in improved care of cystinosis patients and more
insights into the pathogenesis of the disease, we suggest the following directions for the
future studies.
Further unraveling the pathogenesis of cystinosis
Proximal tubular cell model of cystinosis requires further optimalization. Recently with
the help of the group of Bristol (Dr. M. Saleem, Dr. P. Mathiesson) we were able to solve
the problem of insufficient cystine accumulation by using for cell immortalisation the
human Simian Virus containing temperature allele (SV40 T antigen), which was previ-
ously used for the immortalisation of human podocytes [Pavenstadt et al. 2003]. Cells trans-
fected with SV40 T vector proliferate at permissive temperature of 33°C, but stop to pro-
liferate at 37°C. Our preliminary studies showed a spectacular cystine accumulation in
cystinotic PTEC after 10 days differentiation at 37°C (up to 8 nmol cystine/mg protein).
Because PTEC cultured from urine might be contaminated by glomerular podocytes and
tubular cells from distal nephron, obtained cell lines should be subcloned.
In obtained cystinotic and control PTEC lines energy generating capacity should be
studied. To force the cells to use OXPHOS, glycolytic pathway should be inhibited. Our
preliminary data demonstrated a significant increase of mitochondrial ATP production
after incubation of the cells with 2-deoxyglucose.
ROS generation and handling and GSH redox cycle enzymes activity should be inves-
tigated at basal conditions and during increased oxidative stress. Exploring influence of
altered GSH status and impaired ROS handling on apoptotic pathways is also an attrac-
tive direction of research. GSH synthesis can be approached by measuring the activity of
the enzymes of γ-glutamyl cycle with stable isotopes.
Transport of GSSG and GSH conjugates out of cystinotic PTEC is another intriguing
research direction, which could possibly explain the alteration of GSH status in cysti-
nosis.
Further improving medical care of patients with cystinosis
Treatment with cysteamine is difficult to follow because it should be taken every 6 hours
and due to its side-effects such as bad breath odor and gastro-intestinal discomfort. The
development of slow release cysteamine preparation or cysteamine pro-drug would solve
the problem of frequent administration. The origin of halitosis induced by cysteamine
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requires further studies to find pharmacological or cosmetic solutions. Gastro-intestinal
complaints can be successfully treated by proton pump inhibitors (PPI) [Dohil et al. 2003],
however, whether PPI do not affect cysteamine pharmacokinetics is unknown.
Factors involved in the development of interstitial fibrosis in cystinosis are another
subject for further studies. Cystinotic PTEC should serve for this purpose. The identifi-
cation of the mechanisms responsible for the interstitial damage leading to renal failure
in cystinosis might allow new therapeutic strategies.
Solving the mechanisms linking lysosomal cystine accumulation and cellular dysfunc-
tion will lead to new treatment modalities in cystinosis.
CHAPTER 12
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Tijdens de laatste decennia werd qua kennis veel vooruitgang geboekt, en toch blijft bij cys-
tinose het Fanconi syndroom irreversibel en leidt op de lange duur tot terminale nier insuf-
ficiëntie bij de meeste patiënten ondanks cysteamine behandeling. Het feit dat de pathoge-
nese van de verstoorde cel functie veroorzaakt door cystine stapeling nog onbegrepen is,
maakt effectieve behandeling moeilijk. Cysteamine is de enige momenteel bestaande behan-
deling welke de progressie van de nierziekte bij cystinose kan vertragen en de extra-renale
organen kan beschermen, maar helaas kan cysteamine cystinose patiënten niet genezen.
Het doel van ons onderzoek beschreven in dit proefschrift was tweevoudig. Wij heb-
ben bijgedragen aan een betere klinische zorg van cystinose patiënten (Hoofdstukken 2-
7). Tegelijkertijd hebben wij celbiologische studies verricht om nieuw inzicht in de
pathogenese te verkrijgen (Hoofdstukken 8-11).
Verbetering van de klinische zorg van cystinose patiënten
Diagnose van cystinose
Cystine meting
Vroege diagnose van cystinose is voor patiënten van belang omdat de behandeling met
cysteamine dan vroegtijdig kan starten. De diagnose is gebaseerd op de klinische symp-
tomen (meestal een uiting van het renaal Fanconi syndroom) en het meten van een ver-
hoogd cystine gehalte in het weefsel van de patiënt. De meeste centra gebruiken de tota-
le witte bloedcellen voor cystine bepaling terwijl cystine met name in de granulocyten
stapelt [Schulman et al. 1970]. De reden hiervoor is dat de totale witte bloedcellen gemakke-
lijker dan de granulocyten uit bloed geïsoleerd kunnen worden. In Hoofdstuk 2 beschrij-
ven wij ons onderzoek dat heeft gedemonstreerd dat de meting in de granulocyt de
gevoeligheid van de cystine bepaling verbetert, wat van groot belang is voor het stellen
van de diagnose en voor het instellen van de behandeling. Bij twee patiënten was bij het
onderzoek de diagnose van cystinose bijna gemist omdat de cystine gehaltes in de totale
witte bloedcellen binnen de spreiding van de heterozygoten lagen, terwijl ze duidelijk ver-
hoogd waren in de granulocyt.
Ook bij de heterozygoten was de gevoeligheid voor de detectie hoger, wanneer cystine
in de granulocyt werd gemeten, zoals al eerder werd aangetoond door Smolin [1987]. Het
is mogelijk dat de prognose van patiënten bij wie cysteamine therapie wordt bijgesteld
aan de hand van het cystine gehalte in de granulocyt beter zal zijn in vergelijking met
degene bij wie cystine in de totale witte bloedcellen wordt gemeten.
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Moleculaire analyse van het cystinose gen
Wij zijn van mening dat de diagnose van cystinose bevestigd moet worden bij alle patiën-
ten met een tweede methode naast het meten van cystine in de bloedcellen.
Onnauwkeurige isolatie, bewaring of transport van de witte bloedcellen kan tot een valse
verhoging van het cystine gehalte leiden tengevolge van de oxidatie van intracellulaire
cysteine, waarvan de concentratie in de cel ~ 100 hoger is dan die van cystine [de Graaf-
Hess et al. 1999]. In Hoofdstuk 3 beschrijven wij een verbeterde PCR methode voor de
detectie van de binnen de Europese populatie meest voorkomende mutatie van het CTNS
gen: de grote 57 kb deletie, die bij 59% van alle onderzochten allelen werd gevonden. Het
verrichten van 2 aparte PCR reacties bij elke patiënt laat een directe indeling toe tussen
patiënten met een homozygote, heterozygote of geen deletie. Bij patiënten met een hete-
rozygote deletie of geen deletie werd een sequentie analyse van het CTNS verricht, die
andere al eerder beschreven mutaties van het CTNS heeft aangetoond. In onze kleine
patiënten populatie (n=11) kon geen genotype-fenotype correlatie aangetoond worden.
De analyse van de grotere patiënten groepen liet wel de correlatie tussen het genotype en
de klinische vorm van cystinose zien [Attard et al. 1999, Anikster et al. 2000, Thoene et al. 1999].
Momenteel wordt standaard moleculaire analyse van het CTNS gen uitgevoerd voor de
bevestiging van de diagnose, eventuele prenatale diagnostiek en heterozygoten detectie.
Behandeling van cystinose
Multidisciplinaire aanpak 
Cystinose is een multi-orgaan ziekte, die klinisch eerst de nieren en cornea beschadigd. De
aandoeningen van de extra-renale organen uiten zich in hypothyroïdie, diabetes mellitus,
mannelijk hypogonadisme, spieratrofie, retinopathie en zenuwstelselschade en komen
meestal voor na de eerste decade. Dit betekent dat de artsen die volwassen cystinose patiën-
ten behandelen op deze extra-renale complicaties bedacht moeten zijn. Omdat cystinose
een zeldzame aandoening is (in Nederland zijn er in totaal 40 cystinose patiënten bekend,
waarvan 10 volwassenen), hebben de internisten weinig gelegenheid om ervaring te ver-
werven met de behandeling van cystinose patiënten. Wij hebben de klinische zorg geëvalu-
eerd van 10 volwassen cystinose patiënten (Hoofdstuk 4) en konden vaststellen dat bij een
aantal patiënten de extra-renale organen niet regelmatig of zelfs nooit werden gecontro-
leerd. De behandeling met cysteamine werd bij de meeste patiënten ook inadequaat voor-
geschreven (of 2 tot 3 keer per dag, terwijl 4 keer per dag aanbevolen is; of de dosis werd
niet aangepast op basis van een verhoogd cystine gehalte in de witte bloedcellen).
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Resultaten van deze evaluatie hebben ons gemotiveerd om een multidisciplinaire polikli-
niek voor cystinose patiënten in UMC St Radboud te organiseren. Deze polikliniek func-
tioneert momenteel sinds 2 jaar en wordt op prijs gesteld door de patiënten en de behan-
delende nefrologen, die de eindverantwoordelijkheid over hun patiënten blijven dragen.
Behandeling van proteïnurie
De achteruitgang van de nierfunctie bij cystinose wordt geassocieerd met het ontwikke-
len van toenemende tubulo-interstitiële schade [Gubler et al. 1999]. Het mechanisme waar-
door cystine stapeling nierinsufficiëntie veroorzaakt is onbekend. Albuminurie, die bij
alle cystinose patiënten aanwezig is, kan bij het ontstaan van de interstitiële fibrose een
rol spelen. In het Hoofdstuk 5 hebben wij bij 5 patiënten met Fanconi syndroom aange-
toond dat de albuminurie met ~40% verlaagd kan worden door de behandeling met een
ACE-remmer enalapril (0,15 mg/kg eenmaal daags). De excretie van het lage moleculair
gewicht eiwit α-1 microglobuline onder enalapril bleef onveranderd. Dit ondersteunt de
opvatting dat albuminurie bij cystinose (gedeeltelijk) glomerulair is. Vermindering van
de albuminurie kan de achteruitgang van de nierfunctie bij cystinose vertragen zoals het
bij verschillende andere nierziekten werd aangetoond [Ruggenenti et al. 2001]. Enalapril ver-
oorzaakte het dalen van systolische bloeddruk bij alle patiënten en klachten van hypo-
tensie bij 2/5 patiënten. De kreatinine klaring daalde van mediaan 48 tot 45 ml/min/1,73
m2, maar steeg terug naar de oorspronkelijke waarde na het stoppen van enalapril. Het is
mogelijk dat de behandeling met de angiotensine II receptor antagonisten een minder
uitgesproken bloeddrukdalend effect zou hebben en daarom beter door cystinose patiën-
ten zal worden verdragen [Gansevoort et al. 1999].
Verbetering van de effectiviteit van cysteamine behandeling
Cysteamine kan het cystine gehalte in de granulocyt bij cystinose met 80-90% verlagen,
maar helaas kan dit medicijn bij de meeste patiënten de achteruitgang van de nierfunc-
tie en het optreden van de extra-renale complicaties niet voorkomen. In Hoofdstukken
6 en 7 hebben wij de mogelijke redenen van het onbevredigende effect van cysteamine
behandeling onderzocht.
Eerst hebben wij vermoed dat cysteamine als klein molecuul (MW 77,14) bij patiën-
ten met  het Fanconi syndroom met de urine verloren kan gaan. Zoals beschreven in
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Verder hebben wij verondersteld dat de inadequate cysteamine toediening verant-
woordelijk kan zijn voor het falen van de behandeling bij sommige patiënten (Hoofdstuk
7). Om deze hypothese te testen, hebben wij Nederlandse cystinose patiënten gevraagd
om een vragenlijst over hun dagelijkse schema van cysteamine toediening in te vullen. De
meeste patiënten (17 van 22) nemen cysteamine alleen overdag met een nachtpauze van
~ 9 uur, terwijl volgens de pharmacodynamische gegevens een toediening elke 6 uur aan-
bevolen is. Bij 11 patiënten hebben wij het ochtend cystine gehalte in de granulocyt
gemeten 6 uur en 9 uur na de laatste cysteamine dosis ‘s avonds. Na 9 uur nachtpauze was
het cystine gehalte in de granulocyt significant hoger in vergelijking met 6 uur nacht-
pauze (0,73±0,81 versus 0,44±0,52 nmol/mg eiwit, p<0,05). Ondanks het feit dat het nog
niet bekend is of het cystine gehalte in de granulocyt de stapeling van cystine in de ande-
re weefsels adequaat weerspiegelt, raden wij alle cystinose patiënten aan om cysteamine
elke 6 uur in te nemen, ook gedurende de nacht.
Samenvattend, naar aanleiding van de resultaten van onze studies, adviseren wij als
optimale zorg van cystinose patiënten:
1. Een zo vroeg mogelijk diagnose van cystinose door het bepalen van het cystine
gehalte in de granulocyt en het onmiddellijk starten van cysteamine behandeling
na het stellen van de diagnose.
2. Het gebruik van de granulocyt voor de monitoring van cysteamine behandeling
(5 à 6 uur na de laatste cysteamine inname moet het cystine gehalte in de granu-
locyt < 0,5 nmol/mg eiwit zijn).
3. Bevestiging van de diagnose van cystinose door de analyse van het CTNS gen (dit
is mogelijk in het laboratorium van DNA diagnostiek, UMC St Radboud,
Nijmegen).
4. Multidisciplinaire aanpak voor de behandeling van met name volwassen cystino-
se patiënten, die behalve nierziekte ook extra-renale orgaan aandoeningen verto-
nen.
5. Toediening van de ACE inhibitoren of angiotensine II receptor antagonisten bij
patiënten met albuminurie onder controle van de bloeddruk en kreatinine klaring
(vereist verdere studies).
6. Toediening van cysteamine elke 6 uur inclusief ‘s nachts.
Samenvatting
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Nieuwe inzichten in de pathogenese van cystinose
In het tweede deel van ons werk (Hoofdstukken 8-11) hebben wij via celbiologische
experimenten nieuwe inzichten in het mechanisme van celschade bij cystinose proberen
te verkrijgen.
Een patiënt beschreven in het Hoofdstuk 8 heeft een geleidelijke achteruitgang van
proximale tubulus functie vertoond met alleen milde aminoacidurie op de leeftijd van 3
weken en een compleet Fanconi syndroom op de leeftijd van 6 maanden. De verschillen-
de gevoeligheid van de apicale proximale tubulus transporters voor cystine stapeling is
mogelijk in strijd met de algemeen aanvaarde hypothese van ATP synthese tekort als het
belangrijkste pathogenetisch mechanisme bij cystinose.
Studie van energie metabolisme in cystinose
Omdat geen dier- of celmodel van cystinose beschikbaar was, werd de pathogenese van
de ziekte voorheen bestudeerd in proximale tubulus cellen geladen met cystine dimethyl
ester (CDME). CDME lading resulteerde in de inhibitie van proximale tubulus transport
vergelijkbaar met een Fanconi syndroom bij cystinose. In dit model werd een uitgespro-
ken daling van de mitochondriële ATP productie aangetoond. Er werd aangenomen dat
ATP tekort is het onderliggende mechanisme was van verstoorde renale absorptie
[Foreman et al. 1987, Salmon et al. 1990, Coor et al. 1991, Ben-Nun et al. 1993, Sakarcan et al. 1992, Foreman
et al. 1995, Baum 1998]. Tot nu toe werd de storing van energie metabolisme in humane weef-
sels van cystinose patiënten niet aangetoond.
Wij hebben het energie metabolisme in de fibroblasten van cystinose patiënten met
een bekende mutatie in het CTNS gen uitvoerig bestudeerd (Hoofdstuk 9). De fibro-
blasten werden gekozen als cel model omdat zij makkelijk beschikbaar zijn via een huid-
biopt en zij tevens in celkweek cystine stapelen. Bovendien heeft onze groep een uitge-
breide ervaring met het bestuderen van mitochondriële functies in primaire fibroblasten,
die bij patiënten met mitochondriële ziekten verstoorde ATP productie en deficiënte oxi-
datieve phosphorylatie (OXPHOS) vertonen [Visch et al. 2004, Loeffen et al. 2000, Ugalde et al.
2004]. Het intracellulaire ATP gehalte was significant verlaagd in fibroblasten van cysti-
nose patiënten (mediaan (range): 37,3 (26,9-55,0) versus 51,5 (44,7-58,5) nmol/mg eiwit
bij controles, p<0,05). Omdat het ATP gehalte in de fibroblast door de celkweek beïn-
vloed kon worden, hebben wij het intracellulair ATP ook bepaald in de granulocyten
direct afkomstig van cystinose patiënten en gezonde controles. In de granulocyten van
patiënten was het ATP gehalte significant verlaagd in vergelijking met controles (medi-
aan, range: 317 (149-1141) versus 557 (207-1101) nmol/mg eiwit, p<0,05).
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Het intracellulaire ATP gehalte is het resultaat van de ATP synthese door glycolyse
en/of mitochondriële OXPHOS en ATP verbruik. Verminderde productie, verhoogd ver-
bruik of beide factoren kunnen de verlaging van het ATP gehalte veroorzaken. Wij heb-
ben onze studies geconcentreerd op de mitochondriële ATP productie omdat in het
CDME ladingsmodel van cystinose een mogelijk defect van complex I werd aangetoond
[Foreman et al. 1995]. De activiteit van de mitochondriële ademhalingsketen enzymcom-
plexen in mitochondriële verrijkte celfracties en bradykinin- gestimuleerde maximale
ATP productie in intacte cellen waren allen normaal in cystinotische fibroblasten. ATP
verlaging had geen functioneel effect op de activiteit van Na,K ATP-ase, gemeten met Rb+
influx.
Samenvattend, heeft onze studie geen storing van energie genererend vermogen in de
cystinotische fibroblasten aangetoond, wat niet overeenkomt met de hypothese gepostu-
leerd in het CDME ladingsmodel van cystinose. De andere mogelijke verklaringen van
ATP verlaging zoals de inhibitie van de glycolyse of een verhoogd ATP verbruik moeten
verder worden bestudeerd.
Studie van het glutathione metabolisme
Naast het bestuderen van de mitochondriële ATP productie, hebben wij gezocht naar een
andere verklaring voor de verstoorde celfunctie bij cystinose.
De stoornis in het glutathione (GSH) metabolisme was een mogelijkheid. Glutathione
is een tripeptide, gesynthetiseerd uit cysteïne, glutamaat en glycine. GSH functioneert als
een belangrijke redox buffer en verdedigt de cel tegen zuurstof radicalen (ROS). Cystine
stapeling in het lysosoom zou kunnen leiden tot cysteïne tekort in het cytosol, omdat cys-
tine in het cytosol tot cysteïne wordt gereduceerd [Gahl et al. 2001].
Bij patiënten met cystinose, onbehandeld met cysteamine, werd een verhoogde excre-
tie van 5-oxoproline aangetoond, vergelijkbaar met patiënten met GSH synthetase defi-
ciëntie [Larsson et al. 2000]. Het starten van de cysteamine behandeling resulteerde in de
normalisatie van de 5-oxoproline excretie [Rizzo et al. 1999]. Gezien 5-oxoprolinurie niet
werd aangetoond bij patiënten met een idiopatisch Fanconi syndroom, lijkt deze afwij-
king specifiek voor cystinose te zijn. Wij hebben de intracellulaire GSH status in cystino-
tische fibroblasten en de granulocyten bestudeerd (Hoofdstuk 10) en vonden een nor-
maal totaal GSH en vrij cysteïne gehalte in beide celsoorten. Opvallend was het verhoogd
gehalte van glutathione disulfide (GSSG) in de fibroblasten en granulocyten van cystino-
se patiënten in vergelijking met controles (mediaan (range) in fibroblasten: 0,7 (0,5-1,7)
nmol/mg eiwit versus 0,3 (0,2-0,9) bij controles; in de granulocyt: 0,9 (0,3-1,8) nmol/mg
eiwit versus 0,3 (0,2-0,4) in controles). Later werd dit verhoogde GSSG ook in de proxi-
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male tubulus cellen van cystinose patiënten aangetoond (Hoofdstuk 11). Een stijging van
GSSG werd ook geobserveerd door Chol et al. [2004] in geïmmortaliseerde cystinotische
fibroblast cellijnen. Het gestegen GSSG gehalte in 3 cystinotische celsoorten kan een ver-
stoorde peroxidatie en redox status in de cellen reflecteren en wijst mogelijk op een nieuw
pathogenetisch mechanisme bij cystinose dat verdere studie vereist.
In de cel reageert GSH met verschillende stoffen (zoals medicijnen en xenobiotica) die
verder als glutathione-S conjugaten uit de proximale tubuluscel worden geëxporteerd
[Wright et al. 2004, Lash 2005]. Geremd export van GSSG of GSH-conjugaten kan eventueel
ook een verstoorde GSH status in de cystinotische cellen veroorzaken (Figuur 1, pagina
136).
GSSG kan pro-apoptotische protein kinase C δ activeren [Chu et al. 2003] en zou een
pro-apoptotische stimulus bij cystinose kunnen zijn [Park et al. 2002, Park et al. 2005].
Samenvattend hebben wij een verstoorde status van GSH met een verhoging van
GSSG in cystinotische fibroblasten, granulocyten en proximale tubulus kunnen vaststel-
len. Verdere studie moet oorzaak en consequenties van deze observatie onderzoeken.
Ontwikkelen van proximale tubulus celmodel van cystinose
Cystinotische fibroblasten en granulocyten zijn geen ideaal model voor de studie van de
pathogenese bij cystinose ondanks het feit dat ze cystine stapelen. Bij patiënten met cys-
tinose vertonen deze cellen geen duidelijke tekens van de ziekte. Bovendien gebruiken
beide celsoorten in vivo met name anaërobe glycolyse voor de ATP productie [Robinson
1996, Yang et al. 2004]. Proximale tubulus cellen (PTEC) zijn de eerste cellen die klinische
tekens van cystinose vertonen en in vivo bijna volledig afhankelijk zijn van het oxidatie-
ve metabolisme. Deze cellen zouden uiteraard het meest geschikte in vitro cel model voor
cystinose zijn. Omdat nierweefsel van cystinose patiënten niet wordt afgenomen voor het
stellen van de diagnose, werd getracht om cystinotische niercellen uit urine te kweken
[Racussen et al. 1995, Laube et al. 2005].
Het is ons gelukt om proximale tubulus cellen uit urine van 9 cystinose patiënten en
10 controles te isoleren (Hoofdstuk 11). Omdat primaire PTEC stoppen met delen na 4
à 6 passages, waren wij genoodzaakt deze cellen te immortaliseren. De cellen werden
getransfecteerd met humane papilloma virus E6/E7 genen (HPV E6/E7), die vroeger
reeds gebruikt werden voor de immortalisatie van de humane proximale tubulus cellijn
HK-2 [Ryan et al. 1994]. De verkregen cellijnen vertoonden baso-laterale polarisatie, enzy-
matische activiteit van alkalische fosfatase en positieve kleuring met een antilichamen
tegen aminopeptidase M en tegen de megaline, wat hun proximale tubulus oorsprong
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bevestigt. Helaas was het cystine gehalte veel lager in de met HPV E6/E7 geïmmortali-
seerde cystinotische PTEC, in vergelijking met in vivo cystinotisch nierweefsel (0,8±0,9
nmol cystine/mg eiwit versus 0,1±0,01 bij controle PTEC (p<0,05) versus >15 nmol cys-
tine/mg nierweefsel bij patiënten met cystinose).
Vergelijkbaar met cystinotische fibroblasten en granulocyten, vertoonde cystinotische
PTEC een verhoogd GSSG gehalte (1,2±0,8 nmol/mg eiwit versus 0,3±0,2 bij controles,
p<0,05).
Omdat het intracellulaire ATP normaal was in cystinotische PTEC, werden geen stu-
dies van mitochondriële ATP productie in deze cellen uitgevoerd.
Concluderend, hebben wij een geringe verlaging van het ATP gehalte in de cystinoti-
sche fibroblasten en de granulocyten aangetoond. Geen defect in de mitochondriële ATP
productie kon worden aangetoond in de cystinotische fibroblasten. Verstoorde GSH sta-
tus met een verhoging van GSSG gehalte in cystinotische cellen wijst mogelijk op een
nieuw pathogenetisch mechanisme. PTEC cellen kunnen uit urine worden verkregen. De
immortalisatie met HPV E6/E7 resulteerde in geringe cystine stapeling.
Op basis van onze en andere studies, is onze huidige opvatting van de pathogenese van
cystinose samengevat in (zie Figuur 1, pagina 136).
Richtingen van toekomstig onderzoek
Zoals na het lezen van mijn proefschrift duidelijk is, is met name de pathogenese van cys-
tinose nog niet opgehelderd en moet verder onderzoek plaats vinden.
Volgende onderzoeksrichtingen kunnen worden voorgesteld:
Het proximale tubulus celmodel van cystinose moet verbeterd worden. Onlangs konden
wij met de hulp van de groep uit Bristol (Dr. M. Saleem, Dr. P. Mathiesson) het probleem
van onvoldoende cystine stapeling in vitro oplossen. De immortalisatie van primaire PTEC
met een humaan Simian virus met een temperatuur gevoelig allele (SV 40 T) resulteerde in
celproliferatie bij 33°C en proliferatie stop bij 37°C. Onze preliminaire studie heeft een
spectaculaire cystine stapeling in cystinotische PTEC na 10 dagen differentiatie bij 37°C
aangetoond (tot 8 nmol cystine/mg eiwit). Om zuivere PTEC te verkrijgen moeten geïm-
mortaliseerde PTEC gecloneerd worden om de contaminatie door andere niercellen zoals
glomerulaire podocyten en cellen van het distale nephron te voorkomen.
In de cystinotische en controle PTEC moet het energie metabolisme bestudeerd wor-
den. Omdat in kweek PTEC vooral via glycolyse ATP produceren [Felder et al. 2002], moe-
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ten de cellen gestimuleerd worden om OXPHOS te gebruiken. In preliminaire experi-
menten kon dat gerealiseerd worden door de cellen met een inhibitor van glycolyse (2-
deoxyglucose) te incuberen.
ROS productie samen met de activiteit van GSH redox cyclus enzymen moet bestu-
deerd worden in rustcondities en in condities van verhoogde oxidatieve stress. Een ver-
stoorde GSH status kan apoptose stimuleren, wat ook verder onderzocht kan worden. De
GSH synthese kan onderzocht worden door het bestuderen van de activiteit van de enzy-
men van γ-glutamyl cyclus via het gebruik van stabiele isotopen.
Transport van GSSG, GSH en GSH-S conjugaten in cystinotische en controle PTEC is
ons inziens een andere veelbelovende onderzoeksrichting.
Verdere verbetering van de medische zorg van cystinose patiënten
Het is zeer moeilijk om de behandeling met cysteamine vol te houden, omdat de medi-
catie elke 6 uur ingenomen moet worden. Bijwerkingen van cysteamine zoals slechte
adem en gastro-intestinale klachten hebben ook een negatief effect op de therapietrouw.
Het ontwikkelen van preparaten met gereguleerde afgifte of cysteamine pro-drug zou het
probleem van frequente toediening kunnen oplossen. De oorzaken van de slechte adem
moet verder onderzocht worden om hiervoor oplossingen te kunnen zoeken. Gastro-
intestinale klachten kunnen met waterstofionen secretie inhibitoren (PPI) behandeld
worden [Dohil et al. 2003], maar het is niet bekend of deze medicijnen de opname van cys-
teamine beïnvloeden.
De factoren betrokken bij het ontstaan van interstitiële fibrose bij cystinose moeten
verder bestudeerd worden. Cystinotische PTEC kunnen daarvoor worden gebruikt.
Wanneer het mechanisme bekend zou worden waardoor cystine stapeling een stoor-
nis van de celfunctie veroorzaakt, verwachten wij dat er andere behandelingen naast cys-
teamine zullen worden toegepast.
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истиноз – редкое лизосомальное заболевание, главным проявлением которого является
накопление цистина внутри лизосом. олезнь обычно проявляется дисфункцией
проксимальных почечных канальцев, известной как синдром !анкони, и
прогрессирующей к терминальной стадии почечной недостаточности (ESRD). #роме
почек, лизосомальный цистин накапливается во всех тканях, вызывая повреждение
многих органов, что делает цистиноз системным метаболическим заболеванием.
Аминотиол цистамин в настоящее время является единственным лекарственным
препаратом, уменьшающим содержание цистина, который замедляет ухудшение
почечной функции и замедляет развитие экстраренальных осложнений. У больных с
цистинозом терапия цистеамином должна быть назначена как можно в раннем возрасте
и продолжена в течение всей жизни, включая период после трансплантации почки (для
защиты экстраренальных органов) [Gahl и др. 2001, Gahl и др. 2002, Levtchenko и др.
2004]. (есмотря на значительный прогресс в последние три десятилетия, включая
возможность лечения цистеамином, у большинства больных с цистинозом всё же
развивается ESRD и экстраренальные осложнения. *атогенез клеточной дисфункции,
вызванный накоплением цистина, до настоящего времени остается неизвестен.  + своих
исследованиях, представленных в настоящей работе, мы ставили целью улучшение
диагностики и лечения больных цистинозом (лавы 2 - 7). + то же время мы проводили
биохимические и моллекулярные исследования для изучения патогенеза цистиноза
(лавы 8 - 11). 
Улучшение диагностики и лечения цистиноза
иагноз цистиноза
Определение цистина
,ля раннего начала терапии цистеамином необходима ранняя постановка диагноза
цистиноза. ,ля этого нужно определение в тканях пациента повышенного содержания
цистина. *атогномоничным является также обнаружение кристаллов цистина в роговой
оболочке глаза, которые проявляются только после первого года жизни. #летки крови
наиболее доступны для определения цистина и используются для постановки диагноза.
,ля мониторинга терапии цистеамином также требуется определение содержания
цистина в клетках крови. -радиционно цистин определяли в смеси лейкоцитов (ML),
несмотря на то, что он преимущественно накапливается в полиморфноядерных
лейкоцитах (PMN) и в моноцитах , а не в лимфоцитах [Schulman и др. 1970]. -ак как
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количество цистина выражается в nmol/mg белка, содержание в ML, содержащем
значительный процент лимфоцитов, оказывается ниже, чем количество, определяемое в
PMN. + лаве 2 мы описываем наши исследования по сравнению уровня цистина в ML
и PMN, произведенных одновременно методом HPLC. (а основании наших данных, мы
рекомендуем определять уровень цистина в PMN, а не в MN, т.к. это позволяет
увеличить чувствительность определения цистина при постановке диагноза, что важно
для своевременного назначения терапии цистеамином, и обеспечивает более
правильную оценку содержания цистина при мониторинге лечения цистеамином. 
олекулярный анализ гена цистиноза
*о нашему мнению, диагноз цистиноза следует подтверждать у всех больных
дополнительным методом, кроме определения цистина в PMN. Ошибки при изоляции
PMN или транспортировке могут привести к увеличению уровня цистина в результате
окисления внутриклеточного цистеина, который приблизительно в 100 раз превышает
таковой в цитозоле лейкоцитов по сравнению с цистином [Graaf-Hess и др. 1999]. + 1998
году был установлен ген CTNS (17p13), кодирующий лизосомальный белок цистинозин,
транспортирующий цистин из лизозом [Town и др. 1998]. + главе 3 [Heil и др. 2001] мы
описываем улучшенный метод для определения распространенной в популяции
европейцев 57-kb делеции гена NS, которая была обнаружена у 59 % (13/22) из всех
тестированных аллелей. Оставшиеся аллели были подвержены молекулярному анализу и
выявили другие ранее известные мутации во всех, кроме трех аллелей. + настоящее
время разработанный нами молекулярный анализ используется для подтверждения
диагноза цистиноза в .олландии, и может быть применен для пренатальной диагностики
и подтверждения гетерозиготности. 
ечение цистиноза
ультисистемный подход
истиноз является мультисистемным заболеванием, вначале клинически
проявляющимся поражением почек и роговой оболочки. *ри невозможности диализной
терапии и трансплантации почки больные цистинозом обычно умирают до 10 лет, при
этом экстраренальные проявления заболевания преимущественно не обнаруживаются.
олее длительное выживание больных цистинозом благодаря трансплантации почек
выявило поражение эндокринных органов (гипотиреоидизм, сахарный диабет, мужской
гипогонадизм, вакуолярную миопатию, ретинопатию, поражение центральной и
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периферической нервной системы, поражение печени и экзокринной функции
поджелудочной железы), обычно развивающееся в возрасте после 10 лет [Gahl и др.
2002]. Это означает, что врачи, занимающиеся лечением взрослых пациентов с
цистинозом (нефрологи-терапевты) сталкиваются с экстраренальными осложнениями
цистиноза. *оскольку цистиноз является редким заболеванием (например, в
(идерландах имеется всего 40 пациентов с цистинозом, среди них 10 взрослых),
нефрологи, которые лечат взрослых пациентов, не имеют опыта в лечении этих больных.
,ругая ситуация складывается в детской нефрологии, которая сконцентрирована в
нескольких университетских нефрологических центрах. ,ля того, чтобы оценить
адекватность лечения десяти нидерландских взрослых пациентов с цистинозом, мы
тщательно изучили их истории болезни (лава 4). ыло выявлено, что
офтальмологическое обследование никогда не проводилось у двух пациентов,
тиреоидная функция не проверялась у других двух пациентов, и еще у двух пациентов не
проводился контроль сахара крови. -олько 7 нидерландских взрослых пациентов
лечились цистеамином (у троих из них препарат был назначен в двух или трех дозах
ежедневно, в то время как необходимо получение лекарства 4 раза в сутки). 0одержание
цистина в лейкоцитах находилось в рекомендованных границах только у трех пациентов.
(еадекватное лечение нидерландских пациентов с цистинозом [Geelen и др. 2003]
явилось поводом для организации поликлинического приема для взрослых голландских
пациентов, который функционирует в 1едицинском ентре 2адбауд (эймегена в течение
двух лет. + течение одного дня пациенты с цистинозом обследуются опытным
специалистом по метаболическим заболеваниям, офтальмологом, невропатологом (те, у
которых есть соответствующие жалобы), и клиническим генетиком. 
,ополнительно организована помощь социального работника для всех пациентов. #ровь
для определения цистина берут через 5 – 6 часов после приёма цистеамина и подвергают
немедленному анализу. 2екомендации направляются нефрологу, который остается
ведущим специалистом при лечении этих пациентов. + течение последних двух лет мы
выявили двух до этого невыявленных взрослых пациентов с цистинозом и одного
пациента, у которого диагноз цистиноза был снят после 20 лет терапии цистеамином. 
ечение протеинурии
0нижение почечной функции у больных с цистинозом сопровождается прогрессивным
развитием поражения интерстициальной ткани почек, включающих атрофию почечных
канальцев и фиброз [Gubler и др. 1999]. *атогенетические механизмы, путем которых
накопление цистина приводит к падению функции почек, неизвестны. Альбуминурия,
неизменно наблюдаемая у больных с цистинозом, может быть одним из факторов,
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вызывающих интестиальное поражение почек. + лаве 5 [Levtchenko и др. 2003] мы
показали на 5 пациентах с синдромом !анкони, что альбуминурия может быть уменьшена
на 40 % при лечении ингибитором ангиотензин превращающего фермента (ACE) –
эналаприлом (0,15 mg/kg ежедневно). 5нтересно, что лечение эналаприлом не изменяет
повышенную экскрецию низкомолекулярного белка ¿-1 микроглобулина, что
подтверждает гломерулярное происхождение альбуминурии. 0нижение альбуминурии
может замедлить развитие почечной недостаточности при цистинозе, как это было
показано при других заболеваниях почек [Ruggenenti и др. 2001]. (еудивительно, что
лечение эналоприлом сопровождалось снижением систолического кровяного давления и
жалобами на низкое давление у двух из пяти человек. #лиренс креатинина снижался со
средних 48 до 45 ml/min/1.73 м2 и возвращался к прежним значениям после отмены
эналоприла. 
овышение эффективности терапии цистеамином
истеамин может снижать содержание цистина в лейкоцитах на 80-90 %, но только
замедляет снижение функции почек и проявление экстраренальных осложнений у
большинства пациентов. ,ва исследования, описанных в лавах 6 и 7, направлены на
повышение эффективности терапии цистеамином. 
+начале мы предположили, что цистеамин, являясь малой молекулой (мол. вес 77.14),
может выделяться с мочой у больных с цистинозом, страдающих от синдрома !анкони.
#ак показано в лаве 6 [Levtchenko и др. 2002], причина была не в этом, так как менее
чем 1 % введенного цистеамина экскретировалась с мочой. ,алее мы предположили, что
неправильное введение цистеамина может быть причиной неуспешной терапии у
некоторых пациентов (лава 7). ,ля проверки этого предположения мы выявили режим
ежедневного приема цистеамина у нидерландских пациентов. +ыяснилось, что только 5
из 22 пациентов принимали лекарство каждые 6 часов, как им было рекомендовано в
связи с фармакодинамическими данными препарата. ольшинство пациентов принимали
цистеамин только в течение дня, что приводило к ночной паузе приблизительно в 9 часов
между последним вечерним и первым утренним приемом. + 11 случаях утреннее
содержание цистина в PMN было выше значения 0.5 nmo/mg, т.к. прошло 9 часов после
вечернего приема (0.73 + 0.81 по сравнению с 0.44 + 0.52 nmo цистина /mg белка через
6 часов после последнего вечернего приема цистеамина, p < 0.05). (а основании этих
данных мы настойчиво рекомендуем больным с цистинозом принимать цистеамин каждые
6 часов в течение суток. 
Основываясь на результатах наших исследований, для получения оптимального
результата лечения цистиноза мы рекомендуем: 
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1. 1аксимально раннее установление диагноза цистиноза методом исследования
содержания цистина в полиморфноядерных лейкоцитах для немедленного
назначения лечения цистеамином. 
2. 5спользовать определение уровеня цистина в полиморфноядерных лейкоцитах
для мониторинга цистеаминовой терапии (через 5 – 6 часов после последнего
введения цистеамина содержание цистина в PMN кдетках должно быть ниже,
чем 0.5 nmol цистина/mg белка.
3. *одтверждать диагноз цистиноза молекулярным анализом CTNS гена. 
4. 1ультидисциплинарный подход к лечению взрослых больных цистинозом,
страдающих от экстраренальных осложнений этого заболевания. 
5. +ведение ингибиторов ACE, или блокаторов рецептора ангиотензин II больным с
альбуминурией при строгом контроле кровяного давления и креатинина
сыворотки крови.
6. +ведение цистеамина каждые 6 часов, включая ночные часы. 
следование патогенеза цистиноза
+торая часть нашей работы (лавы 8 – 11) включает исследования патогенетических
механизмов клеточной дисфункции при цистинозе. 
+ описании казуса, представленной в лаве 8, показано постепенное развитие
дисфункции проксимальных почечных канальцев, начавшейся с легкой аминоацидурии,
выявленной в возрасте 3 недель, и приведшей к выраженному синдрому !анкони в
возрасте 6 месяцев. 2азличная чувствительность транспортных белков проксимальных
почечных канальцев к накоплению цистина, по нашему мнению, противоречит
общепринятой гипотезе о нарушении синтеза AT!, являющейся основным звеном в
патогенезе цистиноза. 
"зучение энергетического метаболизма при цистинозе
*оскольку ранее не существовало модели цистиноза на животных или клетках, патогенез
заболевания изучали путем культивирования проксимальных почечных канальцев с
эфиром цистина (0D16). #ультивирование с CDME приводило к ингибированию
транспорта в клетках проксимальных почечных канальцев, подобному синдрому !анкони
при цистинозе. (а этой модели было продемонстрировано выраженное снижение синтеза
А-! в митохондриях, которое считали основным патогенетическим механизмом
цистиноза [Foreman и др. 1987, Salmon и др. 1990, Coor и др. 1991, Sakarcan и др. 1992, Ben Nun и др.
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1993, Foreman и др. 1995, Baum 1998]. ,о настоящего времени энергетический метаболизм у
больных цистинозом не был исследован. 
1ы исследовали синтез А-! в первичных культивированных фибробластах от больных с
цистинозом с известными генетическими эффектами гена CTNS (лава 9). !ибробласты
больных накапливали цистин (в среднем 4.3 (2.7 – 5.5) против 0.2 (0.1 – 0.3) nmol/mg
белка (p < 0.01) и содержали сниженное количество внутриклеточной А-! по сравнению
с контрольными фибробластами (в среднем 37.3 (26.9 – 55) против 51.5 (44.7 – 58.5)
nmo/mg белка, p < 0.05). 
,ля подверждения снижения внутриклеточной А-! при цистинозе, мы дополнительно
измеряли содержание А-! в PMN клетках, выделенных из крови больных и здоровых
добровольцев. Аналогично снижению содержания А-! в фибробластах цистинозных
больных, в 21N клетках больных содержание А-! по сравнению с контрольными было
также снижено (среднее: 317 (149 – 1141) против 557 (207 – 1101) nmol/mg белка,
p < 0.05).
Уровень внутриклеточной А-! является результатом динамического процесса продукции
А-! (гликолиз в цитозоле и митохондриальное оксидативное фосфорилирование,
OXPHOS) и потребления А-!.
0нижение продукции А-!, увеличение ее потребления, или комбинация обоих процессов
может привести к снижению уровня внутриклеточной А-!. (аши исследования были
сосредоточены на способности митохондрий продуцировать А-!, так как возможное
снижение активности митохондриального комплекса I было продемонстрировано на CDME
модели цистиноза [Foreman и др. 1995]. 0ледует отметить, что общая способность к
продукции А-!: активность комплексов дыхательной цепи в обогащенных митохондриями
клеточных фракциях и стимулированная брадикинином продукция митохондриальной А-! в
цистинозных фибробластах находились на нормальном уровне. 5нтересно, что после
ингибированного гликолиза 2-дезоксиглюкозой (DOG), или йодацетатом натрия (SIA), не
выявлено различия между внутриклеточным содержанием А-! в цистинозных и
контрольных фибробластах, что дает возможность предположить изменение гликолиза при
цистинозе. ,ля того, чтобы исследовать, сопровождается ли сниженный уровень А-!
функциональными изменениями в фибробластах, мы исследовали активность Na,K А-!-
азы. Это исследование не обнаружило различий между цистинозными и контрольными
клетками, это позволяет допустить, что снижение А-! в цистинозных клетках оставалось
достаточным для нормальной функции Na,K А-!-азного насоса.
+ заключение нужно отметить: наше исследование показало, что снижение содержания
А-! в цистинозных клетках не является результатом снижения генерирующей
способности митохондрий к синтезу А-!, которое было установлено при изучении 0DME
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модели цистиноза. +озможное снижение активности гликолиза или увеличенное
потребление А-! требуют дальнейшего изучения.
"зучение метаболизма глютатиона
*оскольку не было обнаружено изменений митохондриальной генерации А-! при
цистинозе, мы искали альтернативные патогенетические механизмы этого заболевания.
(екоторые теоретические данные указывали на то, что нарушение метаболизма
глютатиона (GSH) могут играть свою роль в этом процессе. GSH - клеточный тиол,
функционирующий как важный окислительно-восстановительный буфер, защищающий
клетки от повреждения свободными радикалами. .лютатион синтезируется из цистеина,
глютамата и глицина. истин, доставленный цистозином в цитозоль, окисляется в
цистеин окислительными системами цитозоля [Gahl и др. 2001]. -еоретически
интрализосомальное накопление цистина при цистинозе может привести к дефициту
цистеина в цитозоле, что может лимитировать синтез GSH. + клиническом исследовании
повышенная экскреция 5-оксипролина была продемонстрирована у цистинозных больных
с синдромом !анкони, нелеченых цистеамином, в отличие от нормальной экскреции 5-
оксипролина у больных с идиопатическим синдромом !анкони. Это наблюдение
подтверждает роль нарушения гомеостаза глютатиона, специфическое для цистинозных
больных, нелеченых цистеамином [Rizzo и др. 1999]. 1ы изучали содержание
внутриклеточного GSH в фибробластах и PMN немедленно после выделения из крови
цистинозных больных (лава 10) и обнаружили, что содержание общего GSH и
свободного цистеина были в пределах нормы в цистинозных клетках [Levtchenko и др.
2005]. + цистинозных фибробластах и PMN клетках показано значительное увеличение
количества глютатион-дисульфида (окисленный GSH или GSSG) (среднее значение в
фибробластах: 0.7 (0.5 – 1.7) nmol/mg белка против 0.3 (0.2 – 0.9) в контрольных
клетках; в клетках PMN: 0.9 (0.3 – 1.8) nmol/mg белка против 0.3 (0.2 – 0.4) в
контрольных клетках (р<0.05). *овышенное содержание GSSG было также обнаружено
в проксимальных клетках почечных канальцев, выделенных из мочи цистинозных больных
(лава 11). Увеличение GSSG, обнаруженное в трех типах клеток у больных цистинозом,
возможно указывает на новый патогенетический механизм цистиноза. *овышенная
продукция кислородных радикалов и/или нарушение транспорта GSSG из клеток может
быть причиной повышения GSSG. GSSG может активировать протеинкиназу 0 ‰ [Chu и
др. 2003], и являться стимулом апоптоза при цистинозе [Park и др. 2002, Park и др.
2005].
+ заключение следует сказать, что причины и последствия изменения статуса GSH с
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возрастанием GSSG,  выявленное в цистинозных фибробластах, PMN и клетках
проксимальных почечных канальцев требует дальнейшего изучения.
%азработка модели клеток проксимальных канальцев при цистинозе
истинозные фибробласты и PMN клетки, несмотря на свою способность к
интенсивному накоплению цистина, не представляют идеальной модели для изучения
патогенеза цистиноза по двум причинам. +о-первых, фибробласты и цистинозные клетки
цистинозных больных не имеют отчетливых признаков этого заболевания in vivo. +о-
вторых, эти клеточные типы in vivo и in vitro для синтеза А-! используют
преимущественно анаэробный гликолиз [Robinson 1996, Yang и др. 2004].
Эпителиальные клетки почечных проксимальных канальцев (PTE0), которые
преимущественно поражаются при цистинозе и in vivo почти полностью зависят от
окислительного метаболизма, могли бы служить более подходящей in vitro моделью для
исследования цистиноза. -ак как почечная ткань при цистинозе обычно недоступна для
исследования из-за того, что почечная биопсия не требуется для постановки диагноза,
делались попытки культивировать почечные клетки, выделяемые с мочой [Racussen и др.
1995, Laube и др. 2004]. 
(ам удалось получить культуры клеток проксимальных канальцев у 9 больных с
цистинозом и у 10 здоровых человек (лава 11). -ак как первичные PTE0 прекращают
деление после 4 – 6 пассажей, то необходимо проведение иммортализации для
получения достаточного количества материала. 1ы заражали клетки PTEC генами
вируса папиломы человека 66/67, которые ранее использовались для иммортализации
хорошо изученных клеточных линий (#-2 проксимальных канальцев человека [Ryan и др.
1994]. *олученные нами линии клеток демонстрировали базо-латеральную поляризацию,
активность щелочной фосфатазы, положительную иммунофлюоресценцию с антителами
к аминопептидазе N и мегалину, что подтверждает их происхождение из проксимальных
канальцев. # сожалению, иммортализованные цистинозные PTE0 накапливали цистин в
значительно меньшей степени по сравнению с цистинозной тканью почки in vivo,
возможно вследствие постоянной клеточной пролиферации в результате иммортализации
(0.8 + 0.9 nmol цистина/mg белка против 0.1 + 0.1 в контроле р < 0.05), в то время как
in vivo более 15 nmol цистина/mg мокрого веса ткани больных). 5нтересно, что в
иммортализованных цистинозных PTE0 обнаружен повышенный уровень GSSG,
который также выявлен в цистинозных фибробластах и PMN клетках (1.2 + 0.8 nmol/mg
белка против 0.3 + 0.2 в контроле, р < 0.05). -ак как содержание внутриклеточного А-!
было нормальным в цистинозных PTE0, мы не производили исследования
энергетического обмена в этих клетках. 
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+ заключение,  мы показали выраженное снижение уровня внутриклеточной А-! в
культивированных фибробластах и PMN клетках цистинозных больных. + цистинозных
фибробластах продукция митохондриальной А-! была в прелелах нормы в отличие от
результатов, полученных при изучении CDME модели цистиноза. *овышенное
содержание окисленного GSH в цистинозных клетках может указывать на наличие
нового патогенетического механизма цистиноза. PTE0 могут быть получены из мочи
цистинозных больных и здоровых людей. 5ммортализация цистинозных клеток с
помощью HPV 66/67 приводит к недостаточному накоплению цистина, которое не
отражает накопление цистина в почке in vivo. (а основании наших и других результатов
мы представляем современное понимание патогенеза этого заболевания в рисунке 1
(стр. 136).
аправление дальнейших исследований
&альнейшее изучение патогенеза цистиноза
1. 1одель клеток проксимальных почечных канальцев должна быть улучшена.
(едавно нам удалось решить проблему недостаточного накопления цистина в
цистинозных PTE0 иммортализованных HPV 66/67 путем использования
человеческого Simian Virus, содержащего аллель, чувствительный к
температуре (SV40 T антиген), который ранее использовался для
иммортализации подоцитов человека (Pavenstadt и др. 2003). #летки,
трансфектированные SV40 T вектором, пролиферируют при температуре 330C,
но прекращают пролиферацию при 3700. (аши предварительные исследования
обнаружили существенное накопление цистина в цистинозных PTE0 после 10
дней дифференцировки при 3700 (до 15 nmol цистина/mg белка). -ак как клетки,
культивированные из мочи, могут быть содержать гломерулярные подоциты и
клетки канальцев дистального нефрона, полученные линии клеток следует
субклонировать. 
2. 0ледует изучить энергетическую способность (OXPHOS и гликолиз) и
потребление А-! в линиях цистинозных и контрольных PTE0. -ак как в культуре
PTE0 аэробный обмен переходит на путь гликолиза [Felder и др. 2002], то
гликолиз следует ингибировать. (аши предварительные данные показали
значительное увеличение продукции митохондриальной А-! после инкубации
PTE0 2-дезоксиглюкозой, ингибирующей гликолиз.
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3. *родукция свободных радикалов кислорода и активность окислительных
ферментов GSH в покое и в условиях повышенного окислительного стресса
следует изучить, т.к. ROS может играть роль в патогенезе цистиноза. 5зменение
обмена GSH могут активировать. ,ефицит синтеза GSH можно показать при
изучении активности ферментов Á-глютамил цикла со стабильными изотопами.
4. -ранспорт GSSG в цистинозных PTE0 – другое интересное направление,
которое, возможно, объяснит механизм клеточной дисфункции при цистинозе. 
&альнейшее улучшение медицинской помощи больным цистинозом
1. 8ечение цистеамином затруднительно, поскольку оно требует введения
препаратов каждые 6 часов. *обочные эффекты этого препарата, такие как
неприятный запах изо рта и желудочно-кишечные нарушения, вызывают
негативное отношение к нему у больных. 2азработка препаратов с медленным
высвобождением цистеамина могло бы решить проблему необходимости частого
введения препарата. *ричина неприятного запаха, вызываемого цистеамином,
должна быть в дальнейшем изучена для того, чтобы найти фармакологические
или косметические пути ее решения. 9елудочно-кишечные проблемы можно
успешно лечить с помощью ингибиторов протонового насоса PPI [Dohil и др.
2003], однако, влияет ли PPI на фармакокинетику цистеамина при его оральном
введении, еще должно быть изучено. 
2. !акторы, влияющие на развитие интерстициального фиброза при цистинозе,
также должны изучаться в дальнейшем. ,ля этой цели могут служить PTEC
больных с цистинозом. 5дентификация механизмов, ответственных за
интерстициальные повреждения, приводящие к почечной недостаточности у
цистинозных больных, может открыть новые терапевтические перспективы. 
3. #огда патогенетические механизмы, связывающие накопление лизосомального
цистина с нарушением функции клеток, станут известны, то, возможно, появятся
другие, кроме введения цистеамина, пути лечения больных цистинозом.
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Abbreviations
ACD Acid-citrate-dextrose
ACE Angiotensin converting enzyme
AT II Angiotensin II
ATP Adenosine triphosphate
ATPase Adenosine triphosphatase
CDME Cystine dimethyl ester







GFR Glomerular filtration rate
GS GSH synthetase
GSH Glutathione
GSSG Glutathione disulfide or oxidized GSH
γ-glut-cys γ-glutamylcysteine
HPLC High performance liquid chromatography
IDDM Insulin-dependent diabetes mellitus
α-1 MG α-1 microglobulin
ML Mixed leukocytes
MRP2/MRP4 Multidrug resistant proteins 2 and 4
OAT1/3 Organic anion transporters 1 and 3
OATP1 Organic anion transporting polypeptide 1
2-OG- 2-oxoglutarate
OXPHOS Oxidative phosphorylation
PCR Polymerase chain reaction
PMN Polymorphonuclear leukocytes
PO Podocytes
PTEC Proximal tubular epithelial cells
SD Standard deviation
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Dankwoord
Het dankwoord in een proefschrift biedt de mogelijkheid om even stil te staan bij de
mensen , die in mijn leven en mijn ontwikkeling van groot belang zijn geweest. Een kans
om te leven, een kans om een opleiding te krijgen, een kans om te promoveren, een kans
om met het onderzoek door te gaan - dit alles was afhankelijk van veel mensen en ik dank
iedereen die mij deze kansen heeft gegeven.
De belangrijkste bron van de inspiratie voor dit onderzoek waren de cystinose patiënten
zelf en hun ouders. Alles is begonnen met een “niet opgeloste” cystinose patiënt, die ik in
Parijs als een casus mocht voorstellen. Beste mensen, ik heb veel van jullie geleerd, de
wijsheid die jullie bezitten is in geen enkel wetenschappelijk boek te vinden. Vechten voor
een “normaal” leven ondanks de ziekte, ondanks de vele medicijnen, ondanks alle onze-
kerheid over de toekomst, dat waardeer ik enorm en ik hoop dat ik jullie nog lang zal
kunnen steunen. Beste Marjolein Bos, de organisator en de inspirator van Cystinose
Groep Nederland, jij betekent heel veel voor al onze patiënten evenals voor mij persoon-
lijk. Jij hebt ervoor gezorgd dat patiënten met de weesziekte cystinose zich niet als een
wees voelen.
Mijn opleider en promotor, Prof. Dr. L. Monnens, beste Professor,
Toen ik na het vallen van de communistische idealen uit Rusland naar Europa kwam, zag
ik U hier in Nijmegen, als een laatste Mohikaan, die écht in idealen geloofde. Ik kon mijn
ogen en oren niet geloven. U hebt me een aantal keren kunnen overtuigen dat uw woor-
den niet alleen woorden waren. Dat heeft me meer verbaasd dan onze bevinding dat cys-
tine in de granulocyten gemeten moest worden. Omdat mensen zoals u bestaan, draait
de wereld toch in de goede richting (wat u overigens zelf betwijfelt). Uw encyclopedische
kennis en enorme eruditie (van 19e eeuwse Russische poëzie tot de recente politieke situ-
atie in Zimbabwe), uw humor en daadkracht hebben er mede voor gezorgd dat dit proef-
schrift tot stand is gekomen.
Mijn copromotor, Dr. Blom, beste Henk,
Ik weet dat ik jou tijdens mijn promotietijd niet tevreden kon stellen - die schuld zal altijd
blijven. Na mijn promotie zal ik er hard aan werken om mijn fietsfrequentie te verdub-
belen. Ik hoop op je steun hierbij. Henk, jij hebt tijdens die jaren veel betekend - leren
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omgaan met problemen, leren schrijven, leren begrijpen van biochemische processen en
methoden. Ik hoop dat wij in de toekomst nog veel “mooie titels” kunnen ontwerpen.
Mijn copromotor, Dr. van den Heuvel, beste Bert,
Jij was onmisbaar voor mijn onderzoek. Jouw doortastende bijdrage, jouw kennis van
celbiologie en moleculaire biologie waren van heel groot belang. Tijdens onze wekelijkse
besprekingen heb ik van jou geleerd hoe men experimenten dient op te stellen en te con-
troleren. En je was steeds bereid om over alle details te praten.
Ik ben je ook ontzettend dankbaar voor alle mogelijkheden die jij geboden hebt om zij-
lijntjes van onderzoek toch te kunnen volgen. Hopelijk worden sommige van deze “zij-
lijntjes” volwaardige wetenschappelijke projecten.
Onze researchanalist, M. Wilmer, beste Martijn,
Jij bent gedurende 4 jaar mijn rechter- en mijn linkerhand geweest. Jij hebt me leren
pipeteren, centrifugeren, in de microscoop kijken (en daar ook iets zien), maar dat is niet
alles. Je wetenschappelijke interesse voor het onderzoek, je kritische blik op de artikels en
je talent voor het maken van figuren en grafieken hebben ervoor gezorgd dat sommige
van onze artikels gepubliceerd zijn. In die jaren ben jij gegroeid van een “schooljongen”
tot een volwassen wetenschapper en ik hoop dat wij samen ons cystinose onderzoek kun-
nen doorzetten.
Analiste Addy de Graaf, beste Addy,
De door jou ontwikkelde methodes van meting van zwavelbevattende stoffen is voor alle
Nederlandse cystinose patiënten van groot belang. Naast deze “routine” metingen was jij
bereid om voor het onderzoek extra werk te doen en daarnaast mee te denken over het
opzetten van de experimenten.
Professor, Bert, Henk, Martijn en Addy,
Onze besprekingen tijdens het cystinose overleg, waren voor mij de leukste momenten
van de afgelopen 4 jaar. Ik heb nooit eerder zo veel lachend geleerd en nooit zo veel leer-
zaam gelachen.
Dr. R. Masereeuw, Dr. J. Koenderink en Prof. Dr. F. Russel,
Jullie deskundige hulp heeft mij veel geholpen. Ik hoop op een verdere goede samenwer-
king in de toekomst.
DANKWOORD
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Dr. P. Willems, Henk-Jan Visch en Sjoerd Verkaart,
De experimenten die wij op jullie lab konden verrichten hebben het cystinose onderzoek
op een hoger niveau gebracht. Jullie hulp bij het schrijven van het ATP artikel en de sub-
sidieaanvraag was van zeer groot belang. Ik hoop dat het ons zal lukken om een nieuwe
subsidie te verkrijgen.
Teamleden van de cystinose polikliniek (Dr. F. Boers, Prof. Dr. J. Cruysberg, Prof. Dr. N.
van Slobbe-Knoers, D. Rozendal),
Samen zijn wij met deze poli gestart en het is de moeite waard.
Mijn collega’s kindernefrologen, beste Marlies, Nicole en Linda,
Ik ben jullie dankbaar voor de ruimte die jullie voor mij hebben gecreëerd om dit onder-
zoek te kunnen doen, voor jullie geduld en begrip, voor mijn professionele en persoon-
lijke problemen. Wij delen het belangrijkste idee dat patiënten altijd prioriteit hebben. Ik
heb er het volste vertrouwen in dat wij samen de hoge standaard van onze subafdeling
gaan voortzetten.
Beste collega’s van de kinderdialyse,
Jaqueline, Anne-Marie, Carla, Do, Dorie, Ingrid, Marga, Riek, Theo, Mieke, Anneke,
Gonnie, Marieke, en Eef en alle mensen van de school, bij jullie voel ik me altijd thuis,
het team gevoel dat wij hebben is uniek en is mij heel veel waard. Margriet, jij hebt me
duizend keer uit de brand geholpen en moeilijke klusjes opgelost.
Dr. I. Hulstijn, beste Ineke,
Jij bent niet alleen de psycholoog voor de patiënten, maar ook voor ons. Tijdens vele
jaren, was jij voor mij een belangrijke gesprekpartner en een schouder om uit te huilen.
Prof. Dr. N. van Slobbe-Knoers, beste Nine,
Jouw passie voor onderzoek, jouw werkhouding, onvermoeibaarheid en enthousiasme
waren regelmatig voor mij een stimulans.
Collega’s internisten-nefrologen en in het bijzonder Prof. Dr. J. Wetzels en Dr. F.
Huysmans,
Ik ben jullie erkentelijk voor jullie interesse en collegiale ondersteuning.
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Collega’s kinderurologen, Dr. W. Feitz en Drs. R. de Gier, beste Wout en Robert,
Zonder jullie “(voor)huidjes” zou de basis van mijn onderzoek ontbreken. Hartelijk
bedankt voor jullie hulp bij het verkrijgen van controlemateriaal.
Prof. Dr. Sergeeva, Prof. Dr. Naumova en andere ex-collega’s Russische kindernefrologen,
Jullie waren de eerste die mijn interesse voor kindernefrologie hebben gewekt.
Prof. Dr. Loeb en Prof. Dr. Vanderplas ben ik dankbaar voor de mogelijkheid om de
opleiding tot kinderarts in België te hebben mogen volgen, Prof. Dr. Ramet voor het
begeleiden van mijn eerste stappen in de kindergeneeskunde in Brussel en Prof. Dr. Piepz
voor het ondersteunen van mijn eerste nefrologisch onderzoek in België. Aan Professor
Dr. R. Sengers dank ik de mogelijkheid om in het UMC St Radboud de opleiding tot kin-
dernefroloog te hebben kunnen volgen.
Lieve papa,
Van jou zou ik nooit mijn promotieonderzoek in Moskou hebben mogen afbreken om
naar België te gaan. Jij zou heel blij zijn om te weten dat ik toch (14 jaar later) zal pro-
moveren. Ik heb de hele tijd aan jou gedacht en heb geprobeerd om jouw verwachtingen
niet teleur te stellen. Ik zal je heel erg missen op de dag van mijn promotie.
Mama, Ivan, Anja, Philippe en Aimé,
Jullie hebben me gemaakt tot wat ik nu ben. Over elk van jullie zou ik een apart “boek-
je” kunnen schrijven, maar dat wordt een heel ander verhaal… .
DANKWOORD
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Curriculum vitae
Elena Levtchenko werd geboren op 3 april 1965 te Malachovka, Rusland. Na het afron-
den van het middelbaar onderwijs in 1982, begon ze hetzelfde jaar met de studie
Geneeskunde aan de 2de Russische Medische Staatsuniversiteit. Het artsexamen (cum
laude) behaalde ze in juni 1988 en vanaf september 1988 begon ze met de opleiding kin-
dergeneeskunde/kindernefrologie aan het Instituut voor Kindergeneeskunde van de
Russische Academie van Medische Wetenschappen (opleiders Prof. Dr. Naumova, Prof.
Dr. Sergeeva). In 1991 werd ze toelaten tot het Master Programma van Medische en
Farmaceutische Wetenschappen aan de Vrije Universiteit Brussel (hoofd Prof. Dr.
Pipeleers). Na het verkrijgen van de graad “Master in Medische en Farmaceutische
Wetenschappen” in september 1993, begon ze met een opleiding kindergeneeskunde
(opleiders Prof. Dr. Loeb, Prof. Dr. Vanderplas) aan de Vrije Universiteit Brussel, welke
werd afgerond in september 1999. Tijdens de specialisatie tot kindernefroloog in UMC St
Radboud te Nijmegen (opleider Prof. Dr. Monnens) begon ze met het promotieonder-
zoek, beschreven in dit proefschrift, “Cystinose: betere behandeling en inzicht in de
pathogenese” onder leiding van Prof. Dr. Monnens, Dr. Blom en Dr. van den Heuvel en
gesubsidieerd door de Nierstichting Nederland. Momenteel werkt ze als kinderarts-nef-
roloog op de afdeling kindergeneeskunde in het UMC St Radboud te Nijmegen (hoofd
Prof. Dr. de Groot). In 2004 ontving ze een Dr. Frije Stipendium van UMC St Radboud.
Elena is getrouwd met Aimé van Gucht en heeft twee kinderen, Anja en Philippe.
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